

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070981 A2

(51) International Patent Classification⁷: **C12Q 1/68**,
C07K 14/35, C12N 5/10, C12R 1/32, A61K 39/04, C12N
15/70, C07K 16/12, G01N 33/569

Unite de genetique Moleculaire Bacterienne, 25-28, rue du
Docteur Roux, 75724 Paris Cedex 15 (FR). **GARNIER,**
Thierry [FR/FR]; c/o Institut Pasteur- Unite de Genetique
Moleculai, re Bacterienne, 25-28, rue du Docteur Roux,
75724 Paris, Cedex 15 (FR).

(21) International Application Number: PCT/IB03/00986

(22) International Filing Date: 25 February 2003 (25.02.2003)

(74) Agent: **MARTIN, Jean-Jacques**; Cabinet Regimbeau, 20,
rue de Chazelles, 75847 Paris, Cedex 17 (FR).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02290458.5 25 February 2002 (25.02.2002) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **INSTI-**
TUT PASTEUR [FR/FR]; 25-28, rue du Docteur Roux,
F-75015 Paris (FR). **VETERINARY LABORATORIES**
AGENCY [GB/GB]; New Ham, Addelstone KT15 3NB,
Surrey (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLE, Stewart**
[GB/FR]; c/o Institut Pasteur- Unite de Genetique Molec-
ulai, re Bacterienne, 25-28 rue du Docteur Roux, 75724
Paris Cedex 15 (FR). **BROSCH, Roland** [AT/FR]; c/o
Institut Pasteur- IP Paris, Unite de Genetique, Moleculaire
Bacterienne, 25-28 rue du Docteur Roux, 75724 Paris
Cedex 15 (FR). **GORDON, Stephen** [IE/GB]; Glyn
Hewinson, Veterinary Laboratories Agency, Woodham
Lane, New Haw, Addelstone, Surrey KT15 3NB (GB).
EIGLMEIER, Karin [DE/FR]; c/o Institut Pasteur,

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: DELETED SEQUENCE IN M. TUBERCULOSIS, METHOD FOR DETECTING MYCOBACTERIA USING THESE SEQUENCES AND VACCINES

(57) Abstract: The present invention is the identification of a nucleotide sequence which make it possible in particular to distinguish an infection resulting from the vast majority of *Mycobacterium tuberculosis strains* from an infection resulting from *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*. The subject of the present invention is also a method for detecting the sequences in question by the products of expression of these sequences and the kits for carrying out these methods. Finally, the subject of the present invention is novel vaccines.

WO 03/070981 A2

DELETED SEQUENCE IN M. TUBERCULOSIS, METHOD FOR DETECTING MYCOBACTERIA USING THESE SEQUENCES AND VACCINES

The present invention pertains to the field of biology, more particularly the subject of
5 the present invention is the identification of a nucleotide sequence which make it possible in
particular to distinguish an infection resulting from *Mycobacterium tuberculosis* from an
infection resulting from *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium*
microti, *Mycobacterium bovis*, *Mycobacterium bovis BCG*. The subject of the present
invention is also a method for detecting the sequences in question by the products of
10 expression of these sequences and the kits for carrying out these methods. Finally, the
subject of the present invention is novel vaccines.

Despite more than a century of research since the discovery of *Mycobacterium*
tuberculosis, the aetiological agent of tuberculosis, this disease remains one of the major
causes of human mortality. *M. tuberculosis* is expected to kill 3 million people annually
15 (Snider, 1989 Rev. Inf. Dis. S335) and the number of new people getting infected each year
is rising and is estimated at 8.8 million. Although the majority of these are in developing
countries, the disease is assuming renewed importance in the western countries due to the
increasing number of homeless people, the impact of the AIDS epidemic, the changing
global migration, and the travel patterns.

20 Early tuberculosis often goes unrecognized in an otherwise healthy individual.
Classical initial methods of diagnosis include examination of a sputum smear under a
microscope for acid-fast mycobacteria and an x-ray of the lungs. However, in a vast majority
of cases the sputum smear examination is negative for Mycobacteria in the early stages of
the disease, and lung changes may not be obvious on an x-ray until several months following
25 infection. Another complicating factor is that acid-fast bacteria in a sputum smear may often
be other species of mycobacteria. Antibiotics used for treating tuberculosis have
considerable side effects, and must be taken as a combination of three or more drugs for a six
to twelve month period. In addition, the possibility of inducing the appearance of drug
resistant tuberculosis prevents therapy from being administered without solid evidence to
30 support the diagnosis. Currently the only absolutely reliable method of diagnosis is based on
culturing *M. tuberculosis* from the clinical specimen and identifying it morphologically and
biochemically. This usually takes anywhere from three to six weeks, during which time a
patient may become seriously ill and infect other individuals. Therefore, a rapid test capable
of reliably detecting the presence of *M. tuberculosis* is vital for the early detection and
35 treatment. Several molecular tests have been developed recently for the rapid detection and

identification of *M. tuberculosis*, such as the Gen-Probe "Amplified *Mycobacterium tuberculosis* Direct Test"; this test amplifies *M. tuberculosis* 16S ribosomal RNA from respiratory specimens and uses a chemiluminescent probe to detect the amplified product with a reported sensitivity of about 91%. The discovery of the IS6110 insertion element
5 (Cave et al., Eisenach *et al.*, 1990 J. Infectious Diseases 161:977-981; Thierry *et al.* 1990 J. Clin. Microbiol. 28: 2668-2673) and the belief that this element may only be present in *Mycobacterium* complex (*M. tuberculosis*, *M. bovis*, *M. bovis*-BCG, *M. africanum*, *M. canettii* and *M. microti*) spawned a whole series of rapid diagnostic strategies (Brisson-Noel *et al.*, 1991 Lancet 338: 364-366; Clarridge *et al.* 1993, J. Clin. Microbiol. 31 :2049-2056 ;
10 Cormican et al. 1992 J. Clin. Pathology 1992, 45 : 601-604 ; Cousins et al., 1992 J. Clin. Microbiol. 30 : 255-258 ; Del Portillo et al. 1991 J. Clin. Microbiol. 29 : 2163-2168 ; Folgueira et al., 1994 Neurology 44 :1336-1338 ; Forbes et al. 1993, J.Clin.Microbiol. 31 :1688-1694 ; Hermans et al. 1990 J. Clin. Microbiol. 28 :1204-1213 ; Kaltwasser et al. 1993 Mol. Cell. Probes 7 : 465-470 ; Kocagoz et al. 1993 J. Clin. Microbiol. 31 :1435-1438 ;
15 Kolk et al. 1992 J.Clin.Microbiol. 30 : 2567-2575 ; Kox et al. 1994 J.Clin.Microbiol. 32 :672-678 ; Liu et al. 1994 Neurology 44 :1161-1164 ; Miller et al. 1994 J. Clin.Microbiol. 32 : 393-397 ; Reischl et al. 1994 Biotechniques 17 :844-845 ; Schluger et al. 1994 Chest 105 :1116-1121 ; Shawar et al. 1993 J. Clin. Microbiol. 31: 61-65; Wilson et al 1993 J.Clin.Microbiol. 28: 2668-2673). These tests employ various techniques to extract DNA
20 from the sputum. PCR is used to amplify IS6110 DNA sequences from the extracted DNA. The successful amplification of this DNA is considered to be an indicator of the presence of *M. tuberculosis* infection. U.S. Pat. Nos. 5,168,039 and 5,370,998 have been issued to Crawford *et al.* for the IS6110 based detection of tuberculosis. European patent EP 0,461,045 has been issued to Guesdon for the IS6110 based detection of tuberculosis.

25 Thus, these molecular assays used to detect *M. tuberculosis* depend on the IS6110 insertion sequence (about 10 copies) or the 16S ribosomal RNA (thousands of copies). However, these methods do not provide any information regarding the sub-type of the mycobacteria. Indeed several dozen species of Mycobacteria are known, and most are non-pathogenic for humans; tuberculosis is usually caused by infection due to *M. tuberculosis*,
30 with a few cases being caused by *M. bovis*, *M. canettii*, and *M. africanum*. In order to choose an appropriate treatment and to conduct epidemiological investigations it is absolutely necessary to be able to rapidly and accurately identify isolates, i.e to distinguish the sub-type of mycobacteria of the *Mycobacterium* complex, originating from potential tuberculosis patients. That's the problem the present invention intends to solve.

The present invention provides an isolated or purified nucleic acid from *Mycobacterium* complex wherein said nucleic acid is selected from the group consisting of:

- a) SEQ ID N°1, named TbD1 region ;
- b) Nucleic acid having a sequence fully complementary to SEQ ID N°1.
- 5 c) Nucleic acid fragment comprising at least 8, 12, 15, 20, 25, 30, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 3000 consecutive nucleotides of SEQ ID N°1;
- d) Nucleic acid having at least 90% sequence identity after optimal alignment with a sequence defined in a) or b);
- 10 e) Nucleic acid that hybridizes under stringent conditions with the nucleic acid defined in a) or b);

As used herein, the terms « isolated » and « purified » according to the invention refer to a level of purity that is achievable using current technology. The molecules of the invention do not need to be absolutely pure (i.e., contain absolutely no molecules of other cellular macromolecules), but should be sufficiently pure so that one of ordinary skill in the art would recognize that they are no longer present in the environment in which they were originally found (i.e., the cellular middle). Thus, a purified or isolated molecule according to the present invention is one that have been removed from at least one other macromolecule present in the natural environment in which it was found. More preferably, the molecules of the invention are essentially purified and/or isolated, which means that the composition in which they are present is almost completely, or even absolutely, free of other macromolecules found in the environment in which the molecules of the invention are originally found. Isolation and purification thus does not occur by addition or removal of salts, solvents, or elements of the periodic table, but must include the removal of at least some macromolecules. The nucleic acids encompassed by the invention are purified and/or isolated by any appropriate technique known to the ordinary artisan. Such techniques are widely known, commonly practiced, and well within the skill of the ordinary artisan. As used herein, the term “nucleic acid” refers to a polynucleotide sequence such as a single or double stranded DNA sequence, RNA sequence, cDNA sequence; such a polynucleotide sequence has been isolated, purified or synthesized and may be constituted with natural or non natural nucleotides. In a preferred embodiment the DNA molecule of the invention is a double stranded DNA molecule. As used herein, the terms “nucleic acid”, “oligonucleotide”, “polynucleotide” have the same meaning and are used indifferently.

By the term “*Mycobacterium* complex” as used herein, it is meant the complex of mycobacteria causing tuberculosis which are *Mycobacterium tuberculosis*, *Mycobacterium*

bovis, *Mycobacterium africanum*, *Mycobacterium microti*, *Mycobacterium canettii* and the vaccine strain *Mycobacterium bovis* BCG.

The present invention encompasses not only the entire sequence SEQ ID N°1, its complement, and its double-stranded form, but any fragment of this sequence, its
5 complement, and its double-stranded form.

In embodiments, the fragment of SEQ ID N°1 comprises at least approximately 8 nucleotides. For example, the fragment can be between approximately 8 and 30 nucleotides and can be designed as a primer for polynucleotide synthesis. In another preferred embodiment, the fragment of SEQ ID N°1 comprises between approximately 1,500 and
10 approximately 2,500 nucleotides, and more preferably 2153 nucleotides corresponding to SEQ ID N°4 (see figure 5). As used herein, "nucleotides" is used in reference to the number of nucleotides on a single-stranded nucleic acid. However, the term also encompasses double-stranded molecules. Thus, a fragment comprising 2,153 nucleotides according to the invention is a single-stranded molecule comprising 2,153 nucleotides, and also a double
15 stranded molecule comprising 2153 base pairs (bp).

In a preferred embodiment, the nucleic acid fragment of the invention is specifically deleted in the genome of *Mycobacterium tuberculosis*, excepted in *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome and present in the genome of
20 *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis* BCG. By the term "few IS6110 sequences inserted in the genome", it is meant less than ten copies in the genome of *M. tuberculosis*, more preferably less than 5 copies, for example less than two copies.

The nucleic acid fragment of the invention is preferably selected from the group
25 consisting of:

- a) SEQ ID N°4;
- b) Nucleic acid having a sequence fully complementary to SEQ ID N°4.
- c) Nucleic acid fragment comprising at least 8, 12, 15, 20, 25, 30, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 3000 consecutive nucleotides of SEQ ID N°4;
- 30 d) Nucleic acid having at least 90% sequence identity after optimal alignment with a sequence defined in a) or b);
- e) Nucleic acid that hybridizes under stringent conditions with the nucleic acid defined in a) or b).

In embodiments, the stringent conditions under which a sequence according to the
35 invention is determined are conditions which are no less stringent than 5X SSPE, 2X

Denhardt's solution, and 0.5% (w/v) sodium dodecyl sulfate at 65°C. More stringent conditions can be utilized by the ordinary artisan, and the proper conditions for a given assay can be easily and rapidly determined without undue or excessive experimentation. As an illustrative embodiment, the stringent hybridization conditions used in order to specifically detect a polynucleotide according to the present invention are advantageously the following:

5 pre-hybridization and hybridization are performed at 65°C in a mixture containing:

- 5X SSPE (1X SSPE is 3 M NaCl, 30 mM tri-sodium citrate)
- 2X Denhardt's solution
- 0.5% (w/v) sodium dodecyl sulfate (SDS)
- 10 - 100 µg ml⁻¹ salmon sperm DNA.

The washings are performed as follows:

- two washings at laboratory temperature (approximately 21-25°C) for 10 min. in the presence of 2X SSPE and 0.1% SDS; and
- one washing at 65°C for 15 min. in the presence of 1X SSPE and 0.1% SDS.

15

The invention also encompasses the isolated or purified nucleic acid of the invention wherein said nucleic acid comprises at least a deletion of a nucleic acid fragment as defined above. Preferably, such an isolated or purified nucleic acid of the invention is the SEQ ID N°21 that corresponds to SEQ ID N°1 in which SEQ ID N°4 is deleted (absent).

20

Polynucleotides of the invention can be characterized by the percentage of identity they show with the sequences disclosed herein. For example, polynucleotides having at least 90% identity with the polynucleotides of the invention, particularly those sequences of the sequence listing, are encompassed by the invention. Preferably, the sequences show at least 90% identity with those of the sequence listing. More preferably, they show at least 92% identity, for example 95% or 99% identity. The skilled artisan can identify sequences according to the invention through the use of the sequence analysis software BLAST (see for example, Coffin et al., eds., "*Retroviruses*", Cold Spring Harbor Laboratory Press, pp. 723-755). Percent identity is calculated using the BLAST sequence analysis program suite, Version 2, available at the NCBI (NIH). All default parameters are used. BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx, all of which are available through the BLAST analysis software suite at the NCBI. These programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (1990, 1993) with a few enhancements.

25

30

Using this publicly available sequence analysis program suite, the skilled artisan can easily identify polynucleotides according to the present invention.

It is well within the skill of the ordinary artisan to identify regions of the nucleic acid sequence of the invention, which would be useful as a probe, primer, or other experimental, diagnostic, or therapeutic aid. For example, the ordinary artisan could utilize any of the widely available sequence analysis programs to select regions (fragments) of these sequences that are useful for hybridization assays such as Southern blots, Northern blots, DNA binding assays, and/or *in vitro*, *in situ*, or *in vivo* hybridizations. Additionally, the ordinary artisan, with the sequences of the present invention, can utilize widely available sequence analysis programs to identify regions that can be used as probes and primers, as well as for design of anti-sense molecules. The only practical limitation on the fragment chosen by the ordinary artisan is the ability of the fragment to be useful for the purpose for which it is chosen. For example, if the ordinary artisan wished to choose a hybridization probe, he would know how to choose one of sufficient length, and of sufficient stability, to give meaningful results. The conditions chosen would be those typically used in hybridization assays developed for nucleic acid fragments of the approximate chosen length.

Thus, the present invention provides short oligonucleotides, such as those useful as probes and primers. In embodiments, the probe and/or primer comprises 8 to 30 consecutive nucleotides of the polynucleotide according to the invention or the polynucleotide complementary thereto. Advantageously, a fragment as defined herein has a length of at least 8 nucleotides, which is approximately the minimal length that has been determined to allow specific hybridization. Preferably the nucleic fragment has a length of at least 12 nucleotides and more preferably 20 consecutive nucleotides of any of SEQ ID N°1 or SEQ ID N°4. The sequence of the oligonucleotide can be any of the many possible sequences according to the invention. Preferably, the sequence is selected from the following group SEQ ID N° 13, SEQ ID N° 14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18. More precisely, the primers SEQ ID N°13, SEQ ID N°14, SEQ ID N°15 and SEQ ID N°16 are contained in the nucleic acid fragment SEQ ID N°4. The primers SEQ ID N°17 and SEQ ID N°18 are contained in the nucleic acid sequence SEQ ID N°1 and are flanking the nucleic acid fragment of SEQ ID N°4 (see figure 5).

Thus, the polynucleotides of SEQ ID N°1 and SEQ ID N°4, and their fragments, can be used to select nucleotide primers, notably for an amplification reaction, such as the amplification reactions further described.

PCR is described in US Patent No. 4,683,202, which is incorporated in its entirety herein. The amplified fragments may be identified by agarose or polyacrylamide gel

electrophoresis, by a capillary electrophoresis, or alternatively by a chromatography technique (gel filtration, hydrophobic chromatography, or ion exchange chromatography). The specificity of the amplification can be ensured by a molecular hybridization using as nucleic probes the polynucleotides of SEQ ID N°1 or SEQ ID N°4, and their fragments,
5 oligonucleotides that are complementary to these polynucleotides or fragments thereof, or their amplification products themselves, and/or even by DNA sequencing.

The following other techniques related to nucleic acid amplification may also be used and are generally preferred to the PCR technique. The Strand Displacement Amplification (SDA) technique is an isothermal amplification technique based on the ability
10 of a restriction enzyme to cleave one of the strands at a recognition site (which is under a hemiphosphorothioate form) and on the property of a DNA polymerase to initiate the synthesis of a new strand from the 3'OH end generated by the restriction enzyme and on the property of this DNA polymerase to displace the previously synthesized strand being localized downstream. The SDA amplification technique is more easily performed than PCR
15 (a single thermostatted water bath device is necessary), and is faster than the other amplification methods. Thus, the present invention also comprises using the nucleic acid fragments according to the invention (primers) in a method of DNA or RNA amplification according to the SDA technique.

When the target polynucleotide to be detected is a RNA, for example a mRNA, a
20 reverse transcriptase enzyme will be used before the amplification reaction in order to obtain a cDNA from the RNA contained in the biological sample. The generated cDNA is subsequently used as the nucleic acid target for the primers or the probes used in an amplification process or a detection process according to the present invention.

The non-labeled polynucleotides or oligonucleotides of the invention can be directly
25 used as probes. Nevertheless, the polynucleotides or oligonucleotides are generally labeled with a radioactive element (^{32}P , ^{35}S , ^3H , ^{125}I) or by a non-isotopic molecule (for example, biotin, acetylaminofluorene, digoxigenin, 5-bromodesoxyuridine, fluorescein) in order to generate probes that are useful for numerous applications. Examples of non-radioactive labeling of nucleic acid fragments are described in French patent N° FR 78 10975 and by
30 Urdea *et al.* (1988, *Nucleic Acids Research* 11:4937-4957) or Sanchez-Pescador *et al.* (1988, *J. Clin. Microbiol.* 26(10):1934-1938), the disclosures of which are hereby incorporated in their entirety. Other labeling techniques can also be used, such as those described in French patents FR 2 422 956 and FR 2 518 755. The hybridization step may be performed in different ways. See, for example, Matthews *et al.*, 1988, *Anal. Biochem.* 169:1-25. A general
35 method comprises immobilizing the nucleic acid that has been extracted from the biological

sample on a substrate (for example, nitrocellulose, nylon, polystyrene) and then incubating, in defined conditions, the target nucleic acid with the probe. Subsequent to the hybridization step, the excess amount of the specific probe is discarded and the hybrid molecules formed are detected by an appropriate method (radioactivity, fluorescence or enzyme activity measurement, etc.).

Amplified nucleotide fragments are useful, among other things, as probes used in hybridization reactions in order to detect the presence of one polynucleotide according to the present invention or in order to detect mutations. The primers may also be used as oligonucleotide probes to specifically detect a polynucleotide according to the invention.

The oligonucleotide probes according to the present invention may also be used in a detection device comprising a matrix library of probes immobilized on a substrate, the sequence of each probe of a given length being localized in a shift of one or several bases, one from the other, each probe of the matrix library thus being complementary to a distinct sequence of the target nucleic acid. Optionally, the substrate of the matrix may be a material able to act as an electron donor, the detection of the matrix positions in which an hybridization has occurred being subsequently determined by an electronic device. Such matrix libraries of probes and methods of specific detection of a target nucleic acid is described in the European patent application N° EP-0 713 016 (Affymax technologies) and also in the US patent N° US-5,202,231 (Drmanac). Since almost the whole length of a mycobacterial chromosome is covered by BAC-based genomic DNA library (i.e. 97% of the *M. tuberculosis* chromosome is covered by the BAC library I-1945), these DNA libraries will play an important role in a plurality of post-genomic applications, such as in mycobacterial gene expression studies where the canonical set of BACs could be used as a matrix for hybridization studies. Thus it is also in the scope of the invention to provide a nucleic acid chips, more precisely a DNA chips or a protein chips that respectively comprises a nucleic acid or a polypeptide of the invention.

The present invention is also providing a vector comprising the isolated DNA molecule of the invention. A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring the replication and/or expression to the attached segment. A vector can have one or more restriction endonuclease recognition sites at which the DNA sequences can be cut in a determinable fashion without loss of an essential biological function of the vector, and into which a DNA fragment can be spliced in order to bring about its replication and cloning. Vectors can further provide primer sites (e.g. for PCR), transcriptional and/or translational initiation and/or regulation sites, recombinational signals, replicons, selectable markers, etc. Beside the use of homologous recombination or restriction enzymes to insert a

desired DNA fragment into the vector, UDG cloning of PCR fragments (US Pat. No. 5,334,575), T:A cloning, and the like can also be applied. The cloning vector can further contain a selectable marker suitable for use in the identification of cells transformed with the cloning vector.

5 The vector can be any useful vector known to the ordinary artisan, including, but not limited to, a cloning vector, an insertion vector, or an expression vector. Examples of vectors include plasmids, phages, cosmids, phagemid, yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), human artificial chromosome (HAC), viral vector, such as adenoviral vector, retroviral vector, and other DNA sequences which are able to replicate or
10 to be replicated *in vitro* or in a host cell, or to convey a desired DNA segment to a desired location within a host cell.

According to a preferred embodiment of the invention, the recombinant vector is a BAC pBeloBAC11 in which the genomic region of *Mycobacterium bovis*-BCG 1173P3 that spans the region corresponding to the locus 1,760,753 bp to 1,830,364 bp in the genome of *M.*
15 *tuberculosis* H37Rv has been inserted into the HindIII restriction site; this recombinant vector is named X229. In this region, the inventors have demonstrated the deletion of a 2153 bp fragment, corresponding to SEQ ID N°4, in the vast majority of *M. tuberculosis* strains excepted strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome. That's the reason why the
20 inventors named this deletion of 2153 bp TbD1 ("*M. tuberculosis* specific deletion 1"). TbD1 is flanked by the sequence GGC CTG GTC AAA CGC GGC TGG ATG CTG and AGA TCC GTC TTT GAC ACG ATC GAC G. External primers hybridizing with such sequences outside TbD1 or the complementary sequences thereof can be used for the amplification of TbD1 to check for the presence or the absence of the deletion of the TbD1.
25 The inventors design for example the following primers:

5'- CTA CCT CAT CTT CCG GTC CA-3' (SEQ ID N°17)

5'- CAT AGA TCC CGG ACA TGG TG-3' (SEQ ID N°18)

In order to get a specific 500 pb probe for hybridization experiments, a PCR amplification of a fragment comprised in TbD1 may be realized by using the plasmid X229 as a matrix. The
30 amplification of a fragment of approximatively 500 bp contained in TbD1 can be performed by using the following primers:

5'- CGT TCA ACC CCA AAC AGG TA-3' (SEQ ID N°13)

5'- AAT CGA ACT CGT GGA ACA CC-3' (SEQ ID N°14)

The amplification of a fragment of approximatively 2,000 bp contained in TbD1 can be
35 performed by using the following primers:

5'- ATT CAG CGT CTA TCG GTT GC-3' (SEQ ID N°15)

5'- AGC AGC TCG GGA TAT CGT AG-3' (SEQ ID N°16)

The PCR conditions are the following: denaturation 95°C 1 min, then 35 cycles of amplification [95°C during 30 seconds, 58°C during 1 min] , then elongation 72°C during 4 min.

Thus, this invention also concerns a recombinant cell host which contains a polynucleotide or recombinant vector according to the invention. The cell host can be transformed or transfected with a polynucleotide or recombinant vector to provide transient, stable, or controlled expression of the desired polynucleotide. For example, the polynucleotide of interest can be subcloned into an expression plasmid at a cloning site downstream from a promoter in the plasmid and the plasmid can be introduced into a host cell where expression can occur. The recombinant host cell can be any suitable host known to the skilled artisan, such as a eukaryotic cell or a microorganism. For example, the host can be a cell selected from the group consisting of *Escherichia coli*, *Bacillus subtilis*, insect cells, and yeasts. According to a preferred embodiment of the invention, the recombinant cell host is a commercially available *Escherichia coli* DH10B (Gibco) containing the BAC named X229 previously described. This *Escherichia coli* DH10B (Gibco) containing the BAC named X229 has been deposited with the Collection Nationale de Cultures de Microorganismes (CNCM), Institut Pasteur, Paris, France, on February 18th, 2002 under number CNCM I-2799.

Another aspect of the invention is the product of expression of all or part of the nucleic acid according to the invention, including the nucleic acid fragment specifically deleted in the genome of *Mycobacterium tuberculosis*, excepted in *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome as defined previously. The expression "product of expression" is understood to mean any isolated or purified protein, polypeptide or polypeptide fragment resulting from the expression of all or part of the above-mentioned nucleotide sequences. Among those product of expression, one can cite the membrane protein mmpL6 corresponding to SEQ ID N°6, the membrane protein mmpS6 corresponding to SEQ ID N°3 or SEQ ID N°10 (the two sequences SEQ ID N°3 and SEQ ID N°10 are identical), and their truncated or rearranged forms due to the deletion of a nucleic acid fragment according to the invention. For example, SEQ ID N°8 is a truncated form of mmpL6 protein, SEQ ID N°12 is a truncated form of mmpS6 protein and SEQ ID N°22 is a fusion product [mmpS6-mmpL6] of both rearranged mmpL6 and mmpS6 proteins.

It is now easy to produce proteins in large amounts by genetic engineering techniques through the use of expression vectors, such as plasmids, phages, and phagemids. The polypeptide of the present invention can be produced by insertion of the appropriate polynucleotide into an appropriate expression vector at the appropriate position within the vector. Such manipulation of polynucleotides is well known and widely practiced by the
5 ordinary artisan. The polypeptide can be produced from these recombinant vectors either *in vitro* or *in vivo*. All the isolated or purified nucleic acids encoding the polypeptide of the invention are in the scope of the invention. The polypeptide of the invention is a polypeptide encoded by a polynucleotide which hybridizes to any of SEQ ID N°1 or N°4 under stringent
10 conditions, as defined herein.

More preferably, said isolated or purified nucleic acid according the invention is selected among:

- the *mmpL6* gene of sequence SEQ ID N°5 contained in SEQ ID N°1 and encoding the *mmpL6* protein of sequence SEQ ID N°6;
- 15 - the truncated form of *mmpL6* gene of sequence SEQ ID N°7 contained in TbD1 of sequence SEQ ID N°4 and encoding a truncated form of *mmpL6* protein of sequence SEQ ID N°8;
- the *mmpS6* gene of sequence SEQ ID N°9 contained in SEQ ID N°1 and encoding the *mmpS6* protein of SEQ ID N°10;
- 20 - the truncated form of *mmpS6* gene of sequence SEQ ID N°11 contained in TbD1 of sequence SEQ ID N°4 and encoding a truncated form of *mmpS6* protein of SEQ ID N°12.
- the chimeric gene of SEQ ID N°21 issued from fusion of both truncated *mmpS6* and *mmpL6* genes due to the deletion of TbD1 in the genome of *M. tuberculosis* excepted
25 strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome. This chimeric gene encodes the fusion polypeptide [*mmpS6-mmpL6*] of sequence SEQ ID N°22.

The present invention also provides a method for the discriminatory detection and
30 identification of:

- *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; versus,
- *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*,
35 *Mycobacterium bovis*, *Mycobacterium bovis BCG* in a biological sample,

comprising the following steps:

- a) isolation of the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample,
- b) detection of the nucleic acid sequences of the mycobacterium present in said biological sample,
- c) analysis for the presence or the absence of a nucleic acid fragment specifically deleted in the genome of *Mycobacterium tuberculosis*, excepted in *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, as previously described.

By a biological sample according to the present invention, it is notably intended a biological fluid, such as sputum, saliva, plasma, blood, urine or sperm, or a tissue, such as a biopsy.

Analysis of the desired sequences may, for example, be carried out by agarose gel electrophoresis. If the presence of a DNA fragment migrating to the expected site is observed, it can be concluded that the analyzed sample contained mycobacterial DNA. This analysis can also be carried out by the molecular hybridization technique using a nucleic probe. This probe will be advantageously labeled with a nonradioactive (cold probe) or radioactive element. Advantageously, the detection of the mycobacterial DNA sequences will be carried out using nucleotide sequences complementary to said DNA sequences. By way of example, they may include labeled or nonlabeled nucleotide probes; they may also include primers for amplification. The amplification technique used may be PCR but also other alternative techniques such as the SDA (Strand Displacement Amplification) technique, the TAS technique (Transcription-based Amplification System), the NASBA (Nucleic Acid Sequence Based Amplification) technique or the TMA (Transcription Mediated Amplification) technique.

The primers in accordance with the invention have a nucleotide sequence chosen from the group comprising SEQ ID N° 13, SEQ ID N° 14, SEQ ID N° 15, SEQ ID N° 16, SEQ ID N° 17, SEQ ID N° 18. The primers SEQ ID N° 13, SEQ ID N° 14, SEQ ID N° 15 and SEQ ID N° 16 are contained in the nucleic acid fragment SEQ ID N° 4, and the primers SEQ ID N° 17 and SEQ ID N° 18 are contained in the nucleic acid of the invention SEQ ID N° 1 but not in the nucleic acid fragment SEQ ID N° 4.

In a variant, the subject of the invention is also a method for the discriminatory detection and identification of:

- *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; versus,

- *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*,
5 *Mycobacterium bovis*, *Mycobacterium bovis BCG* in a biological sample,
comprising the following steps:

- a) bringing the biological sample to be analyzed into contact with at least one pair of primers as defined above, the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand,
- 10 b) amplification of the DNA of the mycobacterium,
- c) visualization of the amplification of the DNA fragments.

The amplified fragments may be identified by agarose or polyacrylamide gel electrophoresis by capillary electrophoresis or by a chromatographic technique (gel filtration, hydrophobic chromatography or ion-exchange chromatography). The specification of the
15 amplification may be controlled by molecular hybridization using probes, plasmids containing these sequences or their product of amplification. The amplified nucleotide fragments may be used as reagent in hybridization reactions in order to detect the presence, in a biological sample, of a target nucleic acid having sequences complementary to those of said amplified nucleotide fragments. These probes and amplicons may be labeled or
20 otherwise with radioactive elements or with nonradioactive molecules such as enzymes or fluorescent elements.

The subject of the present invention is also a kit for the discriminatory detection and identification of:

- *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the
25 sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; versus,

- *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*,
Mycobacterium bovis, *Mycobacterium bovis BCG* in a biological sample,
in a biological sample comprising the following elements:

- 30 a) at least one pair of primers as defined previously,
- b) the reagents necessary to carry out a DNA amplification reaction,
- c) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

Indeed, in the context of the present invention, depending on the pair of primers
35 used, it is possible to obtain very different results. Thus, the use of primers which are

contained in the TbD1 deletion, such as for example SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, is such that no amplification product is detectable in *M. tuberculosis* excepted in strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences in their genome, and that amplification product is detectable in

5 *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*, *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome. The use of a pair of primers outside the TbD1 deletion such as SEQ ID N°17 and SEQ ID N°18 is likely to give rise to an amplicon in *Mycobacterium africanum*,

10 *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*, *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, of about 2100 bp whereas the use of the pair of primers outside the TbD1 deletion will give rise in *M. tuberculosis* excepted in strains having the sequence CTG at codon 463 of gene *katG* and

15 having no or very few IS6110 sequences inserted in their genome, to an amplicon of about few bp.

More generally, the invention pertains to the use of at least one pair of primers as defined previously for the amplification of a DNA sequence from *Mycobacterium tuberculosis* or *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*,

20 *Mycobacterium bovis*, *Mycobacterium bovis BCG*, *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome.

Indeed, the subject of the present invention is also a method for the *in vitro*

25 discriminatory detection of antibodies directed against *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome versus antibodies directed against *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*, *Mycobacterium tuberculosis* having the

30 sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample, comprising the following steps:

a) bringing the biological sample into contact with at least one product of expression of all or part of the nucleic acid fragment specifically deleted in *M. tuberculosis* excepted in strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG*

35 and having no or very few IS6110 sequences inserted in their genome, as previously defined,

- b) detecting the antigen-antibody complex formed.

The subject of the present invention is also a method for the *in vitro* discriminatory detection of a vaccination with *Mycobacterium bovis* BCG, an infection by *M. bovis*, *M. canettii*, *M. microti*, *M. africanum* or *M. tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, versus an infection by *Mycobacterium tuberculosis*, excepted by *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a mammal, comprising the following steps:

- 10 a) preparation of a biological sample containing cells, more particularly cells of the immune system of said mammal and more particularly T cells,
- b) incubation of the biological sample of step a) with at least one product of expression of all or part of the nucleic acid fragment specifically deleted in *M. tuberculosis* excepted in strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, as previously defined,
- 15 c) detection of a cellular reaction indicating prior sensitization of the mammal to said product, in particular cell proliferation and/or synthesis of proteins such as gamma-interferon. Cell proliferation may be measured, for example, by incorporating ³H-Thymidine.

The invention also relates to a kit for the *in vitro* discriminatory diagnosis of a vaccination with *M. bovis* BCG, an infection by *M. bovis*, *M. canettii*, *M. microti*, *M. africanum* versus an infection by *M. tuberculosis* excepted by strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a mammal comprising:

- 20 a) a product of expression of all or part of the nucleic acid fragment specifically deleted in *M. tuberculosis* excepted in strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, as previously defined ,
- b) where appropriate, the reagents for the constitution of the medium suitable for the immunological reaction,
- 30 c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction,
- d) where appropriate, a reference biological sample (negative control) free of antibodies recognized by said product,
- e) where appropriate, a reference biological sample (positive control)
- 35 containing a predetermined quantity of antibodies recognized by said product.

The reagents allowing the detection of the antigen-antibody complexes may carry a marker or may be capable of being recognized in turn by a labeled reagent, more particularly in the case where the antibody used is not labeled.

5 The subject of the invention is also mono- or polyclonal antibodies, their chimeric fragments or antibodies, capable of specifically recognizing a product of expression in accordance with the present invention.

The present invention therefore also relates to a method for the *in vitro* discriminatory detection of the presence of an antigen of *Mycobacterium tuberculosis* excepted of strains having the sequence CTG at codon 463 of gene *katG* and having no or
10 very few IS6110 sequences inserted in their genome, versus the presence of an antigen of *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis*-BCG and *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample comprising the following steps:

- 15 a) bringing the biological sample into contact with an antibody of the invention,
b) detecting the antigen-antibody complex formed.

The invention also relates to a kit for the discriminatory detection of the presence of an antigen of *Mycobacterium tuberculosis* excepted strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences
20 inserted in their genome versus the presence of an antigen of *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis* BCG, *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample comprising the following steps:

- 25 a) an antibody as previously claimed ,
b) the reagents for constituting the medium suitable for the immunological reaction,
c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction.

30 The above-mentioned reagents are well known to a person skilled in the art who will have no difficulty adapting them to the context of the present invention.

The subject of the invention is also an immunogenic composition, characterized in that it comprises at least one product of expression in accordance with the invention. Such an immunogenic composition will be used to protect animals and humans against infections by *M. africanum*, *M. bovis*, *M. canettii*, *M. microti* and *M. tuberculosis*.

In a particular embodiment, such an immunogenic composition will comprise a product of expression of all or part of the nucleic fragment specifically deleted in the genome of *Mycobacterium tuberculosis*, excepted in *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome. And in a preferable embodiment, such an immunogenic composition will comprise a product of expression of all or part of TbD1. In this case, such an immunogenic composition will be used to protect animals and humans against infections by *M. africanum*, *M. bovis*, *M. canettii*, *M. microti* and *M. tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome.

In an other particular embodiment, such an immunogenic composition will comprise the fusion product [mmpS6-mmpL6] of SEQ ID N°22. This fusion product is due to the absence of TbD1 in *M. tuberculosis* excepted strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome. An immunogenic composition comprising this fusion product will be used to protect animals and humans specifically against infection by the vast majority of *M. tuberculosis* strains excepted strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome.

Advantageously, the immunogenic composition in accordance with the invention enters into the composition of a vaccine when it is provided in combination with a pharmaceutically acceptable vehicle and optionally with one or more immunity adjuvant(s) such as alum or a representative of the family of muramylpeptides or incomplete Freund's adjuvant.

The invention also relates to a vaccine comprising at least one product of expression in accordance with the invention in combination with a pharmaceutically compatible vehicle and, where appropriate, one or more appropriate immunity adjuvant(s).

The invention also provide an in vitro method for the detection and identification of *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a biological sample, comprising the following steps:

- a) isolation of the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample,
- b) detection of the nucleic acid sequences of the mycobacterium present in said biological sample,

- c) analysis for the presence or the absence of a nucleic acid fragment of the invention.

In another embodiment, the invention provides an *in vitro* method for the detection and identification of *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a biological sample, comprising the following steps:

- a) bringing the biological sample to be analyzed into contact with at least one pair of primers selected among nucleic acid fragments of the invention, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18, the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand,
- b) amplification of the DNA of the mycobacterium,
- c) visualization of the amplification of the DNA fragments.

The invention also provides a kit for the detection and identification of *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a biological sample, comprising the following elements:

- a) at least one pair of primers selected among nucleic acid fragments of the invention, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18,
- b) the reagents necessary to carry out a DNA amplification reaction,
- c) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

The invention also relates to a method for the *in vitro* detection of antibodies directed against *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample, comprising the following steps:

- a) bringing the biological sample into contact with at least one product of expression of all or part of the nucleic acid fragment specifically deleted in *M. tuberculosis* excepted in strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome,
- b) detecting the antigen-antibody complex formed.

It is also a goal of the invention to use the TbD1 deletion as a genetic marker for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.

It is also a goal of the invention to use mmpL6⁵⁵¹ polymorphism as a genetic marker for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.

5 The use of such genetic marker(s) in association with at least one genetic marker selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, katG⁴⁶³, gyrA⁹⁵, oxyR²⁸⁵, pncA⁵⁷ and the specific insertion element of *M. canettii* (IS canettii) allows the differentiation of *Mycobacterium* strains of *Mycobacterium* complex (see example 4).

10 The present invention provides an *in vitro* method for the detection and identification of *Mycobacteria* from the *Mycobacterium* complex in a biological sample, comprising the following steps:

- a) analysis for the presence or the absence of a nucleic acid fragment specifically deleted in *M. tuberculosis* excepted in strains of *M. tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, and
- 15 b) analysis of at least one additional genetic marker selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, katG⁴⁶³, gyrA⁹⁵, oxyR²⁸⁵, pncA⁵⁷, the specific insertion element of *M. canettii*.

20 In a preferred embodiment, two additional markers are used, preferably RD4 and RD9. The analysis is performed by a technique selected among sequence hybridization, nucleic acid amplification, antigen-antibody complex.

25 It is also a goal of the present invention to provide a kit for the detection and identification of *Mycobacteria* from the *Mycobacterium* complex in a biological sample comprising the following elements:

- a) at least one pair of primers selected among nucleic acid fragments of the invention, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18,
- 30 b) at least one pair of primers specific of the genetic markers selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, katG⁴⁶³, gyrA⁹⁵, oxyR²⁸⁵, pncA⁵⁷, the specific insertion element of *M. canettii*.
- 35 c) the reagents necessary to carry out a DNA amplification reaction,

- d) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

In a preferred embodiment, the kit comprises the following elements:

- 5 a) at least one pair of primers selected among nucleic acid fragments of the invention, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18,
- b) one pair of primers specific of the genetic marker RD4,
- c) one pair of primers specific of the genetic marker RD9,
- 10 d) the reagents necessary to carry out a DNA amplification reaction,
- e) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

15 The figures and examples presented below are provided as further guide to the practitioner of ordinary skill in the art and are not to be construed as limiting the invention in anyway.

FIGURES

20

Figure 1 : Amplicons obtained from strains that have the indicated genomic region present or deleted. Sizes of amplicons in each group are uniform. Numbers correspond to strain designation used in Kremer et al. (1999, J. Clin Microbiol. 37: 2607-2618) (Ref. 8) and Supply et al (2001, J. Clin. Microbiol. 39: 3563-3571) (ref.9).

25

Figure 2 : Sequences in the TbD1 region obtained from strains of various geographic regions.

* refers to groups based on *katG*^{c463}/*gyrA*^{c95} sequence polymorphism defined by Sreevatsan and colleagues (Ref. 2). Numbers correspond to strain designation used in Kremer et al. (1999, J. Clin Microbiol. 37: 2607-2618) (Ref. 8) and Supply et al (2001, J. Clin. Microbiol. 39: 3563-3571) (ref.9).

30

Figure 3 : Spoligotypes of selected *M. tuberculosis* and *M. bovis* strains. Numbers correspond to strain designation used in Kremer et al. (1999, J. Clin Microbiol. 37: 2607-2618) (Ref. 8) and Supply et al (2001, J. Clin. Microbiol. 39: 3563-3571) (ref.9).

- 5 **Figure 4 :** Scheme of the proposed evolutionary pathway of the tubercle bacilli illustrating successive loss of DNA in certain lineages (grey boxes). The scheme is based on presence or absence of conserved deleted regions and on sequence polymorphisms in five selected genes. Note that the distances between certain branches may not correspond to actual phylogenetic differences calculated by other methods.
- 10 Dark arrows indicate that strains are characterized by *katG*^{c463} CTG (Leu), *gyrA*^{c95} ACC (Thr), typical for group 1 organisms. Arrows with white lines indicate that strains belong to group 2 characterized by *katG*^{c463} CGG (Arg), *gyrA*^{c95} ACC (Thr). The arrow with white boxes indicates that strains belong to group 3, characterized by *katG*^{c463} CGG (Arg), *gyrA*^{c95} AGC (Ser), as defined by Sreevatsan and colleagues (Sreevastan et al., 1997 Proc. Natl.
- 15 Acad.Sci USA 151: 9869-9874) (Ref. 2).

- Figure 5 :** Scheme of the TbD1 deletion and surrounding region in Mycobacterium complex.
- A : Scheme of TbD1 and surrounding region in genome of *M. bovis*, *M. bovis* BCG, *M. africanum*, *M. canettii*, *M. microti* and ancestral strains of *M. tuberculosis* characterized by
- 20 having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome. The *mmpL6* gene, the *mmpS6* gene, the different primers, the different nucleic acid fragments and polypeptides coded by them are approximately localized in the region. The 2153 pb deletion named TbD1, specifically deleted in *M. tuberculosis* excepted in ancestral strains of *M. tuberculosis*, is delimited by its
- 25 two end points.
- B : Scheme of TbD1 and surrounding region in genome of *M. tuberculosis* excepted ancestral strains of *M. tuberculosis*. Positions of the TbD1 deletion and of the nucleic acid of sequence SEQ ID N°1 in the genome of *M. tuberculosis* strain H37Rv are marked below the scheme. An chimeric ORF [*mmpS6-mmpL6*] resulting from the absence of TbD1 is drawn,
- 30 the sequence of this chimeric ORF, SEQ ID N°21 and the sequence of the encoded polypeptide, SEQ ID N°22, are approximately localized above the scheme.

- Figure 6 :** Sequence of the specific insertion element in genome of *Mycobacterium canettii* strains. The beginning of this insertion element is at position 399 and the end of this insertion
- 35 element is at position 2378. This insertion element contains the coding sequence of a

putative transposase (sequence in bold characters, from position 517 to position 2307) that shows significant homology with a transposase of *Mycobacterium smegmatis*. This coding sequence is framed by two 20 bp inverted repeats (sequences underlined from position 399 to 418 and from position 2359 to 2378).

5

EXAMPLES

1. MATERIAL AND METHODS:

10

1.1. Bacterial Strains: The 100 *M. tuberculosis* complex strains comprised 46 *M. tuberculosis* strains isolated in 30 countries, 14 *M. africanum* strains, 28 *M. bovis* strains originating in 5 countries, 2 *M. bovis* BCG vaccine strains (Pasteur and Japan), 5 *M. microti* strains, and 5 *M. canettii* strains. The strains were isolated from human and animal sources and were selected to represent a wide diversity including 60 strains that have been used in a multi-center study (8). The *M. africanum* strains were retrieved from the collection of the Wadsworth Center, New York State Department of Health, Albany, New York, whereas the majority of the *M. bovis* isolates came from the collection of the University of Zaragoza, Spain. Four *M. canettii* strains are from the culture collection of the Institut Pasteur, Paris, France. The strains have been extensively characterized by reference typing methods, i.e. IS6110 restriction fragment length polymorphism (RFLP) typing and spoligotyping. *M. tuberculosis* H37Rv, *M. tuberculosis* H37Ra, *M. tuberculosis* CDC1551, *M. bovis* AF2122/97, *M. microti* OV254, and *M. canettii* CIPT 140010059 were included as reference strains. DNA was prepared as previously described (10).

25

1.2. Genome comparisons and primer design

For preliminary genome comparisons between *M. tuberculosis* and *M. bovis* websites <http://genolist.pasteur.fr/TubercuList/> and http://www.sanger.ac.uk/Projects/M_bovis/ as well as inhouse databases were used. For primer design, sequences inside or flanking RD and RvD regions were obtained from the same websites. Primers were designed using the primer 3 website <http://www-genome.wi.mit.edu/cgi-bin/primer/primer3> www.cgi that would amplify ca. 500 base pair fragments in the reference strains (Table 1).

30

1.3. RD-PCR analysis

Reactions were performed in 96 well plates and contained per reaction 1.25 µl of 10 x PCR buffer (600mM Tris HCl pH 8.8, 20 mM MgCl₂, 170 mM (NH₄)₂SO₄, 100 mM β-mercaptoethanol), 1.25 µl 20mM nucleotide mix, 50 nM of each primer, 1-10 ng of template DNA, 10% DMSO, 0.2 units *Taq* polymerase (Gibco-BRL) and sterile distilled water to 12.5 µl. Thermal cycling was performed on a PTC-100 amplifier (MJ Inc.) with an initial denaturation step of 90 seconds at 95°C, followed by 35 cycles of 30 seconds at 95°C, 1 min at 58°C, and 4 min at 72°C.

1.4. Sequencing of junction regions (RDs, TbD1,) *katG*, *gyrA*, *oxyR* and *pncA* genes

PCR products were obtained as described above, using primers listed in Table 1.

For primer elimination, 6 µl PCR product was incubated with 1 unit of Shrimp Alkaline phosphatase (USB), 10 units of exonuclease I (USB), and 2 µl of 5 x buffer (200mM Tris HCl pH 8.8, 5mM MgCl₂) for 15 min at 37°C and then for 15 min at 80°C. To this reaction mixture 2 µl of Big Dye sequencing mix (Applied Biosystems), 2 µl (2µM) of primer and 3 µl of 5 x buffer (5mM MgCl₂, 200mM Tris HCl pH 8.8) were added and 35 cycles (96°C for 30 sec; 56°C for 15 sec; 60°C for 4 min) performed in a thermocycler (MJ-research Inc., Watertown, MA). DNA was precipitated using 80 µl of 76% ethanol, centrifuged, rinsed with 70% ethanol, and dried. Reactions were dissolved in 2 µl of formamide/EDTA buffer, denatured and loaded onto 48 cm, 4 % polyacrylamide gels and electrophoresis performed on 377 automated DNA sequencers (Applied Biosystems) for 10 to 12 h. Alternatively, reactions were dissolved in 0.3 mM EDTA buffer and subjected to automated sequencing on a 3700 DNA sequencer (Applied Biosystems). Reactions generally gave between 500-700 bp of unambiguous sequence.

1.5. Accession Numbers

The sequence of the TbD1 region from the ancestral *M. tuberculosis* strain No. 74 (Ref. 8) containing genes *mmpS6* and *mmpL6* was deposited in the EMBL database under accession No. AJ426486. Sequences bordering RD4, RD7, RD8, RD9 and RD10 in BCG are available under accession numbers AJ003103, AJ007301, AJ131210, Y18604, and AJ132559, respectively.

2. EXPERIMENTAL DATA:

The distribution of 20 variable regions resulting from insertion-deletion events in the genomes of the tubercle bacilli has been evaluated in a total of 100 strains of *Mycobacterium tuberculosis*, *M. africanum*, *M. canettii*, *M. microti* and *M. bovis*. This approach showed that the majority of these polymorphisms did not occur independently in the different strains of the *M. tuberculosis* complex but, rather, result from ancient, irreversible genetic events in common progenitor strains. Based on the presence or absence of an *M. tuberculosis* specific deletion (TbD1), *M. tuberculosis* strains can be divided into ancestral and "modern" strains, the latter comprising representatives of major epidemics like the Beijing, Haarlem and African *M. tuberculosis* clusters. Furthermore, successive loss of DNA, reflected by RD9 and other subsequent deletions, was identified for an evolutionary lineage represented by *M. africanum*, *M. microti* and *M. bovis* that diverged from the progenitor of the present *M. tuberculosis* strains before TbD1 occurred. These findings contradict the often-presented hypothesis that *M. tuberculosis*, the etiological agent of human tuberculosis evolved from *M. bovis*, the agent of bovine disease. *M. canettii* and ancestral *M. tuberculosis* strains lack none of these deleted regions and therefore appear to be direct descendants of tubercle bacilli that existed before the *M. africanum*→*M. bovis* lineage separated from the *M. tuberculosis* lineage. This suggests that the common ancestor of the tubercle bacilli resembled *M. tuberculosis* or *M. canettii* and could well have been a human pathogen already.

The mycobacteria grouped in the *M. tuberculosis* complex are characterized by 99.9% similarity at the nucleotide level and identical 16S rRNA sequences (1, 2) but differ widely in terms of their host tropisms, phenotypes and pathogenicity. Assuming that they are all derived from a common ancestor, it is intriguing that some are exclusive human (*M. tuberculosis*, *M. africanum*, *M. canettii*) or rodent pathogens (*M. microti*) whereas others have a wide host spectrum (*M. bovis*). What was the genetic organization of the last common ancestor of the tubercle bacilli and in which host did it live? Which genetic events may have contributed to the fact that the host spectrum is so different and often specific? Where and when did *M. tuberculosis* evolve? Answers to these questions are important for a better understanding of the pathogenicity and the global epidemiology of tuberculosis and may help to anticipate future trends in the spread of the disease.

Because of the unusually high degree of conservation in their housekeeping genes it has been suggested that the members of the *M. tuberculosis* complex underwent an evolutionary bottleneck at the time of speciation, estimated to have occurred roughly 15,000 – 20,000 years ago (2). It also has been speculated that *M. tuberculosis*, the most widespread etiological agent of human tuberculosis has evolved from *M. bovis*, the agent of bovine

tuberculosis, by specific adaptation of an animal pathogen to the human host (3). However, both hypotheses were proposed before the whole genome sequence of *M. tuberculosis* (4) was available and before comparative genomics uncovered several variable genomic regions in the members of the *M. tuberculosis* complex. Differential hybridization arrays identified
5 14 regions (RD1 –14) ranging in size from 2 to 12.7 kb that were absent from BCG Pasteur relative to *M. tuberculosis* H37Rv (5, 6). In parallel, six regions, RvD1-5, and TbD1, that were absent from the *M. tuberculosis* H37Rv genome relative to other members of the *M. tuberculosis* complex were revealed by comparative genomics approaches employing pulsed-field gel electrophoresis (PFGE) techniques (5, 7) and *in silico* comparisons of the
10 near complete *M. bovis* AF2122/97 genome sequence and the *M. tuberculosis* H37Rv sequence.

In the present study the inventors have analyzed the distribution of these 20 variable regions situated around the genome (Table 1) in a representative and diverse set of 100 strains belonging to the *M. tuberculosis* complex. The strains were isolated from different
15 hosts, from a broad range of geographic origins, and exhibit a wide spectrum of typing characteristics like IS6110 and spoligotype hybridization patterns or variable-number tandem repeats of mycobacterial interspersed repetitive units (MIRU-VNTR) (8, 9). The inventors have found striking evidence that deletion of certain variable genomic regions did not occur independently in the different strains of the *Mycobacterium* complex and, assuming that
20 there is little or no recombination of chromosomal segments between the various lineages of the complex, this allows the inventors to propose a completely new scenario for the evolution of the *Mycobacterium* complex and the origin of human tuberculosis.

Variable genomic regions and their occurrence in the members of the *M. tuberculosis* complex.

25

The PCR screening assay for the 20 variable regions (Table 1) within 46 *M. tuberculosis*, 14 *M. africanum*, 5 *M. canettii*, 5 *M. microti*, 28 *M. bovis* and 2 BCG strains employed oligonucleotides internal to known RDs and RvDs, as well as oligonucleotides
30 flanking these regions (Table 1). This approach generated a large data set that was robust, highly reliable, and internally controlled since PCR amplicons obtained with the internal primer pair correlated with the absence of an appropriately sized amplicon with the flanking primer-pair, and *vice-versa*.

According to the conservation of junction sequences flanking the variable regions
35 three types of regions were distinguished, each having different importance as an

evolutionary marker. The first type included mobile genetic elements, like the prophages phiRv1 (RD3) and phiRv2 (RD11) and insertion sequences IS1532 (RD6) and IS6110 (RD5), whose distribution in the tubercle bacilli was highly divergent (Table 2). The second type of deletion is mediated by homologous recombination between adjacent IS6110 insertion elements resulting in the loss of the intervening DNA segment (RvD2, RvD3, RvD4, and RvD5 (7)) and is variable from strain to strain (Table 2).

The third type includes deletions whose bordering genomic regions typically do not contain repetitive sequences. Often this type of deletion occurred in coding regions resulting in the truncation of genes that are still intact in other strains of the *M. tuberculosis* complex. The exact mechanism leading to this type of deletion remains obscure, but possibly rare strand slippage errors of DNA polymerase may have contributed to this event. As shown in detail below, RD1, RD2, RD4, RD7, RD8, RD9, RD10, RD12, RD13, RD14, and TbD1 are representatives of this third group whose distribution among the 100 strains allows us to propose an evolutionary scenario for the members of the *M. tuberculosis* complex, that identified *M. tuberculosis* and/or *M. canettii* as most closely related to the common ancestor of the tubercle bacilli.

2.1. *M. tuberculosis* strains:

Investigation of the 46 *M. tuberculosis* strains by deletion analysis revealed that most RD regions were present in all *M. tuberculosis* strains tested (Table 2). Only regions RD3 and RD11, corresponding to the two prophages phiRv1 and phiRv2 of *M. tuberculosis* H37Rv (4), RD6 containing the insertion sequence IS1532, and RD5 that is flanked by a copy of IS6110 (5) were absent in some strains. This is an important observation as it implies that *M. tuberculosis* strains are highly conserved with respect to RD1, RD2, RD4, RD7, RD8, RD9, RD10, RD12, RD13, and RD14, and that these RDs represent regions that can differentiate *M. tuberculosis* strains independent of their geographical origin and their typing characteristics from certain other members of the *M. tuberculosis* complex. Furthermore, this suggests that these regions may be involved in the host specificity of *M. tuberculosis*.

In contrast, the presence or absence of RvD regions in *M. tuberculosis* strains was variable. The region which showed the greatest variability was RvD2, since 18 from 46 tested *M. tuberculosis* strains did not carry the RvD2 region. Strains with a high copy number of IS6110 (>14) missed regions RvD2 to RvD5 more often than strains with only a few copies. As an example, all six tested strains belonging to the Beijing cluster (8) lacked regions RvD2 and RvD3. This is in agreement with the proposed involvement of recombination of two adjacent copies of IS6110 in this deletion event (7).

However, the most surprising finding concerning the RvD regions was that TbD1 was absent from 40 of the tested *M. tuberculosis* strains (87 %), including representative strains from major epidemics such as the Haarlem, Beijing and Africa clusters (8). To accentuate this result we named this region "*M. tuberculosis* specific deletion 1" (TbD1). *In silico* sequence comparison of *M. tuberculosis* H37Rv with the corresponding section in *M. bovis* AF2122/97 revealed that in *M. bovis* this locus comprises two genes encoding membrane proteins belonging to a large family, whereas in *M. tuberculosis* H37Rv one of these genes (*mmpS6*) was absent and the second was truncated (*mmpL6*). Unlike the RvD2-RvD5 deletions, the TbD1 region is not flanked by a copy of IS6110 in *M. tuberculosis* H37Rv, suggesting that insertion elements were not involved in the deletion of the 2153 bp fragment. To further investigate whether the 40 *M. tuberculosis* strains lacking the TbD1 region had the same genomic organization of this locus as *M. tuberculosis* H37Rv, we amplified the TbD1-junction regions of the various strains by PCR using primers flanking the deleted region (Table 1). This approach showed that the size of the amplicons obtained from multiple strains was uniform (Fig. 1) and subsequent sequence analysis of the PCR products revealed that in all tested TbD1-deleted strains the sequence of the junction regions was identical to that of *M. tuberculosis* H37Rv (Fig.2). The perfect conservation of the junction sequences in TbD1-deleted strains of wide geographical diversity suggests that the genetic event which resulted in the deletion occurred in a common progenitor. However, six *M. tuberculosis* strains, all characterized by very few or no copies of IS6110 and spoligotypes that resembled each other (Fig. 3) still had the TbD1 region present. Interestingly, these six strains were also clustered together by MIRU-VNTR analysis (9).

Analysis of partial gene sequences of *oxyR*, *pncA*, *katG*, and *gyrA* which have been described as variable between different tubercle bacilli (2, 11, 12, 13) revealed that all tested *M. tuberculosis* strains showed *oxyR* and *pncA* partial sequences typical for *M. tuberculosis* (*oxyR* - nucleotide 285 (*oxyR*²⁸⁵):G, *pncA* - codon 57 (*pncA*⁵⁷: CAC). Based on the *katG* codon 463 (*katG*⁴⁶³) and *gyrA* codon 95 (*gyrA*⁹⁵) sequence polymorphism, Sreevatsan and colleagues (2) defined three groups among the tubercle bacilli, group 1 showing *katG*⁴⁶³ CTG (Leu), *gyrA*⁹⁵ ACC (Thr), group 2 exhibiting *katG*⁴⁶³ CGG (Arg), *gyrA*⁹⁵ ACC (Thr), and group 3 showing *katG*⁴⁶³ CGG (Arg), *gyrA*⁹⁵ AGC (Ser). According to this scheme, in our study 16 of the 46 tested *M. tuberculosis* strains belonged to group 1, whereas 27 strains belonged to group 2 and only 3 isolates to group 3. From the 40 strains that were deleted for region TbD1, 9 showed characteristics of group 1, including the strains belonging to the Beijing cluster, 28 of group 2, including the strains from the Haarlem and Africa clusters and 3 of group 3, including H37Rv and H37Ra. Most interestingly, all six *M. tuberculosis* strains

where the TbD1 region was not deleted, contained a leucine (CTG) at *katG*⁴⁶³, which was described as characteristic for ancestral *M. tuberculosis* strains (group 1) (2). As shown in Figure 4, this suggests that during the evolution of *M. tuberculosis* the *katG* mutation at codon 463 CTG (Leu) → CGG (Arg) occurred in a progenitor strain that had region TbD1 deleted. This proposal is supported by the finding that strains belonging to group 1 may or may not have deleted region TbD1, whereas all 30 strains belonging to groups 2 and 3 lacked TbD1 (Fig. 4). Furthermore, all strains of groups 2 and 3 characteristically lacked spacer sequences 33-36 in the direct repeat (DR) region (Fig. 3). It appears that such spacers may be lost but not gained (14). Therefore, TbD1 deleted strains will be referred to hereafter as “modern” *M. tuberculosis* strains.

2.2. *M. canettii*:

M. canettii is a very rare smooth variant of *M. tuberculosis*, isolated usually from patients from, or with connection to, Africa. Although it shares identical 16S rRNA sequences with the other members of the *Mycobacterium* complex, *M. canettii* strains differ in many respects including polymorphisms in certain house-keeping genes, IS1081 copy number, colony morphology, and the lipid content of the cell wall (15, 16). Therefore, we were surprised to find that in *M. canettii* all the RD, RvD, and TbD1 regions except the prophages (phiRv1, phiRv2) were present. In contrast, we identified a region (RD^{can}) being specifically absent from all five *M. canettii* strains that partially overlapped RD12 (Fig. 4).

The conservation of the RD, RvD, and TbD1 regions in the genome of *M. canettii* in conjunction with the many described and observed differences suggest that *M. canettii* diverged from the common ancestor of the *Mycobacterium* complex before RD, RvD and TbD1 occurred in the lineages of tubercle bacilli (Fig. 4). This hypothesis is supported by the finding that *M. canettii* was shown to carry 26 unique spacer sequences in the direct repeat region (14), that are no longer present in any other member of the *Mycobacterium* complex. An other specific feature of *M. canettii* is the presence of an insertion element whose sequence has been searched, by using PCR and hybridization approaches, without success in the other member strains of *Mycobacterium* complex (including *M. tuberculosis*, *M. bovis*, *M. africanum* and *M. microti*). This insertion element contained an ORF encoding a putative transposase framed by two inverted repeats. The sequence of this insertion element is represented in figure 6 and in SEQ ID N°19 where it begins at position 399 and ends at position 2378. The amino acids sequence of the putative transposase is drawn in SEQ ID N°20. As such, this insertion element can be used to differentiate between *M. tuberculosis* ancestral strains and *M. canettii* strains that may show the same TbD1, RD4 and RD9

profiles. Therefore, *M. canettii* represents a fascinating tubercle bacillus, whose detailed genomic analysis may reveal further insights into the evolution of *Mycobacterium* complex.

2.3. *M. africanum*:

5 The isolates designated as *M. africanum* studied here originate from West and East-African sources. 11 strains were isolated in Sierra Leone, Nigeria and Guinea and 2 strains in Uganda. One strain comes from the Netherlands.

 For the 11 West African isolates, RD analysis indicated that these strains all lack the RD9 region containing *cobL*. Sequence analysis of the RD9 junction region showed that the
10 genetic organization of this locus in West African strains was identical to that of *M. bovis* and *M. microti* in that the 5' part of *cobL* as well as the genes Rv2073c and Rv2074c were absent. In addition, six strains (2 from Sierra Leone, 4 from Guinea) also lacked RD7, RD8 and RD10 (Table 2). The junction sequences bordering RD7, RD8 and RD10, like those for
15 RD9, were identical to those of *M. bovis* and *M. microti* strains. As regards the two prophages phiRv1 and phiRv2, the West African strains all contained phiRv2, whereas phiRv1 was absent. No variability was seen for the RvD regions. RvD1-RvD5 and TbD1 were present in all tested West African strains. This shows that *M. africanum* prevalent in West Africa can be differentiated from "modern" *M. tuberculosis* by at least two variable genetic markers, namely the absence of region RD9 and the presence of region TbD1.

20 In contrast, for East African *M. africanum* and for the isolate from the Netherlands, no genetic marker was found which could differentiate them from *M. tuberculosis* strains. With the exception of prophage phiRv1 (RD3) the 3 strains from Uganda and the Netherlands did not exhibit any of the RD deletions, but lacked the TbD1 region, as do
25 "modern" *M. tuberculosis* strains. The absence of the TbD1 region was also confirmed by sequence analysis of the TbD1 junction region, which was found to be identical to that of TbD1 deleted *M. tuberculosis* strains. These results indicate a very close genetic relationship of these strains to *M. tuberculosis* and suggest that they should be regarded as *M. tuberculosis* rather than *M. africanum* strains.

2.4. *M. microti*:

30 *M. microti* strains were isolated in the 1930's from voles (17) and more recently from immuno-suppressed patients (18). These strains are characterized by an identical, characteristic spoligotype, but differ in their IS6110 profiles. Both, the vole and the human isolates, lacked regions RD7, RD8, RD9, and RD10 as well as a region that is specifically
35 deleted from *M. microti* (RD^{mic}). RD^{mic} was revealed by a detailed comparative genomics

study of *M. microti* isolates (19) using clones from a *M. microti* Bacterial Artificial Chromosome (BAC) library. RD^{mic} partially overlaps RD1 from BCG (data not shown). Furthermore, vole isolates missed part of the RD5 region, whereas this region was present in the human isolate. As the junction region of RD5 in *M. microti* was different to that in BCG (data not shown), RD5 was not used as an evolutionary marker.

2.5. *M. bovis* and *M. bovis* BCG:

M. bovis has a very large host spectrum infecting many mammalian species, including man. The collection of *M. bovis* strains that was screened for the RD and RvD regions consisted of 2 BCG strains and 18 "classical" *M. bovis* strains generally characterized by only one or two copies of IS6110 from bovine, llama and human sources in addition to three goat isolates, three seal isolates, two oryx isolates, and two *M. bovis* strains from humans that presented a higher number of IS6110 copies.

Excluding prophages, the distribution of RDs allowed us to differentiate five main groups among the tested *M. bovis* strains. The first group was formed by strains that lack RD7, RD8, RD9, and RD10. Representatives of this group are three seal isolates and two human isolates containing between three and five copies of IS6110 (data not shown). Two oryx isolates harboring between 17 and 20 copies of IS6110 formed the second group that lacked parts of RD5 in addition to RD7-RD10, and very closely resembled the *M. microti* isolates. However, they did not show RD^{mic}, the deletion characteristic of *M. microti* strains (data not shown). Analysis of partial *oxyR* and *pncA* sequences from strains belonging to groups one and two, showed sequence polymorphisms characteristic of *M. tuberculosis* strains (*oxyR*²⁸⁵: G, *pncA*⁵⁷: CAC, Ref. 12, 13).

Group three consists of goat isolates that lack regions RD5, RD7, RD8, RD9, RD10, RD12, and RD13. As previously described by Aranaz and colleagues, these strains exhibited an adenosine at position 285 of the *oxyR* pseudogene that is specific for "classical" *M. bovis* strains whereas the sequence of the *pncA*⁵⁷ polymorphism was identical to that in *M. tuberculosis* (20). This is in good agreement with our results from sequence analysis (Table 2) and the finding that except for RD4, the goat isolates displayed the same deletions as "classical" *M. bovis* strains. Taken together, this suggests that the *oxyR*²⁸⁵ mutation (G → A) occurred in *M. bovis* strains before RD4 was lost. Interestingly, the most common *M. bovis* strains ("classical" *M. bovis* (21)), isolated from cattle from Argentina, the Netherlands, the UK and Spain, as well as from humans (e. g. multi-drug resistant *M. bovis* from Spain (22)) showed the greatest number of RD deletions and appear to have undergone

the greatest loss of DNA relative to other members of the *M. tuberculosis* complex. These lacked regions RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD12 and RD13, confirming results obtained with reference strains (5, 6). These strains together with the two BCG strains were the only ones that showed the *pncA*⁵⁷ polymorphism GAC (Asp) in addition to the
5 *oxyR*²⁸⁵ mutation (G → A) characteristic of *M. bovis*. Analysis of BCG strains indicate that BCG lacked the same RD regions as “classical” *M. bovis* strains in addition to RD1, RD2 and RD14 which apparently occurred during and after the attenuation process (Fig. 4) (6, 23).

In contrast to RDs, the RvD regions were highly conserved in the *M. bovis* strains.
10 With the exception of the two IS6110-rich oryx isolates, that lacked RvD2, RvD3 and RvD4, all other strains had the five RvD regions present. It is particularly noteworthy that TbD1 was present in all *M. bovis* strains.

However, except for the two human isolates, containing between three and five copies of IS6110 from group 1, strains designated as *M. bovis* showed a single nucleotide
15 polymorphism in the TbD1 region at codon 551 (AAG) of the *mmpL6* gene, relative to *M. canettii*, *M. africanum* and ancestral *M. tuberculosis* strains, which are characterized by codon AAC. Even the strains isolated from seals and from oryx with *oxyR* or *pncA* loci like those of *M. tuberculosis* and with fewer deleted regions than the classical *M. bovis* strains, showed the *mmpL6*⁵⁵¹AAG polymorphism typical for *M. bovis* and *M. microti* (Table 2, Fig.
20 4). As such, this polymorphism could serve as a very useful genetic marker for the differentiation of strains that lack RD7, RD8, RD9, and RD10 and have been classified as *M. bovis* or *M. africanum*, but may differ from other strains of the same taxon.

3. DISCUSSION

25

3.1. Origin of human tuberculosis

For many years, it was thought that human tuberculosis evolved from the bovine disease by adaptation of an animal pathogen to the human host (3). This hypothesis is based on the property of *M. tuberculosis* to be almost exclusively a human pathogen, whereas *M.*
30 *bovis* has a much broader host range. However, the results from this study unambiguously show that *M. bovis* has undergone numerous deletions relative to *M. tuberculosis*. This is confirmed by the preliminary analysis of the near complete genome sequence of *M. bovis* AF2122/97, a “classical” *M. bovis* strain isolated from cattle, which revealed no new gene clusters that were confined specifically to *M. bovis*. This indicates that the genome of *M.*
35 *bovis* is smaller than that of *M. tuberculosis* (24). It seems plausible that *M. bovis* is the final

member of a separate lineage represented by *M. africanum* (RD9), *M. microti* (RD7, RD8, RD9, RD10) and *M. bovis* (RD4, RD5, RD7, RD8, RD9, RD10, RD12, RD13) (25) that branched from the progenitor of *M. tuberculosis* isolates. Successive loss of DNA may have contributed to clonal expansion and the appearance of more successful pathogens in certain new hosts.

Whether the progenitor of extant *M. tuberculosis* strains was already a human pathogen when the *M. africanum* → *M. bovis* lineage separated from the *M. tuberculosis* lineage is a subject for speculation. However, we have two reasons to believe that this was the case. Firstly, the six ancestral *M. tuberculosis* strains (TbD1⁺, RD9⁺) (Fig.3) that resemble the last common ancestor before the separation of *M. tuberculosis* and *M. africanum* are all human pathogens. Secondly, *M. canettii*, which probably diverged from the common ancestor of today's *M. tuberculosis* strains prior to any other known member of the *M. tuberculosis* complex is also a human pathogen. Taken together, this means that those tubercle bacilli, which are thought to most closely resemble the progenitor of *M. tuberculosis* are human and not animal pathogens. It is also intriguing that most of these strains were of African or Indian origin (Fig. 3). It is likely that these ancestral strains predominantly originated from endemic foci (15, 26), whereas "modern" *M. tuberculosis* strains that have lost TbD1 may represent epidemic *M. tuberculosis* strains that were introduced into the same geographical regions more recently as a consequence of the worldwide spread of the tuberculosis epidemic.

3.2. The evolutionary timescale of the *M. tuberculosis* complex

Because of the high sequence conservation in housekeeping genes, Sreevatsan *et al.* previously hypothesized that the tubercle bacilli encountered a major bottleneck 15,000 – 20,000 years ago (2). As the conservation of the TbD1 junction sequence in all tested TbD1 deleted strains suggests descendance from a single clone, the TbD1 deletion is a perfect indicator that "modern" *M. tuberculosis* strains that account for the vast majority of today's tuberculosis cases definitely underwent such a bottleneck and then spread around the world.

As described in detail in the results section, our analysis showed that the *katG*⁴⁶³ CTG→CGG and the subsequent *gyrA*⁹⁵ ACC →AGC mutations, that were used by Sreevatsan and colleagues to designate groups 2 and 3 of their proposed evolutionary pathway of the tubercle bacilli (2), occurred in a lineage of *M. tuberculosis* strains that had already lost TbD1 (Fig.4). Although deletions are more stable markers than point mutations, which may be subject to reversion, a perfect correlation of deletion and point mutation data was found for the tested strains.

This information, together with results from a recent study by Fletcher and colleagues (27), who have shown that *M. tuberculosis* DNAs amplified from naturally mummified Hungarian villagers from the 18th and 19th century belonged to *katG*⁴⁶³/*gyrA*⁹⁵ groups 2 and 3, suggests that the TbD1 deletion occurred in the lineage of *M. tuberculosis* before the 18th century. This could mean that the dramatic increase of tuberculosis cases later in the 18th century in Europe mainly involved “modern” *M. tuberculosis* strains. In addition, it shows that tuberculosis was caused by *M. tuberculosis* and not by *M. bovis*, a fact which is also described for cases in rural medieval England (28).

There is good evidence that mycobacterial infections occurred in man several thousand years ago. We know that tuberculosis occurred in Egypt during the reign of the pharaohs because spinal and rib lesions pathognomonic of tuberculosis have been identified in mummies from that period (29). Identification of acid fast bacilli as well as PCR amplification of IS6110 from Peruvian mummies (30) also suggest that tuberculosis existed in pre-Columbian societies of Central and South America. To estimate when the TbD1 bottleneck occurred, it would now be very interesting to know whether the Egyptian and South American mummies carried *M. tuberculosis* DNA that had TbD1 deleted or not.

The other major bottleneck, which seems to have occurred for members of the *M. africanum* → *M. microti* → *M. bovis* lineage is reflected by RD9 and the subsequent RD7, RD8 and RD10 deletions (Fig. 4). These deletions seem to have occurred in the progenitor of tubercle bacilli that - today - show natural host spectra as diverse as humans in Africa, voles on the Orkney Isles (UK), seals in Argentina, goats in Spain, and badgers in the UK. For this reason it is difficult to imagine that spread and adaptation of RD9-deleted bacteria to their specific hosts could have appeared within the postulated 15,000 – 20,000 years of speciation of the *M. tuberculosis* complex.

However, more insight into this matter could be gained by RD analysis of ancient DNA samples, e. g. mycobacterial DNA isolated from a 17,000 year old bison skeleton (31). The mycobacterium whose DNA was amplified showed a spoligotype that was most closely related to patterns of *M. africanum* and could have been an early representative of the lineage *M. africanum* → *M. bovis*. With the TbD1 and RD9 junction sequences that we supply here, PCR analyses of ancient DNAs should enable very focused studies to be undertaken to learn more about the timescale within which the members of the *M. tuberculosis* complex have evolved.

3.3. Concluding comments

Our study provides an overview of the diversity and conservation of variable regions

in a broad range of tubercle bacilli. Deletion analysis of 100 strains from various hosts and countries has identified some evolutionarily "old" *M. canettii*, *M. tuberculosis* and *M. africanum* strains, most of them of African origin, as well as "modern" *M. tuberculosis* strains, the latter including representatives from major epidemic clusters like Beijing, Haarlem and Africa. The use of deletion analysis in conjunction with molecular typing and analysis of specific mutations was shown to represent a very powerful approach for the study of the evolution of the tubercle bacilli and for the identification of evolutionary markers. In a more practical perspective, these regions, primarily RD9 and TbD1 but also RD1, RD2, RD4, RD7, RD8, RD10, RD12 and RD13 represent very interesting candidates for the development of powerful diagnostic tools for the rapid and unambiguous identification of members of the *M. tuberculosis* complex (32). This genetic approach for differentiation can now be used to replace the often confusing traditional division of the *M. tuberculosis* complex into rigidly defined subspecies.

Moreover, functional analyses will show whether the TbD1 deletion confers some selective advantage to "modern" *M. tuberculosis*, or whether other circumstances contributed to the pandemic of the TbD1 deleted *M. tuberculosis* strains.

EXAMPLE 4

20

The members of the *M. tuberculosis* complex share an unusually high degree of conservation such that the commercially-available nucleic acid probes and amplification assays cannot differentiate these organisms. In addition conventional identification methods are often ambiguous, cumbersome and time consuming because of the slow growth of the organisms.

25

In the present invention the inventors, by a deletion analysis, solve the problem faced by clinical mycobacteriology laboratories for differentiation within the *M. tuberculosis* complex.

This approach allows to perform a diagnostic on a biological fluid by using at least three markers including TbD1. The following table 3 illustrates such a combinaison sufficient to realize the distinction between the members of the *Mycobacterium* complex.

30

MYCOBACTERIUM STRAIN	MARKERS		
	RD4	RD9	TbD1
<i>M. bovis</i> BCG	-	-	+
<i>M. bovis</i>	-	-	+
<i>M. africanum</i>	+	-	+
<i>M. tuberculosis</i>	+	+	-
<i>M. tuberculosis</i> ancestral	+	+	+
<i>M. canettii</i>	+	+	+

Table 3

Beside TbD1 marker, preferably at least 2 other markers should be used. Examples of such additional markers available in the literature are listed in the following table 1.

- 5 Although ancestral strains of *Mycobacterium tuberculosis* represent only 5% of all *Mycobacterium tuberculosis* strains, persons who would be interested in distinguishing the ancestral strains of *Mycobacterium tuberculosis* from the strains of *Mycobacterium canettii*, could consider using the genetic marker RD12 in combination with the three markers described in table 3. Because the region RD^{can} partially overlapped RD12 in genome of
- 10 *Mycobacterium canettii*, flanking primers as described in table 1 do not hybridize on genomic DNA of *Mycobacterium canettii*. Therefore, PCR amplification with these flanking

primers results in 2.8 kb PCR product in *Mycobacterium tuberculosis* and no PCR product in *Mycobacterium canettii*.

An other way to distinguish ancestral strains of *Mycobacterium tuberculosis* from *Mycobacterium canettii* would be the detection of the insertion element specific for *M.*
5 *canettii* strains and corresponding to SEQ ID N° 19.

Supplemental data:

10

Table 1: RD, RvD and TbD1 regions and selected primers

Region absent from BCG	Gene	Size (kb)	Internal Primerpair	Flanking primers or 2 nd internal * primerpair
RD1	Rv3871-Rv3879c	9.5	RD1in-Rv3878F GTC AGC CAA GTC AGG CTA CC RD1in-Rv3878R CAA CGT TGT GGT TGT TGA GG	RD1-flank.left GAA ACA GTC CCC AGC AGG T RD1-flank.right TTC AAC GGG TTA CTG CGA AT
RD2	Rv1978-Rv1988	10.8	RD2-Rv1979.int.F TAT AGC TCT CGG CAG GTT CC RD2-Rv1979-int.R ATC GGC ATC TAT GTC GGT GT	RD2-flank.F CTC GAC CGC GAC GAT GTG C RD2-flank.R CCT CGT TGT CAC CGC GTA TG
RD3*	Rv1573-Rv1586c	9.2	RD3-Rv1586.int.F TTA TCT TGG CGT TGA CGA TG RD3-Rv1586.int.R CAT ATA AGG GTG CCC GCT AC	RD3-int-REP.F CTG ACG TCG TTG TCG AGG TA* RD3-int-REP.R GTA CCC CCA GGC GAT CTT*
RD4	Rv1505c-Rv1516c	12.7	RD4-Rv1516.int.F CAA GGG GTA TGA GGT TCA CG RD4-Rv1516.int.R CGG TGA TTC GTG ATT GAA CA	RD4-flank.F CTC GTC GAA GGC CAC TAA AG RD4-flank.R AAG GCG AAC AGA TTC AGC AT

Table 1 (continued)

RD5*	Rv2346c-Rv2353c	9.0	RD5A-Rv2348.int.F AAT CAC GCT GCT GCT ACT CC RD5A-Rv2348.int.R GTG CTT TTG CCT CTT GGT C	RD5B-plcA.int.F CAA GTT GGG TCT GGT CGA AT RD5B-plcA.int.R GCT ACC CAA GGT CTC CTG GT
RD6*	Rv3425-Rv3428c	4.9	RD6-IS1532F CAG CTG GTG AGT TCA AAT GC RD6-IS1532R CTC CCG ACA CCT GTT CGT	ND ND
RD7	Rv1964-Rv1977	12.7	RD7-Rv1976.int.F TGG ATT GTC GAC GGT ATG AA RD7-Rv1976.int.R GGT CGA TAA GGT CAC GGA AC	RD7-flank.F GGT AAT CGT GGC CGA CAA G RD7-flank.R CAG CTC TTC CCC TCT CGA C
RD8	<i>ephA-lpqG</i>	5.9	RD8-ephA.F GGT GTG ATT TGG TGA GAC GAT G RD8-ephA.R AGT TCC TCC TGA CTA ATC CAG GC	RD8-flank.F CAA TCA GGG CTG TGC TAA CC RD8-flank.R CGA CAG TTG TGC GTA CTG GT
RD9	<i>cobL</i> -Rv2075	2.0	RD9-intF CGA TGG TCA ACA CCA CTA CG RD9-intR CTG GAC CTC GAT GAC CAC TC	RD9-flankF GTG TAG GTC AGC CCC ATC C RD9-flankR GCC CAA CAG CTC GAC ATC
RD10	Rv0221-Rv0223	1.9	RD10-intF GTA ACC GCT TCA CCG GAA T RD10-intR GTC AAC TCC ACG GAA AGA CC	RD10-flankF CTG CAA CCA TCC GGT ACA C RD10-flankR GTC ATG AAC GCC GGA CAG
RD11	Rv2645-Rv2695c	11.0	RD11-Rv2646F CGG CAG CTA GAC GAC CTC RD11-Rv2646R AAC GTG CTG CGA TAG GTT TT	RD11-fla-F TCA CAT AGG GGC TGC GAT AG RD11-fla-R AGA GGA ACC TTT CGG TGG TT
RD12	<i>sseC</i> -Rv3121	2.8	RD12-Rv3120.int.F GAA ATA CGA GTG CGC TGA CC RD12-Rv3120.int.R CTC TGA ACC ATC GGT GTC G	RD12-flank.F GCC ATC AAC GTC AAG AAC CT RD12-flank.R CGG CCA GGT AAC AAG GAG T
RD13	Rv1255c-Rv1257c	3.0	RD13intF GGA TGT CAC TCG GAA CGG CA RD13intR CAC CGG GCT GAT CGA GCG A	RD13-flank.F CGA TGG TGT TTC TTG GTG AG RD13-flank.R GGA TCG GCT CAG TGA ATA CC
RD14	Rv1765c-Rv1773c	9.0	RD14-Rv1769.int.F GTG GAG CAC CTT GAC CTG AT RD14-Rv1769.int.R CGT CGA ATA CGA GTC GAA CA	RD14-flankF TTG ATT CGC CAA CAA CTG AA RD14-flankR GGG CTG GTT AGT GTC GAT TC

Table 1 (continued)

Region missing from *M. tuberculosis* H37Rv

RvD1*		5.0	RvD1-int1F AGC GCG TCG AAC ACC GGC RvD1-int1R CCT GAA TCC GCG CAA TTC CAT	RvD1-int2.F GAG CCA CTC CGA TGT TGA CT RvD1-int2.R CAC GCG AAC CCT ACC TAC AT
RvD2*	<i>plcD</i>	5.1	RvD2-int1F GTT CTC CTG TCG AAC CTC CA RvD2-int1R ACT TCA CCG GTT TCA TCT CG	RvD2-int2F GGA CGG TGA CGG TAT TTG TC RvD2-int2R TCG CCA ACT TCT ATG GAC CT
RvD3		1.0	RvD3-intF ATC GAT CAG GTC GTC AAT GC RvD3-intR ACG CCA CCA TCA AGA TCC	RvD3-flank.F AAA CCA TGC AGC GTC TGC CA RvD3-flankR GCG TTT CTG CGT CTG GTT GA
RvD4*	PPE gene	0.8	RvD4-intF-PPE GGT TGC CAA CGT TAC CGA TGC RvD4-intR-PPE CCG GTG GTG GTG GCG GCT	ND ND
RvD5	<i>moa</i>	4.0	RvD5intF GGG TTC ACG TTC ATT ACT GTT C RvD5intR CCT GCG CTT ATC TCT AGC GG	RvD5-flankF CCC ATC GTG GTC GTT CAC C RvD5-flankR GTA CCC GCA CCA CCT GCT G
TbD1	<i>mmpL6</i>	2.1	TbD1intS.F CGT TCA ACC CCA AAC AGG TA TbD1intS.R AAT CGA ACT CGT GGA ACA CC	TbD1fla1-F CTA CCT CAT CTT CCG GTC CA TbD1fla1-R CAT AGA TCC CGG ACA TGG TG
<i>katG</i>, <i>gyrA</i>, <i>oxyR'</i>, <i>pncA</i> and <i>mmpL6</i> PCR and sequencing primers				
<i>katG</i> ⁴⁶³			<i>katG</i> -2154,225-PCR-F CTA CCA GCA CCG TCA TCT CA <i>katG</i> -2155,157-PCR-R AGG TCG TAT GGA CGAACA CC	<i>katG</i> -2154,872-SEQ-R ACA AGC TGA TCC ACC GAG AC
<i>gyrA</i> ⁹⁵			<i>gyrA</i> -7,127-PCR-F GTT CGT GTG TTG CGT CAA GT <i>gyrA</i> -8,312-PCR-R CAG CTG GGT GTG CTT GTA AA	<i>gyrA</i> -7,461F CGG GTG CTC TAT GCA ATG TT
<i>oxyR</i> ²⁸⁵			<i>oxyR</i> 2725,559F TAT GCG ATC AGG CGT ACT TG <i>oxyR</i> -2726,024-PCR-R CAA AGC AGT GGT TCA GCA GT	<i>oxyR</i> -2726,024-SEQ-R CAA AGC AGT GGT TCA GCA GT

Table 1 (continued)

	<i>pncA</i> -2288,678-PCR-F	<i>pncA</i> - 2289,319-SEQ-R
<i>pncA</i> ⁵⁷	ATC AGG AGC TGC AAA CCA AC	GGC GTC ATG GAC CCT ATA TC
	<i>pncA</i> - 2289,319-PCR-R	
	GGC GTC ATG GAC CCT ATA TC	
	<i>mmpL</i> -seq5F	<i>mmpL</i> -seq5F
<i>mmpL</i> ⁵⁵¹	GTA TCA GAG GGA CCG AGC AG	GTA TCA GAG GGA CCG AGC AG
	TBD1fla1-R	
	CAT AGA TCC CGG ACA TGG TG	

The RD nomenclature used in this table is based on that used by Brosch *et al.* (2000), (Ref. 25) and differs from that proposed by Behr and coworkers (1999), (Ref. 6). Primer sequences are shown in 5' → 3' direction.

* Regions where a second pair of internal primers was used rather than flanking primers, due to

5 flanking repetitive regions, and/or mobile genetic elements.

REFERENCES

1. Boddingtonhaus, B., Rogall, T., Flohr, T., Blocker, H. & Bottger, E. C. (1990) *J Clin Microbiol* **28**, 1751-9.
2. Sreevatsan, S., Pan, X., Stockbauer, K. E., Connell, N. D., Kreiswirth, B. N., Whittam, T. S. & Musser, J. M. (1997) *Proc Natl Acad Sci USA* **94**, 9869-74.
3. Stead, W. W., Eisenach, K. D., Cave, M. D., Beggs, M. L., Templeton, G. L., Thoen, C. O. & Bates, J. H. (1995) *Am J Respir Crit Care Med* **151**, 1267-8.
- 15 4. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., 3rd, Tekaiia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Barrell, B. G. & et al. (1998) *Nature* **393**, 537-44.
5. Gordon, S. V., Brosch, R., Billault, A., Garnier, T., Eiglmeier, K. & Cole, S. T.
- 20 (1999) *Mol Microbiol* **32**, 643-55.
6. Behr, M. A., Wilson, M. A., Gill, W. P., Salamon, H., Schoolnik, G. K., Rane, S. & Small, P. M. (1999) *Science* **284**, 1520-3.
7. Brosch, R., Philipp, W. J., Stavropoulos, E., Colston, M. J., Cole, S. T. & Gordon, S. V. (1999) *Infect Immun* **67**, 5768-74.

8. Kremer, K., van Soolingen, D., Frothingham, R., Haas, W. H., Hermans, P. W., Martin, C., Palittapongarnpim, P., Plikaytis, B. B., Riley, L. W., Yakrus, M. A., Musser, J. M. & van Embden, J. D. (1999) *J Clin Microbiol* **37**, 2607-18.
9. Supply, P., Lesjean, S., Savine, E., Kremer, K., van Soolingen, D., & Locht, C.
5 (2001) *J Clin Microbiol* **39**, 3563-71.
10. Van Soolingen, D., de Haas, P. E. W., Hermans, P. W. M. & van Embden, J. D. A. (1994) *Methods Enzymol* **235**, 196-205.
11. Heym, B., Honore, N., Truffot-Pernot, C., Banerjee, A., Schurra, C., Jacobs, W. R., Jr., van Embden, J. D., Grosset, J. H. & Cole, S. T. (1994) *Lancet* **344**, 293-8.
- 10 12. Scorpio, A., Collins, D., Whipple, D., Cave, D., Bates, J. & Zhang, Y. (1997) *J Clin Microbiol* **35**, 106-10.
13. Sreevatsan, S., Escalante, P., Pan, X., Gillies, D. A., 2nd, Siddiqui, S., Khalaf, C. N., Kreiswirth, B. N., Bifani, P., Adams, L. G., Ficht, T., Perumaalla, V. S., Cave, M. D., van Embden, J. D. & Musser, J. M. (1996) *J Clin Microbiol* **34**, 2007-10.
- 15 14. Van Embden, J. D., van Gorkom, T., Kremer, K., Jansen, R., van Der Zeijst, B. A. & Schouls, L. M. (2000) *J Bacteriol* **182**, 2393-401.
15. Van Soolingen, D., Hoogenboezem, T., de Haas, P. E., Hermans, P. W., Koedam, M. A., Teppema, K. S., Brennan, P. J., Besra, G. S., Portaels, F., Top, J., Schouls, L. M. & Van Embden, J. D. (1997) *Int J Syst Bacteriol* **47**, 1236-45.
- 20 16. Papa, F., Laszlo, A., David, H. L. & Daffe, M. (1989) *Acta Leprol* **7** (Suppl.) 98-101.
17. Wells, A. Q., (1937) *Lancet* 1221.
18. Van Soolingen, D., Van der Zanden, A. G., de Haas, P. E., Noordhoek, G. T., Kiers, A., Foudraïne, N. A., Portaels, F., Kolk, A. H., Kremer, K. & Van Embden, J. D. (1998) *J Clin Microbiol* **36**, 1840-5.
- 25 19. Brodin, P., *et al.* (2002) in preparation
20. Aranaz, A., Liebana, E., Gomez-Mampaso, E., Galan, J. C., Cousins, D., Ortega, A., Blazquez, J., Baquero, F., Mateos, A., Suarez, G. & Dominguez, L. (1999) *Int J Syst Bacteriol* **49**, 1263-73.
- 30 21. Van Soolingen, D., P.E.W. de Haas, J. Haagsma, T. Eger, P.W.M. Hermans, V. Ritacco, A. Alito, & J.D.A van Embden. (1994) *J. Clin. Microbiol.* **32**, 2425-33.
22. Samper, S., Martin, C., Pinedo, A., Rivero, A., Blazquez, J., Baquero, F., van Soolingen, D. & Van Embden, J. (1997) *Aids* **11**, 1237-42.
23. Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C. & Stover, C. K. (1996) *J Bacteriol* **178**, 1274-82.
- 35

24. Gordon, S. V., Eiglmeier, K., Garnier, T., Brosch, R., Parkhill, J., Barrell, B., Cole, S. T. & Hewinson, R. G. (2001) *Tuberculosis* **81**, 157-63.
25. Brosch, R., S. V. Gordon, K. Eiglmeier, T. Garnier, F. Tekaiia, E. Yeramian, & S. T. Cole. (1999) in *Molecular genetics of mycobacteria*, eds. Hatful G. F. & Jacobs, W. R. Jr. (American Society for Microbiology, Washington, D.C.), pp. 19-36.
- 5 26. Radhakrishnan, I., K. M. Y., Kumar, R. A. & Mundayoor, S. (2001) *J Clin Microbiol* **39**, 1683.
27. Fletcher, H. A., Donoghue, H. D., Holton, J., Pap, I. & Spigelman, M. (2002) *Am. J. Phys. Anthropol*, in press.
- 10 28. Mays, S., Taylor, G. M., Legge, A. J., Young, D. B. & Turner-Walker, G. (2001) *Am J Phys Anthropol* **114**, 298-311.
29. Nerlich, A. G., Haas, C. J., Zink, A., Szeimies, U. & Hagedorn, H. G. (1997) *Lancet* **350**, 1404.
30. Salo, W. L., Aufderheide, A. C., Buikstra, J. & Holcomb, T. A. (1994) *Proc Natl Acad Sci USA* **91**, 2091-4.
- 15 31. Rothschild, B. M., Martin, L. D., Lev, G., Bercovier, H., Bar-Gal, G. K., Greenblatt, C., Donoghue, H., Spigelman, M. & Brittain, D. (2001) *Clin Infect Dis* **33**, 305-11.
32. Parsons, L.M., Brosch, R., Cole, S. T., Somoskovi, A., Loder, A., Britzel, G., van Soolingen, D., Hale, Y., & Salfinger, M. (2001) in preparation

20

25

30

35

CLAIMS

1. An isolated or purified nucleic acid wherein said nucleic acid is selected from the group consisting of:
 - a. SEQ ID N°1;
 - b. Nucleic acid having a sequence fully complementary to SEQ ID N°1;
 - c. Nucleic acid having at least 90% sequence identity after optimal alignment with a sequence defined in a) or b);
 - d. Nucleic acid that hybridizes under stringent conditions with the nucleic acid defined in a) or b).
2. A nucleic acid fragment comprising at least 8 to 2000 consecutive nucleotides comprised in at least one nucleic acid according to claim 1.
3. The nucleic acid fragment according to claim 2, characterized in that it is susceptible to be used as a probe or a primer specific of SEQ ID N°1.
4. The nucleic acid fragment according to claim 2, selected from the group consisting of : SEQ ID N°17, SEQ ID N°18.
5. The nucleic acid fragment according to claim 2, characterized in that it is obtained by specific amplification of SEQ ID N°1 with the pair of primers SEQ ID N°17 and SEQ ID N°18.
6. The nucleic acid fragment according to claim 2 wherein said nucleic acid fragment is:
 - specifically deleted from the genome of *Mycobacterium tuberculosis*, excepted in *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; and,
 - present in the genome of *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*.
7. The nucleic acid fragment according to claim 2 or 6 selected from the group consisting of :

- a) SEQ ID N°4;
b) Nucleic acid having a sequence fully complementary to SEQ ID N°4;
c) Nucleic acid having at least 90% sequence identity after optimal alignment with a sequence defined in a) or b);
5 d) Nucleic acid that hybridizes under stringent conditions with the nucleic acid defined in a) or b).
8. A nucleic acid fragment comprising at least 8 to 2000 consecutive nucleotides of at least one nucleic acid according to claim 7.
- 10 9. The nucleic acid fragment according to claim 2 or 8, characterized in that it is susceptible to be used as a probe or a primer specific of SEQ ID N°1 and SEQ ID N°4.
- 15 10. The nucleic acid fragment according to claim 9, selected from the group consisting of : SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16.
- 20 11. A nucleic acid fragment according to claim 9, characterized in that is obtained by specific amplification of SEQ ID N°1 or SEQ ID N°4 with one pair of primers chosen in the group consisting of SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16.
- 25 12. The nucleic acid fragment according to claim 9, characterized in that it is obtained by specific amplification of SEQ ID N°1 or SEQ ID N°4 with the pair of primers SEQ ID N°13 and SEQ ID N°14.
- 30 13. The nucleic acid fragment according to claim 9, characterized in that it is obtained by specific amplification of SEQ ID N°1 or SEQ ID N°4 with the pair of primers SEQ ID N°15 and SEQ ID N°16.
14. The isolated or purified nucleic acid according to claim 1 wherein said nucleic acid comprises at least a deletion of a nucleic acid fragment according to any of claims 6, 7 and 8.

15. An isolated or purified polypeptide encoded by the nucleic acid according to any of claims 1, 2, 6, 7, 8 and 14.
- 5 16. The polypeptide according to claim 15 selected among polypeptides with sequence SEQ ID N°6, SEQ ID N°8, SEQ ID N°10, SEQ ID N°12, SEQ ID N°22 and fragments thereof.
17. An isolated or purified nucleic acid encoding a polypeptide according to claim 16.
- 10 18. The isolated or purified nucleic acid according to claim 17, wherein said nucleic acid is selected among :
- SEQ ID N°5 encoding the polypeptide of SEQ ID N°6;
 - SEQ ID N°7 encoding the polypeptide of SEQ ID N°8;
 - SEQ ID N°9 encoding the polypeptide of SEQ ID N°10;
 - 15 - SEQ ID N°11 encoding the polypeptide of SEQ ID N°12;
 - SEQ ID N°21 encoding the polypeptide of SEQ ID N°22;
- and fragments thereof.
19. A recombinant vector comprising a nucleic acid sequence selected among nucleic acids according to any of claims 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13 and 14.
- 20 20. The recombinant vector of claim 19 consisting of vector named X229 introduced into the recombinant *Escherichia coli* deposited at the CNCM on February 18th, 2002 under N° I-2799.
- 25 21. A recombinant cell comprising a nucleic acid sequence selected among nucleic acids according to any of claims 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13 and 14 or a vector according to claim 19 or 20.
- 30 22. The recombinant cell according to claim 21 consisting of the *Escherichia coli* deposited at the CNCM on February 18th, 2002 under N° I-2799.
23. A method for the discriminatory detection and identification of :

- *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; versus,
- *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium microti*,
5 *Mycobacterium bovis*, *Mycobacterium bovis BCG* in a biological sample,
comprising the following steps:
- a) isolation of the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample,
 - b) detection of the nucleic acid sequences of the mycobacterium present in said
10 biological sample,
 - c) analysis for the presence or the absence of a nucleic acid fragment according to any of claims 6, 7 and 8.
24. The method as claimed in claim 23, wherein the detection of the mycobacterial DNA
15 sequences is carried out using nucleotide sequences complementary to said DNA sequences.
25. The method as claimed in claim 23 or 24, wherein the detection of the mycobacterial DNA sequences is carried out by amplification of these sequences using primers.
20
26. The method as claimed in claim 25, wherein the primers have a nucleotide sequence chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18.
- 25 27. A method for the discriminatory detection and identification of :
- *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; versus,
- *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium microti*,
30 *Mycobacterium bovis*, *Mycobacterium bovis BCG* in a biological sample,
comprising the following steps:
- a) bringing the biological sample to be analyzed into contact with at least one pair of primers as defined in claim 25 or 26, the DNA contained in the sample having been, where appropriate, made accessible to the hybridization beforehand,
 - b) amplification of the DNA of the mycobacterium,
35

c) visualization of the amplification of the DNA fragments.

28. A kit for the discriminatory detection and identification of :

- *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome; versus,
- *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG* in a biological sample,

comprising the following elements:

- a) at least one pair of primers as defined in claim 25 or 26,
- b) the reagents necessary to carry out a DNA amplification reaction,
- c) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

29. The use of at least one pair of primers as defined in claim 25 or 26 for the amplification of a DNA sequence from *Mycobacterium tuberculosis*, *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis* or *Mycobacterium bovis BCG*.

30. The use of at least one pair of primers or at least one nucleic acid fragment according to any of claims 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 for the detection of a DNA sequence from *Mycobacterium tuberculosis*, *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis* or *Mycobacterium bovis BCG*.

31. A product of expression of all or part of the nucleic acid fragment as claimed in any of claims 6, 7 and 8.

32. A method for the *in vitro* discriminatory detection of antibodies directed against *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, versus antibodies directed against *Mycobacterium africanum*, *Mycobacterium canetti*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*, in a biological sample, comprising the following steps:

- a) bringing the biological sample into contact with at least one product as defined in claim 31,
- b) detecting the antigen-antibody complex formed.

5 33. A method for the *in vitro* discriminatory detection of a vaccination with *Mycobacterium bovis* BCG, an infection by *M. bovis*, *M. canettii*, *M. microti*, *M. africanum* or *M. tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome versus
10 an infection by *Mycobacterium tuberculosis*, excepted *Mycobacterium Tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a mammal, comprising the following steps :

- a) preparation of a biological sample containing cells, more particularly cells of the immune system of said mammal and more particularly T cells,
- 15 b) incubation of the biological sample of step a) with at least one product as defined in claim 31,
- c) detection of a cellular reaction indicating prior sensitization of the mammal to said product, in particular cell proliferation and/or synthesis of proteins such as gamma-interferon.

20

34. A kit for the *in vitro* discriminatory diagnosis of a vaccination with *M. bovis* BCG, an infection by *M. bovis*, *M. canettii*, *M. microti*, *M. africanum* versus an infection by *M. tuberculosis* excepted by strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in
25 a mammal comprising :

25

- a) a product as defined in claim 31,
- b) where appropriate, the reagents for the constitution of the medium suitable for the immunological reaction,
- c) the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction,
- 30 d) where appropriate, a reference biological sample (negative control) free of antibodies recognized by said product,
- e) where appropriate, a reference biological sample (positive control) containing a predetermined quantity of antibodies recognized by said product.

35

35. A mono- or polyclonal antibody, a chimeric fragment or a chimeric antibody thereof, characterized in that it is capable of specifically recognizing a product as defined in claim 31.

5

36. A method for the *in vitro* discriminatory detection of the presence of an antigen of *Mycobacterium tuberculosis* excepted of strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome versus an antigen of *Mycobacterium africanum*, *Mycobacterium canetti*,
10 *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG* or *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a biological sample comprising the following steps :

15

- a) bringing the biological sample into contact with an antibody as claimed in claim 35,
- b) detecting the antigen-antibody complex formed.

20

37. A kit for the *in vitro* discriminatory detection of the presence of an antigen of *Mycobacterium tuberculosis* excepted of strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome versus an antigen of *Mycobacterium africanum*, *Mycobacterium canetti*,
25 *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*, or *Mycobacterium tuberculosis* having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample comprising the following steps :

25

- a) an antibody as claimed in claim 35,
- b) the reagents for constituting the medium suitable for the immunological reaction,
- c) the reagents allowing the detection of the antigen-antibody complexes
30 produced by the immunological reaction.

30

38. An immunogenic composition, characterized in that it comprises at least one product as defined in claim 31.

39. A vaccine, characterized in that it comprises at least one product as defined in claim 31 in combination with a pharmaceutically compatible vehicle and, where appropriate, one or more appropriate immunity adjuvants.

5 40. An *in vitro* method for the detection and identification of *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a biological sample, comprising the following steps :

10 a) isolation of the DNA from the biological sample to be analyzed or production of a cDNA from the RNA of the biological sample,

b) detection of the nucleic acid sequences of the mycobacterium present in said biological sample,

c) analysis for the presence or the absence of a nucleic acid fragment according to any of claims 6, 7 and 8.

15

41. An *in vitro* method for the detection and identification of *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome in a biological sample, comprising the following steps:

20 a) bringing the biological sample to be analyzed into contact with at least one pair of primers selected among nucleic acids according to any of claims 1 to 14, 17 and 18, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18, the DNA contained in the sample having been, where

25 appropriate, made accessible to the hybridization beforehand,

b) amplification of the DNA of the mycobacterium,

c) visualization of the amplification of the DNA fragments.

30

42. A kit for the detection and identification of *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample, comprising the following elements :

a) at least one pair of primers selected among nucleic acids according to any of claims 1 to 14, 17 and 18, and more preferably selected among the primers

chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18,

- b) the reagents necessary to carry out a DNA amplification reaction,
- c) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

5

43. A method for the *in vitro* detection of antibodies directed against *Mycobacterium tuberculosis* excepted *Mycobacterium tuberculosis* strains having the sequence CTG at codon 463 of gene *katG* and having no or very few IS6110 sequences inserted in their genome, in a biological sample, comprising the following steps :

10

- a) bringing the biological sample into contact with at least one product as defined in claim 31,
- b) detecting the antigen-antibody complex formed.

15

44. Use of TbD1 deletion as a genetic marker for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.

45. Use of mmpL6⁵⁵¹ polymorphism as a genetic marker for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.

20

46. Use of the genetic marker according to claim 44 in association with at least one genetic markers selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, *katG*⁴⁶³, *gyrA*⁹⁵, *oxyR*²⁸⁵, *pncA*⁵⁷, mmpL6⁵⁵¹, the specific insertion element of *M. canettii* for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.

25

47. An *in vitro* method for the detection and identification of *Mycobacteria* from the *Mycobacterium* complex in a biological sample, comprising the following steps :

- c) analysis for the presence or the absence of a nucleic acid fragment of a sequence according to claim 6, 7, or 8, and
- d) analysis of at least one additional genetic marker selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, *katG*⁴⁶³, *gyrA*⁹⁵, *oxyR*²⁸⁵, *pncA*⁵⁷, mmpL6⁵⁵¹, the specific insertion element of *M. canettii*.

30

35

48. The *in vitro* method of claim 47 wherein two additional markers are used, preferably RD4 and RD9.
49. The *in vitro* method of claim 47 wherein three additional markers are used, preferably RD4, RD9 and RD12.
50. The method according to claim 47 wherein the analysis is performed by a technique selected among sequence hybridization, nucleic acid amplification, antigen-antibody complex.
51. A kit for the detection and identification of *Mycobacteria* from the *Mycobacterium* complex in a biological sample comprising the following elements :
- a) at least one pair of primers selected among nucleic acids according to any of claims 1 to 14, 17 and 18, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18,
 - b) at least one pair of primers specific of the genetic markers selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, *katG*⁴⁶³, *gyrA*⁹⁵, *oxyR*²⁸⁵, *pncA*⁵⁷, *mmpL6*⁵⁵¹, the specific insertion element of *M. canettii*
 - c) the reagents necessary to carry out a DNA amplification reaction,
 - d) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.
52. A kit according to claim 51 comprising the following elements :
- a) at least one pair of primers selected among nucleic acids according to any of claims 1 to 14, 17 and 18, and more preferably selected among the primers chosen from the group comprising SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°16, SEQ ID N°17, SEQ ID N°18,
 - b) one pair of primers specific of the genetic marker RD4,
 - c) one pair of primers specific of the genetic marker RD9,
 - d) the reagents necessary to carry out a DNA amplification reaction,
 - e) optionally, the necessary components which make it possible to verify or compare the sequence and/or the size of the amplified fragment.

53. An immunogenic composition, characterized in that it comprises the polypeptide of sequence SEQ ID N°22.
54. A vaccine, characterized in that it comprises the polypeptide of sequence SEQ ID N°22 in combination with a pharmaceutically compatible vehicle and, where appropriate, one or more appropriate immunity adjuvants.
55. Use of the genetic marker according to claim 45 in association with at least one genetic markers selected among RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD10, RD11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, TbD1, katG⁴⁶³, gyrA⁹⁵, oxyR²⁸⁵, pncA⁵⁷, the specific insertion element of *M. canettii* for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.
56. A nucleic acid specifically present in strains of *M. canettii* and absent from all other members of the *Mycobacterium* complex and having the sequence from position 399 to position 2378 of SEQ ID N°19.
57. Use of the nucleic acid according to claim 53 as a genetic marker for the differentiation of *Mycobacterium* strains of *Mycobacterium* complex.
58. A reagent for the identification of a *Mycobacterium* infection comprising at least polynucleotide sequences capable to hybridize under stringent conditions with at least 8 to 20 nucleotides of the RD1, RD4, RD9 and TbD1 genetic markers.
59. A reagent for the identification of a *Mycobacterium* infection comprising at least one polypeptide encoded by each of the RD1, RD4, RD9 and TbD1 genetic markers capable to react with an antibody or an immune serum raised against the same immunogenic molecules or fragments thereof.




FIGURE 1




FIGURE 2





FIGURE 3






Figure 5

6 / 6

gatcccgtcg	ccgcggcgct	ggagctggcc	gccggggccc	cagccgcccc	gcgcgaggtc	60
gtgctggcga	gcaaagccac	catgcgcgcc	acagccagcc	ccggatcgct	ggaccttgag	120
caacacgaac	tcgccaaacg	cttagaactt	gggcccgcagg	cgaaatcggt	ccagtcgccc	180
gagttcgccg	ctcgcttggc	tgccgctcaa	cacaggtagc	gcctaccagc	ctcgctgggt	240
tccatggcgt	gccccagtc	gaagctgctg	ctgcttgact	ccgcgcgctg	ggccccgagc	300
cgcgctgttg	tacggcccaa	acggcgctgc	ggtgtacagt	cgcgcgctcg	cggttcagt	360
ccggccccc	gactccggca	ggcccgaacg	cgcccagcgc	<u>tagcccgaag</u>	<u>ttcccccttg</u>	420
taggggccc	ctgagtttcg	atctgtttcg	tgagcaggtg	tttctgtgtt	caacttcct	480
caacatgtac	tcatgtatta	ttgagaatag	ctcggcgtgt	catcctctga	tgacgtatt	540
atcgcgctga	ccgcgtgtta	taaagtaatc	atgtacatta	ccgggttacc	caaccgggga	600
tccccgccgg	cggtgctgtt	gcggaagagc	ttccgcgaaa	acggcaaggt	caagacgcgt	660
accctggcca	acctctcacg	ctggcccag	cacaagctgg	acagactgga	ccgggcgctt	720
aagggcttgc	cgcccgcgga	ctgggatcta	gccgaggcct	tcgatatcac	ccgcagcctg	780
ccgcacgggc	atgtggccgc	ggtggccggc	accgccgaga	agctgggcat	acccgagctg	840
atcgacccca	ccccgtcgcg	gcgccgcaac	ctggtgctgg	ccatgctgat	cgggcagatc	900
atcgagcccg	gacgaaact	ggcgatcgcg	cgcgggctgc	gcgccagac	gccaccagc	960
acgctgggtg	cggtgctggg	tgtctcgggc	gccgatgagg	acgacctgta	tgacgcgatg	1020
gactgggcgc	tggagcgcaa	agacggcatc	gaaaacgcct	tggccgcacg	gcatctgacc	1080
aacggcaccc	tgggtgctcta	tgacgtatcc	tcggcgcgct	tcgagggcca	cacctgccc	1140
ctgggagcga	tcgggcacgc	ccgcgacggg	gtcaaaggcc	ggctgcagat	cgtctacggg	1200
ctgctgtgct	cacccaagg	agcgcgggtg	gccatcgagg	tgttcaagg	caacaccgcc	1260
gacccgaaaa	ctctgaaagc	tcaaatacgac	aagctcaaaa	cccggttcgg	gttgaccgcg	1320
atcgccctgg	tgggcgatcg	gggcatgctc	acttccgcgc	gcattcgtga	cgagctgcgt	1380
ccggcgccac	tggattggat	cagcgcgctg	cgcgccccgc	agatcaagat	cctgctcgag	1440
gacggggcgc	tgcagctgtc	gctgttcgat	gagcagaacc	tgttcgagat	cactcacc	1500
gactatcccc	gtgagcggct	ggtgtgctgc	cacaaccccg	ccctggccga	cgagcgcgcc	1560
cgcaaacgcg	ccgagctgct	ggcgccacc	gaaaaggagc	tgcaggccat	cgccgaagcc	1620
acccgccgcc	aacgccggcc	gttacgcggt	acagacaaga	tcggcctgcg	ggtgggcaag	1680
gtgcgcaaca	agttcaagat	ggccaagcac	tttgacctgc	acatcaccga	tgaggccttc	1740
agcttcaccc	gcaaccagaa	'cagtatcgcc	gccgaggccg	ccctcgacgg	catctacgtg	1800
ctacgcacca	gcctgcccga	caacgccttg	ggccgcgacg	acgtggtggg	ccgctacaaa	1860
gacctcgccg	acgtcgaaac	cttcttccgc	accctcaaca	gcgaactgga	cgtacgcccc	1920
atccggcate	ggctggccga	ccgggtccgc	gcccacatgt	tcttgacat	gctctcctac	1980
tacatcagct	ggcacatgaa	acaagccctg	gcccacatcc	tgttcaccga	caacgacaaa	2040
cccgcgcgcg	ccgccaaacg	cgccgacccc	gtcgcgccag	cccaacgctc	cgacgaagcg	2100
ctgaacaagg	cagcacgcaa	acgcaccgaa	gacaaccaac	cggtgcacag	cttcaccagc	2160
ctgctcaccg	acctggccac	catctgcgcc	aactacatcc	aacccacaga	cgacctgcca	2220
gcattcacca	aaaccaccac	ccccaccccc	acacaacggc	gcgccttcga	cctactggcc	2280
gtttcccacc	gccacggcct	ggcgtagtca	gtaccgaacc	acaaatgccc	aggtcaacga	2340
cacaaaccgc	gccggatcag	<u>ggggaacttc</u>	<u>gggctagccg</u>	ggcgcgccgg		2390

Figure 6

SEQUENCE LISTING

<110> INSTITUT PASTEUR
VETERINARY LABORATORIES AGENCY

<120> DELETED SEQUENCE IN M. TUBERCULOSIS, METHOD FOR
DETECTING MYCOBACTERIA USING THESE SEQUENCES AND
VACCINES

<130> D20110

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 3953

<212> DNA

<213> Mycobacterium tuberculosis strain 74 ("ancestral" strain)

<220>

<221> CDS

<222> (735)..(3638)

<400> 1

```

tccagcgcgg ccatcagcga tgaactctgg gacctgctac ccggctacct catcttccgg 60
tccatcatcc ccaaccggcc gccacccag gacacggtgc aagccctcgt cgacgacgtg 120
atactcccca gcctcaccgg atccaccggt tgagtcagcg gtgcgaatgg ctgggacaccg 180
ttgtggtgtc cgggtcccga ccgtactgtt gaatccgcgg atccccgcct gaggtacggg 240
gcgtgggtcgc gccccgggca atagcgtcgc cggttatcga aaggctaacg ggtgcagggg 300
atttcagtga ctggcctggt caaacgcggc tggatggtgc tggttgccgt ggcggtggtg 360
gcggtcgcgg gattcagcgt ctatcggttg cacggcatct tcggctcgca cgacaccacc 420
tcgaccgccc gtggtgtcgc gaacgacatc aagccgttca accccaaaca ggtaaccctc 480
gaggtctttg gcgctcccgg aaccgtggca acgatcaatt atctggacgt ggatgccaca 540
cctcggcaag tcctggacac gaccctgcgg tggtcataca cgatcacgac gaccctgccc 600
gcgggtcttcg ccaatgttgt cgcgcaaggc gacagcaatt ccatcggtg ccgcatcacc 660
gtcaacggtg tagtcaagga cgaaaggatc gtcaacgaag tgcgcgccta taccttctgc 720
ctcgacaagt cctc atg agc aac cac cac cgc ccg cgg cct tgg ttg ccg 770
          Met Ser Asn His His Arg Pro Arg Pro Trp Leu Pro
          1              5              10

cac acc atc cga cgg ctt tcg ttg ccg atc ttg ctg ttt tgg gtg ggt 818
His Thr Ile Arg Arg Leu Ser Leu Pro Ile Leu Leu Phe Trp Val Gly
          15              20              25

gtg gcc gcc ata acc aat gcc gcc gtg ccg caa ttg gag gtg gtc ggg 866
Val Ala Ala Ile Thr Asn Ala Ala Val Pro Gln Leu Glu Val Val Gly
          30              35              40

```

gag gcg cat aac gtc gca cag agc tcc ccg gat gac ccg tcg ctg cag	914
Glu Ala His Asn Val Ala Gln Ser Ser Pro Asp Asp Pro Ser Leu Gln	
45 50 55 60	
gcg atg aaa cgc atc ggc aag gtg ttc cac gag ttc gat tcc gac agt	962
Ala Met Lys Arg Ile Gly Lys Val Phe His Glu Phe Asp Ser Asp Ser	
65 70 75	
gcg gcc atg atc gtc ttg gaa ggc gat aag ccg ctc ggc aac gac gcc	1010
Ala Ala Met Ile Val Leu Glu Gly Asp Lys Pro Leu Gly Asn Asp Ala	
80 85 90	
cac cgg ttc tac gac acc ctg ctc cgc aac ctt tca aac gac acc aaa	1058
His Arg Phe Tyr Asp Thr Leu Arg Asn Leu Ser Asn Asp Thr Lys	
95 100 105	
cac gtc gag cac gtt cag gac ttc tgg ggc gat ccg ctg acc gcg gcc	1106
His Val Glu His Val Gln Asp Phe Trp Gly Asp Pro Leu Thr Ala Ala	
110 115 120	
ggc tcg caa agc acc gac ggc aaa gcc gcc tac gtt cag gtc tat ctc	1154
Gly Ser Gln Ser Thr Asp Gly Lys Ala Ala Tyr Val Gln Val Tyr Leu	
125 130 135 140	
gcc ggc aac caa ggc gag gcg ttg tca atc gag tcc gtc gac gcg gtg	1202
Ala Gly Asn Gln Gly Glu Ala Leu Ser Ile Glu Ser Val Asp Ala Val	
145 150 155	
cgc gac atc gtc gcc cat acg cca cca ccg gcc ggg gtc aag gcc tac	1250
Arg Asp Ile Val Ala His Thr Pro Pro Pro Ala Gly Val Lys Ala Tyr	
160 165 170	
gtc acc ggc gcg gcc ccg ctc atg gcc gat cag ttt cag gtg ggc agc	1298
Val Thr Gly Ala Ala Pro Leu Met Ala Asp Gln Phe Gln Val Gly Ser	
175 180 185	
aaa gga acc gcg aaa gtt acc' ggg ata act ctg gtt gtg atc gcg gtg	1346
Lys Gly Thr Ala Lys Val Thr Gly Ile Thr Leu Val Val Ile Ala Val	
190 195 200	
atg ttg ctc ttc gta tac cgt tcc gtc gtc acc atg gtc ctg gtg ctt	1394
Met Leu Leu Phe Val Tyr Arg Ser Val Val Thr Met Val Leu Val Leu	
205 210 215 220	
atc acg gtt ctt att gag ttg gcc gcg gcc cgc ggg atc gtc gct ttt	1442
Ile Thr Val Leu Ile Glu Leu Ala Ala Ala Arg Gly Ile Val Ala Phe	
225 230 235	
ctc gga aac gcc ggg gta atc ggg ctg tcg aca tac tcg acg aat ctg	1490
Leu Gly Asn Ala Gly Val Ile Gly Leu Ser Thr Tyr Ser Thr Asn Leu	
240 245 250	
ctc aca cta ttg gta atc gcg gcg ggc aca gac tac gcg att ttt gtc	1538
Leu Thr Leu Leu Val Ile Ala Ala Gly Thr Asp Tyr Ala Ile Phe Val	
255 260 265	
ctc ggc cgc tat cac gag gcg cgc tac gcc gca cag gat cgg gaa acg	1586
Leu Gly Arg Tyr His Glu Ala Arg Tyr Ala Ala Gln Asp Arg Glu Thr	
270 275 280	
gcc ttc tac acg atg tat cgc ggg acc gcc cac gtc gtc ttg ggc tcg	1634

Ala Phe Tyr Thr Met Tyr Arg Gly Thr Ala His Val Val Leu Gly Ser
 285 290 295 300
 ggt ctg acc gtt gcc ggc gcg gtg tat tgc ctg agc ttt acc cgg cta 1682
 Gly Leu Thr Val Ala Gly Ala Val Tyr Cys Leu Ser Phe Thr Arg Leu
 305 310 315
 ccc tat ttt caa agc ctg ggt att ccc gcc tcg ata ggg gtg atg att 1730
 Pro Tyr Phe Gln Ser Leu Gly Ile Pro Ala Ser Ile Gly Val Met Ile
 320 325 330
 gcg ttg gca gcc gcg ctc agc ctg gcc cca tcc gtg ctc atc ttg ggc 1778
 Ala Leu Ala Ala Ala Leu Ser Leu Ala Pro Ser Val Leu Ile Leu Gly
 335 340 345
 agt cgt ttc ggt tgt ttc gaa ccc aag cgc agg atg agg acc agg gga 1826
 Ser Arg Phe Gly Cys Phe Glu Pro Lys Arg Arg Met Arg Thr Arg Gly
 350 355 360
 tgg cgg cgc atc ggc acg gcc atc gtg cgt tgg ccg gga ccc atc ctg 1874
 Trp Arg Arg Ile Gly Thr Ala Ile Val Arg Trp Pro Gly Pro Ile Leu
 365 370 375 380
 gca gtg gcg tgc gca att gcg gtg gtg ggt ctg ctc gcg ctg ccg gga 1922
 Ala Val Ala Cys Ala Ile Ala Val Val Gly Leu Leu Ala Leu Pro Gly
 385 390 395
 tac aaa acg agc tac gac gct cgc tat tac atg ccc gcc acc gcc ccg 1970
 Tyr Lys Thr Ser Tyr Asp Ala Arg Tyr Tyr Met Pro Ala Thr Ala Pro
 400 405 410
 gcc aat att ggc tac atg gcc gcg gag cga cat ttt ccc caa gcg cgg 2018
 Ala Asn Ile Gly Tyr Met Ala Ala Glu Arg His Phe Pro Gln Ala Arg
 415 420 425
 ctg aat ccc gaa cta ctg atg atc gag acg gat cac gat atg cgc aat 2066
 Leu Asn Pro Glu Leu Leu Met Ile Glu Thr Asp His Asp Met Arg Asn
 430 435 440
 ccg gcc gac atg ctc atc ttg gat agg atc gcc aag gct gtc ttc cat 2114
 Pro Ala Asp Met Leu Ile Leu Asp Arg Ile Ala Lys Ala Val Phe His
 445 450 455 460
 ctg ccc ggc ata ggg ctg gtg cag gcc atg acc cgg ccg cta gga acc 2162
 Leu Pro Gly Ile Gly Leu Val Gln Ala Met Thr Arg Pro Leu Gly Thr
 465 470 475
 ccg att gac cac agc tcg ata ccg ttt cag atc agc atg caa agc gtc 2210
 Pro Ile Asp His Ser Ser Ile Pro Phe Gln Ile Ser Met Gln Ser Val
 480 485 490
 ggc cag att cag aat ctc aag tat cag agg gac cga gca gcc gac ttg 2258
 Gly Gln Ile Gln Asn Leu Lys Tyr Gln Arg Asp Arg Ala Ala Asp Leu
 495 500 505
 ctg aag cag gcc gaa gag ctg ggg aag acg atc gaa atc ttg cag cgc 2306
 Leu Lys Gln Ala Glu Glu Leu Gly Lys Thr Ile Glu Ile Leu Gln Arg
 510 515 520
 caa tat gcc cta cag cag gaa ctc gcg gcc gct act cac gag caa gcc 2354
 Gln Tyr Ala Leu Gln Gln Glu Leu Ala Ala Ala Thr His Glu Gln Ala

525	530	535	540	
gaa agc ttt cac caa acg atc gcc acg gta aac gaa ctg cga gat agg				2402
Glu Ser Phe His Gln Thr Ile Ala Thr Val Asn Glu Leu Arg Asp Arg				
	545	550	555	
atc gcc aat ttc gac gat ttc ttc agg ccg att cgt agt tac ttt tac				2450
Ile Ala Asn Phe Asp Asp Phe Phe Arg Pro Ile Arg Ser Tyr Phe Tyr				
	560	565	570	
tgg gaa aag cac tgc tac gat atc ccg agc tgc tgg gcg ctg aga tcc				2498
Trp Glu Lys His Cys Tyr Asp Ile Pro Ser Cys Trp Ala Leu Arg Ser				
	575	580	585	
gtc ttt gac acg atc gac ggt atc gac caa ctc ggc gag cag ctg gcc				2546
Val Phe Asp Thr Ile Asp Gly Ile Asp Gln Leu Gly Glu Gln Leu Ala				
	590	595	600	
agc gtg acc gta acc ttg gac aag ttg gct gcg atc cag cct caa ttg				2594
Ser Val Thr Val Thr Leu Asp Lys Leu Ala Ala Ile Gln Pro Gln Leu				
	605	610	615	620
gtg gcg ctg cta cca gac gag atc gcc agc cag cag atc aat cgg gaa				2642
Val Ala Leu Leu Pro Asp Glu Ile Ala Ser Gln Gln Ile Asn Arg Glu				
	625	630	635	
ctg gcg ctg gct aac tac gcc acc atg tcc ggg atc tat gcc cag acg				2690
Leu Ala Leu Ala Asn Tyr Ala Thr Met Ser Gly Ile Tyr Ala Gln Thr				
	640	645	650	
gcg gcc ttg atc gaa aac gct gcc gcc atg gga caa gcc ttt gac gcc				2738
Ala Ala Leu Ile Glu Asn Ala Ala Ala Met Gly Gln Ala Phe Asp Ala				
	655	660	665	
gcc aag aac gac gac tcc ttc tat ctg ccg ccg gag gct ttt gac aac				2786
Ala Lys Asn Asp Asp Ser Phe Tyr Leu Pro Pro Glu Ala Phe Asp Asn				
	670	675	680	
cca gat ttc cag cgc ggc ctg aaa ttg ttc ctg tcg gca gac ggt aag				2834
Pro Asp Phe Gln Arg Gly Leu Lys Leu Phe Leu Ser Ala Asp Gly Lys				
	685	690	695	700
gcg gct cgg atg atc atc tcc cat gaa ggc gat ccc gcc acc ccc gaa				2882
Ala Ala Arg Met Ile Ile Ser His Glu Gly Asp Pro Ala Thr Pro Glu				
	705	710	715	
ggc att tcg cat atc gac gcg atc aag cag gcg gcc cac gag gcc gtg				2930
Gly Ile Ser His Ile Asp Ala Ile Lys Gln Ala Ala His Glu Ala Val				
	720	725	730	
aag ggc act ccc atg gcg ggt gct ggg atc tat ctg gcc ggc acg gcc				2978
Lys Gly Thr Pro Met Ala Gly Ala Gly Ile Tyr Leu Ala Gly Thr Ala				
	735	740	745	
gcc acc ttc aag gac att caa gac ggc gcc acc tac gac ctc ctg atc				3026
Ala Thr Phe Lys Asp Ile Gln Asp Gly Ala Thr Tyr Asp Leu Leu Ile				
	750	755	760	
gcc gga ata gcc gcg ctg agc ttg att ttg ctc atc atg atg atc att				3074
Ala Gly Ile Ala Ala Leu Ser Leu Ile Leu Leu Ile Met Met Ile Ile				
	765	770	775	780

acc cga agc ctg gtt gcg gcg ctg gtg atc gtg ggc acg gtg gcg ctg 3122
 Thr Arg Ser Leu Val Ala Ala Leu Val Ile Val Gly Thr Val Ala Leu
 785 790 795

tcg ttg ggc gct tct ttt ggc ctg tcc gtg ctg gtg tgg cag cat ctt 3170
 Ser Leu Gly Ala Ser Phe Gly Leu Ser Val Leu Val Trp Gln His Leu
 800 805 810

ctc ggt atc cag ttg tac tgg atc gtg ctc gcg ctg gcc gtc atc ctg 3218
 Leu Gly Ile Gln Leu Tyr Trp Ile Val Leu Ala Leu Ala Val Ile Leu
 815 820 825

ctc ctg gcc gtg gga tcg gac tat aac ttg ctg ctg att tcc cga ttc 3266
 Leu Leu Ala Val Gly Ser Asp Tyr Asn Leu Leu Ile Ser Arg Phe
 830 835 840

aag gag gag atc ggt gca ggt ttg aac acc ggc atc atc cgt gcg atg 3314
 Lys Glu Glu Ile Gly Ala Gly Leu Asn Thr Gly Ile Ile Arg Ala Met
 845 850 855 860

gcc ggc acc ggc ggg gtg gtg acc gct gcc ggc ctg gtg ttc gcc gcc 3362
 Ala Gly Thr Gly Gly Val Val Thr Ala Ala Gly Leu Val Phe Ala Ala
 865 870 875

act atg tct tcg ttc gtg ttc agt gat ttg cgg gtc ctc ggt cag atc 3410
 Thr Met Ser Ser Phe Val Phe Ser Asp Leu Arg Val Leu Gly Gln Ile
 880 885 890

ggg acc acc att ggt ctt ggg ctg ctg ttc gac acg ctg gtg gtg cgc 3458
 Gly Thr Thr Ile Gly Leu Gly Leu Leu Phe Asp Thr Leu Val Val Arg
 895 900 905

gcg ttc atg acc ccg tcc atc gcg gtg ctg ctc ggg cgc tgg ttc tgg 3506
 Ala Phe Met Thr Pro Ser Ile Ala Val Leu Leu Gly Arg Trp Phe Trp
 910 915, 920

tgg ccg caa cga gtg cgc ccg cgc cct gcc agc agg atg ctt cgg ccg 3554
 Trp Pro Gln Arg Val Arg Pro Arg Pro Ala Ser Arg Met Leu Arg Pro
 925 930 935 940

tac ggc ccg cgg ccc gtg gtt cgt gaa ttg ctg ctg cgc gag ggc aac 3602
 Tyr Gly Pro Arg Pro Val Val Arg Glu Leu Leu Leu Arg Glu Gly Asn
 945 950 955

gat gac ccg aga act cag gtg gct acc cac cgt taa ggtggtggga 3648
 Asp Asp Pro Arg Thr Gln Val Ala Thr His Arg
 960 965

tgccgctttc aggggaatat gcgccgagcc cgctcgactg gtcgcgcgag caagccgaca 3708

cgtatatgaa gtccggcgga accgagggca cacagctgca gggaaagccg gtcatacctgc 3768

tcaccaccgt cggggcggaag accggcaaac tccgtaagac cccgctgatg cgcgtcgagc 3828

acgacggcca gtacgcgatc gtcgcctcgc tgggtggggc gccgaaaaat cgggtctggt 3888

accacaacgt cgtgaagaac ccacgggtcg agctgcagga cggcaccgga ccggcgacta 3948

cgacg 3953

<210> 2

<211> 967

<212> PRT

<213> Mycobacterium tuberculosis strain 74 ("ancestral" strain)

<220>

<223> mmpL6 protein

<400> 2

```

Met Ser Asn His His Arg Pro Arg Pro Trp Leu Pro His Thr Ile Arg
 1             5             10             15

Arg Leu Ser Leu Pro Ile Leu Leu Phe Trp Val Gly Val Ala Ala Ile
      20             25             30

Thr Asn Ala Ala Val Pro Gln Leu Glu Val Val Gly Glu Ala His Asn
      35             40             45

Val Ala Gln Ser Ser Pro Asp Asp Pro Ser Leu Gln Ala Met Lys Arg
      50             55             60

Ile Gly Lys Val Phe His Glu Phe Asp Ser Asp Ser Ala Ala Met Ile
      65             70             75             80

Val Leu Glu Gly Asp Lys Pro Leu Gly Asn Asp Ala His Arg Phe Tyr
      85             90             95

Asp Thr Leu Leu Arg Asn Leu Ser Asn Asp Thr Lys His Val Glu His
      100            105            110

Val Gln Asp Phe Trp Gly Asp Pro Leu Thr Ala Ala Gly Ser Gln Ser
      115            120            125

Thr Asp Gly Lys Ala Ala Tyr Val Gln Val Tyr Leu Ala Gly Asn Gln
      130            135            140

Gly Glu Ala Leu Ser Ile Glu Ser Val Asp Ala Val Arg Asp Ile Val
      145            150            155            160

Ala His Thr Pro Pro Pro Ala Gly Val Lys Ala Tyr Val Thr Gly Ala
      165            170            175

Ala Pro Leu Met Ala Asp Gln Phe Gln Val Gly Ser Lys Gly Thr Ala
      180            185            190

Lys Val Thr Gly Ile Thr Leu Val Val Ile Ala Val Met Leu Leu Phe
      195            200            205

Val Tyr Arg Ser Val Val Thr Met Val Leu Val Leu Ile Thr Val Leu
      210            215            220

Ile Glu Leu Ala Ala Ala Arg Gly Ile Val Ala Phe Leu Gly Asn Ala
      225            230            235            240

Gly Val Ile Gly Leu Ser Thr Tyr Ser Thr Asn Leu Leu Thr Leu Leu
      245            250            255

Val Ile Ala Ala Gly Thr Asp Tyr Ala Ile Phe Val Leu Gly Arg Tyr
      260            265            270

```

His Glu Ala Arg Tyr Ala Ala Gln Asp Arg Glu Thr Ala Phe Tyr Thr
 275 280 285
 Met Tyr Arg Gly Thr Ala His Val Val Leu Gly Ser Gly Leu Thr Val
 290 295 300
 Ala Gly Ala Val Tyr Cys Leu Ser Phe Thr Arg Leu Pro Tyr Phe Gln
 305 310 315 320
 Ser Leu Gly Ile Pro Ala Ser Ile Gly Val Met Ile Ala Leu Ala Ala
 325 330 335
 Ala Leu Ser Leu Ala Pro Ser Val Leu Ile Leu Gly Ser Arg Phe Gly
 340 345 350
 Cys Phe Glu Pro Lys Arg Arg Met Arg Thr Arg Gly Trp Arg Arg Ile
 355 360 365
 Gly Thr Ala Ile Val Arg Trp Pro Gly Pro Ile Leu Ala Val Ala Cys
 370 375 380
 Ala Ile Ala Val Val Gly Leu Leu Ala Leu Pro Gly Tyr Lys Thr Ser
 385 390 395 400
 Tyr Asp Ala Arg Tyr Tyr Met Pro Ala Thr Ala Pro Ala Asn Ile Gly
 405 410 415
 Tyr Met Ala Ala Glu Arg His Phe Pro Gln Ala Arg Leu Asn Pro Glu
 420 425 430
 Leu Leu Met Ile Glu Thr Asp His Asp Met Arg Asn Pro Ala Asp Met
 435 440 445
 Leu Ile Leu Asp Arg Ile Ala Lys Ala Val Phe His Leu Pro Gly Ile
 450 455 460
 Gly Leu Val Gln Ala Met Thr Arg Pro Leu Gly Thr Pro Ile Asp His
 465 470 475 480
 Ser Ser Ile Pro Phe Gln Ile Ser Met Gln Ser Val Gly Gln Ile Gln
 485 490 495
 Asn Leu Lys Tyr Gln Arg Asp Arg Ala Ala Asp Leu Leu Lys Gln Ala
 500 505 510
 Glu Glu Leu Gly Lys Thr Ile Glu Ile Leu Gln Arg Gln Tyr Ala Leu
 515 520 525
 Gln Gln Glu Leu Ala Ala Ala Thr His Glu Gln Ala Glu Ser Phe His
 530 535 540
 Gln Thr Ile Ala Thr Val Asn Glu Leu Arg Asp Arg Ile Ala Asn Phe
 545 550 555 560
 Asp Asp Phe Phe Arg Pro Ile Arg Ser Tyr Phe Tyr Trp Glu Lys His
 565 570 575
 Cys Tyr Asp Ile Pro Ser Cys Trp Ala Leu Arg Ser Val Phe Asp Thr
 580 585 590
 Ile Asp Gly Ile Asp Gln Leu Gly Glu Gln Leu Ala Ser Val Thr Val

595	600	605
Thr Leu Asp Lys Leu Ala Ala Ile Gln Pro Gln Leu Val Ala Leu Leu 610 615 620		
Pro Asp Glu Ile Ala Ser Gln Gln Ile Asn Arg Glu Leu Ala Leu Ala 625 630 635 640		
Asn Tyr Ala Thr Met Ser Gly Ile Tyr Ala Gln Thr Ala Ala Leu Ile 645 650 655		
Glu Asn Ala Ala Ala Met Gly Gln Ala Phe Asp Ala Ala Lys Asn Asp 660 665 670		
Asp Ser Phe Tyr Leu Pro Pro Glu Ala Phe Asp Asn Pro Asp Phe Gln 675 680 685		
Arg Gly Leu Lys Leu Phe Leu Ser Ala Asp Gly Lys Ala Ala Arg Met 690 695 700		
Ile Ile Ser His Glu Gly Asp Pro Ala Thr Pro Glu Gly Ile Ser His 705 710 715 720		
Ile Asp Ala Ile Lys Gln Ala Ala His Glu Ala Val Lys Gly Thr Pro 725 730 735		
Met Ala Gly Ala Gly Ile Tyr Leu Ala Gly Thr Ala Ala Thr Phe Lys 740 745 750		
Asp Ile Gln Asp Gly Ala Thr Tyr Asp Leu Leu Ile Ala Gly Ile Ala 755 760 765		
Ala Leu Ser Leu Ile Leu Leu Ile Met Met Ile Ile Thr Arg Ser Leu 770 775 780		
Val Ala Ala Leu Val Ile Val Gly Thr Val Ala Leu Ser Leu Gly Ala 785 790 795 800		
Ser Phe Gly Leu Ser Val Leu Val Trp Gln His Leu Leu Gly Ile Gln 805 810 815		
Leu Tyr Trp Ile Val Leu Ala Leu Ala Val Ile Leu Leu Leu Ala Val 820 825 830		
Gly Ser Asp Tyr Asn Leu Leu Leu Ile Ser Arg Phe Lys Glu Glu Ile 835 840 845		
Gly Ala Gly Leu Asn Thr Gly Ile Ile Arg Ala Met Ala Gly Thr Gly 850 855 860		
Gly Val Val Thr Ala Ala Gly Leu Val Phe Ala Ala Thr Met Ser Ser 865 870 875 880		
Phe Val Phe Ser Asp Leu Arg Val Leu Gly Gln Ile Gly Thr Thr Ile 885 890 895		
Gly Leu Gly Leu Leu Phe Asp Thr Leu Val Val Arg Ala Phe Met Thr 900 905 910		
Pro Ser Ile Ala Val Leu Leu Gly Arg Trp Phe Trp Trp Pro Gln Arg 915 920 925		

Val Arg Pro Arg Pro Ala Ser Arg Met Leu Arg Pro Tyr Gly Pro Arg
 930 935 940

Pro Val Val Arg Glu Leu Leu Leu Arg Glu Gly Asn Asp Asp Pro Arg
 945 950 955 960

Thr Gln Val Ala Thr His Arg
 965

<210> 3

<211> 148

<212> PRT

<213> Mycobacterium tuberculosis strain 74 ("ancestral" strain)

<220>

<223> mmpS6 protein

<400> 3

Val Gln Gly Ile Ser Val Thr Gly Leu Val Lys Arg Gly Trp Met Val
 1 5 10 15

Leu Val Ala Val Ala Val Val Ala Val Ala Gly Phe Ser Val Tyr Arg
 20 25 30

Leu His Gly Ile Phe Gly Ser His Asp Thr Thr Ser Thr Ala Gly Gly
 35 40 45

Val Ala Asn Asp Ile Lys Pro Phe Asn Pro Lys Gln Val Thr Leu Glu
 50 55 60

Val Phe Gly Ala Pro Gly Thr Val Ala Thr Ile Asn Tyr Leu Asp Val
 65 70 75 80

Asp Ala Thr Pro Arg Gln Val Leu Asp Thr Thr Leu Pro Trp Ser Tyr
 85 90 95

Thr Ile Thr Thr Thr Leu Pro Ala Val Phe Ala Asn Val Val Ala Gln
 100 105 110

Gly Asp Ser Asn Ser Ile Gly Cys Arg Ile Thr Val Asn Gly Val Val
 115 120 125

Lys Asp Glu Arg Ile Val Asn Glu Val Arg Ala Tyr Thr Phe Cys Leu
 130 135 140

Asp Lys Ser Ser
 145

<210> 4

<211> 2153

<212> DNA

<213> Mycobacterium tuberculosis strain 74 ("ancestral" strain)

<220>

<223> Sequence specifically deleted in "modern" strains of
 Mycobacterium tuberculosis

<400> 4

```

ctggttgccg tggcggtggt ggcggtcgcg ggattcagcg tctatcggtt gcacggcatc 60
ttcggtctcg acgacaccac ctcgaccgcc ggtggtgtcg cgaacgacat caagccgttc 120
aaccaccaaac aggtaacctt cgaggtcttt ggcgtctccg gaaccgtggc aacgatcaat 180
tatctggacg tggatgccac acctcggaac gtcctggaca cgacctgccc gtggtcatac 240
acgatcacga cgacctgcc cgtcaacggt gccaatgttg tcgcgcaagg cgacagcaat 300
tccatcggtt gccgcatcac cgtcaacggt gtagtcaagg acgaaaggat cgtcaacgaa 360
gtgcgcgcct atacctttctg cctcgacaag tctcatgag caaccaccac cgcccgcggc 420
cttgggttgcc gcacaccatc cgacggcttt cgttgccgat cttgctgttt tgggtgggtg 480
tggccgccat aaccaatgcc gccgtgccgc aattggaggt ggtcggggag gcgcataacg 540
tcgcacagag ctccccggat gaccgcgcgc tgcaggcgat gaaacgcac ggcaagggtg 600
tccacgagtt cgattccgac agtgcggcca tgatcgtctt ggaaggcgat aagccgctcg 660
gcaacgacgc ccaccggttc tacgacacc tgctccgcaa ctttcaaac gacaccaaac 720
acgtcgagca cgttcaggac ttctggggcg atccgctgac cgcgccgggc tcgcaaagca 780
ccgacggcaa agccgcctac gttcaggctc atctcgccgg caaccaaggc gaggcggtgt 840
caatcgagtc cgtcgagcgc gtgcgcgaca tcgtcgccca tacgccacca ccggcgggg 900
tcaaggccta cgtcacgggc ggcgccccgc tcatggccga tcagtttcag gtgggcagca 960
aaggaaaccgc gaaagttacc gggataactc tgggtgtgat cgcggtgatg ttgctcttcg 1020
tataccgttc cgtcgtcac atggtcctgg tgcctatcac ggttcttatt gatttggccg 1080
cggcccgcg gatcgctcgt tttctcgga acgccgggg aatcgggctg tcgacatact 1140
cgacgaatct gctcacacta ttggtaatcg cggcgggcac agactacgcg atttttgtcc 1200
tcggccgcta tcacgaggcg cgtacgcgc cacaggatcg ggaaacggcc ttctacacga 1260
tgtatcgcg gaccgcccac gtgctcttgg gctcggtct gaccgttgcc ggcgcggtgt 1320
attgcctgag ctttaccgg ctacctatt ttcaaagcct gggtattccc gcctcgatag 1380
gggtgatgat tgcgttggca gcgcgctca gcctggcccc atccgtgctc atcttgggca 1440
gtcgtttcgg ttgtttcgaa cccaagcgca ggatgaggac caggggatgg cggcgcatcg 1500
gcacggccat cgtgcgttgg ccgggacca tctggcagt ggcgtgcga attgcggtgg 1560
tgggtctgct cgcgtgcgc ggatacaaaa cgagctacga cgctcgctat tacatgcccg 1620
ccaccgcccc ggccaatatt ggctacatgg ccgcggagcg acattttccc caagcgcgcc 1680
tgaatcccg actactgat atcgagacgg atcacgatat gcgcaatccg gccgacatgc 1740
tcatcttgga taggatcgcc aaggctgtct tccatctgcc cggcataggg ctggtgcagg 1800
ccatgaccgg gccgctagga accccgattg accacagctc gataccgttt cagatcagca 1860
tgcaaagcgt cggccagatt cagaatctca agtatcagag ggaccgagca gccgacttgc 1920
tgaagcaggc cgaagagctg gggaagacga tcgaaatctt gcagcgccaa tatgccctac 1980
agcaggaact cgcggcgct actcacgagc aagccgaaa ctttcaccaa acgatcgcca 2040
cggtaaacga actgcgagat aggatcgcca atttcgacga tttcttcagg ccgattcgta 2100
gttactttta ctgggaaaag cactgctacg atatcccgag ctgctgggcg ctg 2153

```

<210> 5

<211> 2904

<212> DNA

<213> Mycobacterium complex

<220>

<223> mmpL6 coding sequence and protein

<220>

<221> CDS

<222> (1)..(2901)

<400> 5

```

atg agc aac cac cac cgc cgc cgg cct tgg ttg ccg cac acc atc cga 48
Met Ser Asn His His Arg Pro Arg Pro Trp Leu Pro His Thr Ile Arg
1 5 10 15

cgg ctt tcg ttg ccg atc ttg ctg ttt tgg gtg ggt gtg gcc gcc ata 96
Arg Leu Ser Leu Pro Ile Leu Leu Phe Trp Val Gly Val Ala Ala Ile
20 25 30

acc aat gcc gcc gtg ccg caa ttg gag gtg gtc ggg gag gcg cat aac 144

```

Thr Asn Ala Ala Val Pro Gln Leu Glu Val Val Gly Glu Ala His Asn
 35 40 45
 gtc gca cag agc tcc ccg gat gac ccg tcg ctg cag gcg atg aaa cgc 192
 Val Ala Gln Ser Ser Pro Asp Asp Pro Ser Leu Gln Ala Met Lys Arg
 50 55 60
 atc ggc aag gtg ttc cac gag ttc gat tcc gac agt gcg gcc atg atc 240
 Ile Gly Lys Val Phe His Glu Phe Asp Ser Asp Ser Ala Ala Met Ile
 65 70 75 80
 gtc ttg gaa ggc gat aag ccg ctc ggc aac gac gcc cac cgg ttc tac 288
 Val Leu Glu Gly Asp Lys Pro Leu Gly Asn Asp Ala His Arg Phe Tyr
 85 90 95
 gac acc ctg ctc cgc aac ctt tca aac gac acc aaa cac gtc gag cac 336
 Asp Thr Leu Leu Arg Asn Leu Ser Asn Asp Thr Lys His Val Glu His
 100 105 110
 gtt cag gac ttc tgg ggc gat ccg ctg acc gcg gcc ggc tcg caa agc 384
 Val Gln Asp Phe Trp Gly Asp Pro Leu Thr Ala Ala Gly Ser Gln Ser
 115 120 125
 acc gac ggc aaa gcc gcc tac gtt cag gtc tat ctc gcc ggc aac caa 432
 Thr Asp Gly Lys Ala Ala Tyr Val Gln Val Tyr Leu Ala Gly Asn Gln
 130 135 140
 ggc gag gcg ttg tca atc gag tcc gtc gac gcg gtg cgc gac atc gtc 480
 Gly Glu Ala Leu Ser Ile Glu Ser Val Asp Ala Val Arg Asp Ile Val
 145 150 155 160
 gcc cat acg cca cca ccg gcc ggg gtc aag gcc tac gtc acc ggc gcg 528
 Ala His Thr Pro Pro Pro Ala Gly Val Lys Ala Tyr Val Thr Gly Ala
 165 170 175
 gcc ccg ctc atg gcc gat cag ttt cag gtg ggc agc aaa gga acc gcg 576
 Ala Pro Leu Met Ala Asp Gln Phe Gln Val Gly Ser Lys Gly Thr Ala
 180 185 190
 aaa gtt acc ggg ata act ctg gtt gtg atc gcg gtg atg ttg ctc ttc 624
 Lys Val Thr Gly Ile Thr Leu Val Val Ile Ala Val Met Leu Leu Phe
 195 200 205
 gta tac cgt tcc gtc gtc acc atg gtc ctg gtg ctt atc acg gtt ctt 672
 Val Tyr Arg Ser Val Val Thr Met Val Leu Val Leu Ile Thr Val Leu
 210 215 220
 att gag ttg gcc gcg gcc cgc ggg atc gtc gct ttt ctc gga aac gcc 720
 Ile Glu Leu Ala Ala Ala Arg Gly Ile Val Ala Phe Leu Gly Asn Ala
 225 230 235 240
 ggg gta atc ggg ctg tcg aca tac tcg acg aat ctg ctc aca cta ttg 768
 Gly Val Ile Gly Leu Ser Thr Tyr Ser Thr Asn Leu Leu Thr Leu Leu
 245 250 255
 gta atc gcg gcg ggc aca gac tac gcg att ttt gtc ctc ggc cgc tat 816
 Val Ile Ala Ala Gly Thr Asp Tyr Ala Ile Phe Val Leu Gly Arg Tyr
 260 265 270
 cac gag gcg cgc tac gcc gca cag gat cgg gaa acg gcc ttc tac acg 864

His	Glu	Ala	Arg	Tyr	Ala	Ala	Gln	Asp	Arg	Glu	Thr	Ala	Phe	Tyr	Thr		
		275					280					285					
atg	tat	cgc	ggg	acc	gcc	cac	gtc	gtc	ttg	ggc	tcg	ggg	ctg	acc	gtt	912	
Met	Tyr	Arg	Gly	Thr	Ala	His	Val	Val	Leu	Gly	Ser	Gly	Leu	Thr	Val		
		290				295					300						
gcc	ggc	gcg	gtg	tat	tgc	ctg	agc	ttt	acc	cgg	cta	ccc	tat	ttt	caa	960	
Ala	Gly	Ala	Val	Tyr	Cys	Leu	Ser	Phe	Thr	Arg	Leu	Pro	Tyr	Phe	Gln		
		305			310					315					320		
agc	ctg	ggg	att	ccc	gcc	tcg	ata	ggg	gtg	atg	att	gcg	ttg	gca	gcc	1008	
Ser	Leu	Gly	Ile	Pro	Ala	Ser	Ile	Gly	Val	Met	Ile	Ala	Leu	Ala	Ala		
				325					330					335			
gcg	ctc	agc	ctg	gcc	cca	tcc	gtg	ctc	atc	ttg	ggc	agt	cgt	ttc	ggg	1056	
Ala	Leu	Ser	Leu	Ala	Pro	Ser	Val	Leu	Ile	Leu	Gly	Ser	Arg	Phe	Gly		
				340					345					350			
tgt	ttc	gaa	ccc	aag	cgc	agg	atg	agg	acc	agg	gga	tgg	cgg	cgc	atc	1104	
Cys	Phe	Glu	Pro	Lys	Arg	Arg	Met	Arg	Thr	Arg	Gly	Trp	Arg	Arg	Ile		
		355					360					365					
ggc	acg	gcc	atc	gtg	cgt	tgg	ccg	gga	ccc	atc	ctg	gca	gtg	gcg	tgc	1152	
Gly	Thr	Ala	Ile	Val	Arg	Trp	Pro	Gly	Pro	Ile	Leu	Ala	Val	Ala	Cys		
		370				375					380						
gca	att	gcg	gtg	gtg	ggg	ctg	ctc	gcg	ctg	ccg	gga	tac	aaa	acg	agc	1200	
Ala	Ile	Ala	Val	Val	Gly	Leu	Leu	Ala	Leu	Pro	Gly	Tyr	Lys	Thr	Ser		
		385			390					395					400		
tac	gac	gct	cgc	tat	tac	atg	ccc	gcc	acc	gcc	ccg	gcc	aat	att	ggc	1248	
Tyr	Asp	Ala	Arg	Tyr	Tyr	Met	Pro	Ala	Thr	Ala	Pro	Ala	Asn	Ile	Gly		
				405					410					415			
tac	atg	gcc	gcg	gag	cga	cat	ttt	ccc	caa	gcg	cgg	ctg	aat	ccc	gaa	1296	
Tyr	Met	Ala	Ala	Glu	Arg	His	Phe	Pro	Gln	Ala	Arg	Leu	Asn	Pro	Glu		
		420						425					430				
cta	ctg	atg	atc	gag	acg	gat	cac	gat	atg	cgc	aat	ccg	gcc	gac	atg	1344	
Leu	Leu	Met	Ile	Glu	Thr	Asp	His	Asp	Met	Arg	Asn	Pro	Ala	Asp	Met		
		435					440					445					
ctc	atc	ttg	gat	agg	atc	gcc	aag	gct	gtc	ttc	cat	ctg	ccc	ggc	ata	1392	
Leu	Ile	Leu	Asp	Arg	Ile	Ala	Lys	Ala	Val	Phe	His	Leu	Pro	Gly	Ile		
		450				455					460						
ggg	ctg	gtg	cag	gcc	atg	acc	cgg	ccg	cta	gga	acc	ccg	att	gac	cac	1440	
Gly	Leu	Val	Gln	Ala	Met	Thr	Arg	Pro	Leu	Gly	Thr	Pro	Ile	Asp	His		
		465			470				475					480			
agc	tcg	ata	ccg	ttt	cag	atc	agc	atg	caa	agc	gtc	ggc	cag	att	cag	1488	
Ser	Ser	Ile	Pro	Phe	Gln	Ile	Ser	Met	Gln	Ser	Val	Gly	Gln	Ile	Gln		
				485				490						495			
aat	ctc	aag	tat	cag	agg	gac	cga	gca	gcc	gac	ttg	ctg	aag	cag	gcc	1536	
Asn	Leu	Lys	Tyr	Gln	Arg	Asp	Arg	Ala	Ala	Asp	Leu	Leu	Lys	Gln	Ala		
		500						505					510				
gaa	gag	ctg	ggg	aag	acg	atc	gaa	atc	ttg	cag	cgc	caa	tat	gcc	cta	1584	

Glu Glu Leu Gly Lys Thr Ile Glu Ile Leu Gln Arg Gln Tyr Ala Leu
 515 520 525

cag cag gaa ctc gcg gcc gct act cac gag caa gcc gaa agc ttt cac 1632
 Gln Gln Glu Leu Ala Ala Ala Thr His Glu Gln Ala Glu Ser Phe His
 530 535 540

caa acg atc gcc acg gta aag gaa ctg cga gat agg atc gcc aat ttc 1680
 Gln Thr Ile Ala Thr Val Lys Glu Leu Arg Asp Arg Ile Ala Asn Phe
 545 550 555 560

gac gat ttc ttc agg ccg att cgt agt tac ttt tac tgg gaa aag cac 1728
 Asp Asp Phe Phe Arg Pro Ile Arg Ser Tyr Phe Tyr Trp Glu Lys His
 565 570 575

tgc tac gat atc ccg agc tgc tgg gcg ctg aga tcc gtc ttt gac acg 1776
 Cys Tyr Asp Ile Pro Ser Cys Trp Ala Leu Arg Ser Val Phe Asp Thr
 580 585 590

atc gac ggt atc gac caa ctc ggc gag cag ctg gcc agc gtg acc gta 1824
 Ile Asp Gly Ile Asp Gln Leu Gly Glu Gln Leu Ala Ser Val Thr Val
 595 600 605

acc ttg gac aag ttg gct gcg atc cag cct caa ttg gtg gcg ctg cta 1872
 Thr Leu Asp Lys Leu Ala Ala Ile Gln Pro Gln Val Ala Leu Leu
 610 615 620

cca gac gag atc gcc agc cag cag atc aat cgg gaa ctg gcg ctg gct 1920
 Pro Asp Glu Ile Ala Ser Gln Gln Ile Asn Arg Glu Leu Ala Leu Ala
 625 630 635 640

aac tac gcc acc atg tcc ggg atc tat gcc cag acg gcg gcc ttg atc 1968
 Asn Tyr Ala Thr Met Ser Gly Ile Tyr Ala Gln Thr Ala Ala Leu Ile
 645 650 655

gaa aac gct gcc gcc atg gga caa gcc ttt gac gcc gcc aag aac gac 2016
 Glu Asn Ala Ala Ala Met Gly Gln Ala Phe Asp Ala Ala Lys Asn Asp
 660 665 670

gac tcc ttc tat ctg ccg ccg gag gct ttt gac aac cca gat ttc cag 2064
 Asp Ser Phe Tyr Leu Pro Pro Glu Ala Phe Asp Asn Pro Asp Phe Gln
 675 680 685

cgc ggc ctg aaa ttg ttc ctg tgc gca gac ggt aag gcg gct cgg atg 2112
 Arg Gly Leu Lys Leu Phe Leu Ser Ala Asp Gly Lys Ala Ala Arg Met
 690 695 700

atc atc tcc cat gaa ggc gat ccc gcc acc ccc gaa ggc att tcg cat 2160
 Ile Ile Ser His Glu Gly Asp Pro Ala Thr Pro Glu Gly Ile Ser His
 705 710 715 720

atc gac gcg atc aag cag gcg gcc cac gag gcc gtg aag ggc act ccc 2208
 Ile Asp Ala Ile Lys Gln Ala Ala His Glu Ala Val Lys Gly Thr Pro
 725 730 735

atg gcg ggt gct ggg atc tat ctg gcc ggc acg gcc gcc acc ttc aag 2256
 Met Ala Gly Ala Gly Ile Tyr Leu Ala Gly Thr Ala Ala Thr Phe Lys
 740 745 750

gac att caa gac ggc gcc acc tac gac ctc ctg atc gcc gga ata gcc 2304
 Asp Ile Gln Asp Gly Ala Thr Tyr Asp Leu Leu Ile Ala Gly Ile Ala

755	760	765	
gcg ctg agc ttg att ttg ctc atc atg atg atc att acc cga agc ctg Ala Leu Ser Leu Ile Leu Leu Ile Met Met Ile Ile Thr Arg Ser Leu 770 775 780			2352
gtt gcg gcg ctg gtg atc gtg ggc acg gtg gcg ctg tcg ttg ggc gct Val Ala Ala Leu Val Ile Val Gly Thr Val Ala Leu Ser Leu Gly Ala 785 790 795 800			2400
tct ttt ggc ctg tcc gtg ctg gtg tgg cag cat ctt ctc ggt atc cag Ser Phe Gly Leu Ser Val Leu Val Trp Gln His Leu Leu Gly Ile Gln 805 810 815			2448
ttg tac tgg atc gtg ctc gcg ctg gcc gtc atc ctg ctc ctg gcc gtg Leu Tyr Trp Ile Val Leu Ala Leu Ala Val Ile Leu Leu Leu Ala Val 820 825 830			2496
gga tcg gac tat aac ttg ctg ctg att tcc cga ttc aag gag gag atc Gly Ser Asp Tyr Asn Leu Leu Leu Ile Ser Arg Phe Lys Glu Glu Ile 835 840 845			2544
ggt gca ggt ttg aac acc ggc atc atc cgt gcg atg gcc ggc acc ggc Gly Ala Gly Leu Asn Thr Gly Ile Ile Arg Ala Met Ala Gly Thr Gly 850 855 860			2592
ggg gtg gtg acc gct gcc ggc ctg gtg ttc gcc gcc act atg tct tcg Gly Val Val Thr Ala Ala Gly Leu Val Phe Ala Ala Thr Met Ser Ser 865 870 875 880			2640
ttc gtg ttc agt gat ttg cgg gtc ctc ggt cag atc ggg acc acc att Phe Val Phe Ser Asp Leu Arg Val Leu Gly Gln Ile Gly Thr Thr Ile 885 890 895			2688
ggt ctt ggg ctg ctg ttc gac acg ctg gtg gtg cgc gcg ttc atg acc Gly Leu Gly Leu Leu Phe Asp Thr Leu Val Val Arg Ala Phe Met Thr 900 905 910			2736
ccg tcc atc gcg gtg ctg ctc ggg cgc tgg ttc tgg tgg ccg caa cga Pro Ser Ile Ala Val Leu Leu Gly Arg Trp Phe Trp Trp Pro Gln Arg 915 920 925			2784
gtg cgc ccg cgc cct gcc agc agg atg ctt cgg ccg tac ggc ccg ccg Val Arg Pro Arg Pro Ala Ser Arg Met Leu Arg Pro Tyr Gly Pro Arg 930 935 940			2832
ccc gtg gtt cgt gaa ttg ctg ctg cgc gag ggc aac gat gac ccg aga Pro Val Val Arg Glu Leu Leu Leu Arg Glu Gly Asn Asp Asp Pro Arg 945 950 955 960			2880
act cag gtg gct acc cac cgt taa Thr Gln Val Ala Thr His Arg 965			2904

<210> 6

<211> 967

<212> PRT

<213> Mycobacterium complex

<220>

<223> mmpL6 protein

<400> 6

Met Ser Asn His His Arg Pro Arg Pro Trp Leu Pro His Thr Ile Arg
 1 5 10 15

Arg Leu Ser Leu Pro Ile Leu Leu Phe Trp Val Gly Val Ala Ala Ile
 20 25 30

Thr Asn Ala Ala Val Pro Gln Leu Glu Val Val Gly Glu Ala His Asn
 35 40 45

Val Ala Gln Ser Ser Pro Asp Asp Pro Ser Leu Gln Ala Met Lys Arg
 50 55 60

Ile Gly Lys Val Phe His Glu Phe Asp Ser Asp Ser Ala Ala Met Ile
 65 70 75 80

Val Leu Glu Gly Asp Lys Pro Leu Gly Asn Asp Ala His Arg Phe Tyr
 85 90 95

Asp Thr Leu Leu Arg Asn Leu Ser Asn Asp Thr Lys His Val Glu His
 100 105 110

Val Gln Asp Phe Trp Gly Asp Pro Leu Thr Ala Ala Gly Ser Gln Ser
 115 120 125

Thr Asp Gly Lys Ala Ala Tyr Val Gln Val Tyr Leu Ala Gly Asn Gln
 130 135 140

Gly Glu Ala Leu Ser Ile Glu Ser Val Asp Ala Val Arg Asp Ile Val
 145 150 155 160

Ala His Thr Pro Pro Pro Ala Gly Val Lys Ala Tyr Val Thr Gly Ala
 165 170 175

Ala Pro Leu Met Ala Asp Gln Phe Gln Val Gly Ser Lys Gly Thr Ala
 180 185 190

Lys Val Thr Gly Ile Thr Leu Val Val Ile Ala Val Met Leu Leu Phe
 195 200 205

Val Tyr Arg Ser Val Val Thr Met Val Leu Val Leu Ile Thr Val Leu
 210 215 220

Ile Glu Leu Ala Ala Ala Arg Gly Ile Val Ala Phe Leu Gly Asn Ala
 225 230 235 240

Gly Val Ile Gly Leu Ser Thr Tyr Ser Thr Asn Leu Leu Thr Leu Leu
 245 250 255

Val Ile Ala Ala Gly Thr Asp Tyr Ala Ile Phe Val Leu Gly Arg Tyr
 260 265 270

His Glu Ala Arg Tyr Ala Ala Gln Asp Arg Glu Thr Ala Phe Tyr Thr
 275 280 285

Met Tyr Arg Gly Thr Ala His Val Val Leu Gly Ser Gly Leu Thr Val
 290 295 300

Ala Gly Ala Val Tyr Cys Leu Ser Phe Thr Arg Leu Pro Tyr Phe Gln
 305 310 315 320
 Ser Leu Gly Ile Pro Ala Ser Ile Gly Val Met Ile Ala Leu Ala Ala
 325 330 335
 Ala Leu Ser Leu Ala Pro Ser Val Leu Ile Leu Gly Ser Arg Phe Gly
 340 345 350
 Cys Phe Glu Pro Lys Arg Arg Met Arg Thr Arg Gly Trp Arg Arg Ile
 355 360 365
 Gly Thr Ala Ile Val Arg Trp Pro Gly Pro Ile Leu Ala Val Ala Cys
 370 375 380
 Ala Ile Ala Val Val Gly Leu Leu Ala Leu Pro Gly Tyr Lys Thr Ser
 385 390 395 400
 Tyr Asp Ala Arg Tyr Tyr Met Pro Ala Thr Ala Pro Ala Asn Ile Gly
 405 410 415
 Tyr Met Ala Ala Glu Arg His Phe Pro Gln Ala Arg Leu Asn Pro Glu
 420 425 430
 Leu Leu Met Ile Glu Thr Asp His Asp Met Arg Asn Pro Ala Asp Met
 435 440 445
 Leu Ile Leu Asp Arg Ile Ala Lys Ala Val Phe His Leu Pro Gly Ile
 450 455 460
 Gly Leu Val Gln Ala Met Thr Arg Pro Leu Gly Thr Pro Ile Asp His
 465 470 475 480
 Ser Ser Ile Pro Phe Gln Ile Ser Met Gln Ser Val Gly Gln Ile Gln
 485 490 495
 Asn Leu Lys Tyr Gln Arg Asp Arg Ala Ala Asp Leu Leu Lys Gln Ala
 500 505 510
 Glu Glu Leu Gly Lys Thr Ile Glu Ile Leu Gln Arg Gln Tyr Ala Leu
 515 520 525
 Gln Gln Glu Leu Ala Ala Ala Thr His Glu Gln Ala Glu Ser Phe His
 530 535 540
 Gln Thr Ile Ala Thr Val Lys Glu Leu Arg Asp Arg Ile Ala Asn Phe
 545 550 555 560
 Asp Asp Phe Phe Arg Pro Ile Arg Ser Tyr Phe Tyr Trp Glu Lys His
 565 570 575
 Cys Tyr Asp Ile Pro Ser Cys Trp Ala Leu Arg Ser Val Phe Asp Thr
 580 585 590
 Ile Asp Gly Ile Asp Gln Leu Gly Glu Gln Leu Ala Ser Val Thr Val
 595 600 605
 Thr Leu Asp Lys Leu Ala Ala Ile Gln Pro Gln Leu Val Ala Leu Leu
 610 615 620
 Pro Asp Glu Ile Ala Ser Gln Gln Ile Asn Arg Glu Leu Ala Leu Ala

BNSDOCID: <WO_____03070981A2_I_>

945

950

955

960

Thr Gln Val Ala Thr His Arg
965

<210> 7

<211> 1758

<212> DNA

<213> Mycobacterium complex

<220>

<221> CDS

<222> (1)..(1758)

<220>

<223> mmpl6 truncated coding sequence and protein

<400> 7

atg agc aac cac cac cgc ccg cgg cct tgg ttg ccg cac acc atc cga 48
Met Ser Asn His His Arg Pro Arg Pro Trp Leu Pro His Thr Ile Arg
1 5 10 15

cgg ctt tcg ttg ccg atc ttg ctg ttt tgg gtg ggt gtg gcc gcc ata 96
Arg Leu Ser Leu Pro Ile Leu Leu Phe Trp Val Gly Val Ala Ala Ile
20 25 30

acc aat gcc gcc gtg ccg caa ttg gag gtg gtc ggg gag gcg cat aac 144
Thr Asn Ala Ala Val Pro Gln Leu Glu Val Val Gly Glu Ala His Asn
35 40 45

gtc gca cag agc tcc ccg gat gac ccg tcg ctg cag gcg atg aaa cgc 192
Val Ala Gln Ser Ser Pro Asp Asp Pro Ser Leu Gln Ala Met Lys Arg
50 55 60

atc ggc aag gtg ttc cac gag ttc gat tcc gac agt gcg gcc atg atc 240
Ile Gly Lys Val Phe His Glu Phe Asp Ser Asp Ser Ala Ala Met Ile
65 70 75 80

gtc ttg gaa ggc gat aag ccg ctc ggc aac gac gcc cac cgg ttc tac 288
Val Leu Glu Gly Asp Lys Pro Leu Gly Asn Asp Ala His Arg Phe Tyr
85 90 95

gac acc ctg ctc cgc aac ctt tca aac gac acc aaa cac gtc gag cac 336
Asp Thr Leu Leu Arg Asn Leu Ser Asn Asp Thr Lys His Val Glu His
100 105 110

gtt cag gac ttc tgg ggc gat ccg ctg acc gcg gcc ggc tcg caa agc 384
Val Gln Asp Phe Trp Gly Asp Pro Leu Thr Ala Ala Gly Ser Gln Ser
115 120 125

acc gac ggc aaa gcc gcc tac gtt cag gtc tat ctc gcc ggc aac caa 432
Thr Asp Gly Lys Ala Ala Tyr Val Gln Val Tyr Leu Ala Gly Asn Gln
130 135 140

ggc gag gcg ttg tca atc gag tcc gtc gac gcg gtg cgc gac atc gtc 480
Gly Glu Ala Leu Ser Ile Glu Ser Val Asp Ala Val Arg Asp Ile Val
145 150 155 160

gcc cat acg cca cca ccg gcc ggg gtc aag gcc tac gtc acc ggc gcg 528

Ala His Thr Pro Pro Pro Ala Gly Val Lys Ala Tyr Val Thr Gly Ala	165	170	175	
gcc ccg ctc atg gcc gat cag ttt cag gtg ggc agc aaa gga acc gcg				576
Ala Pro Leu Met Ala Asp Gln Phe Gln Val Gly Ser Lys Gly Thr Ala	180	185	190	
aaa gtt acc ggg ata act ctg gtt gtg atc gcg gtg atg ttg ctc ttc				624
Lys Val Thr Gly Ile Thr Leu Val Val Ile Ala Val Met Leu Leu Phe	195	200	205	
gta tac cgt tcc gtc gtc acc atg gtc ctg gtg ctt atc acg gtt ctt				672
Val Tyr Arg Ser Val Val Thr Met Val Leu Val Leu Ile Thr Val Leu	210	215	220	
att gag ttg gcc gcg gcc cgc ggg atc gtc gct ttt ctc gga aac gcc				720
Ile Glu Leu Ala Ala Ala Arg Gly Ile Val Ala Phe Leu Gly Asn Ala	225	230	235	240
ggg gta atc ggg ctg tcg aca tac tcg acg aat ctg ctc aca cta ttg				768
Gly Val Ile Gly Leu Ser Thr Tyr Ser Thr Asn Leu Leu Thr Leu Leu	245	250	255	
gta atc gcg gcg ggc aca gac tac gcg att ttt gtc ctc ggc cgc tat				816
Val Ile Ala Ala Gly Thr Asp Tyr Ala Ile Phe Val Leu Gly Arg Tyr	260	265	270	
cac gag gcg cgc tac gcc gca cag gat cgg gaa acg gcc ttc tac acg				864
His Glu Ala Arg Tyr Ala Ala Gln Asp Arg Glu Thr Ala Phe Tyr Thr	275	280	285	
atg tat cgc ggg acc gcc cac gtc gtc ttg ggc tcg ggt ctg acc gtt				912
Met Tyr Arg Gly Thr Ala His Val Val Leu Gly Ser Gly Leu Thr Val	290	295	300	
gcc ggc gcg gtg tat tgc ctg agc ttt acc cgg cta ccc tat ttt caa				960
Ala Gly Ala Val Tyr Cys Leu' Ser Phe Thr Arg Leu Pro Tyr Phe Gln	305	310	315	320
agc ctg ggt att ccc gcc tcg ata ggg gtg atg att gcg ttg gca gcc				1008
Ser Leu Gly Ile Pro Ala Ser Ile Gly Val Met Ile Ala Leu Ala Ala	325	330	335	
gcg ctc agc ctg gcc cca tcc gtg ctc atc ttg ggc agt cgt ttc ggt				1056
Ala Leu Ser Leu Ala Pro Ser Val Leu Ile Leu Gly Ser Arg Phe Gly	340	345	350	
tgt ttc gaa ccc aag cgc agg atg agg acc agg gga tgg cgg cgc atc				1104
Cys Phe Glu Pro Lys Arg Arg Met Arg Thr Arg Gly Trp Arg Arg Ile	355	360	365	
ggc acg gcc atc gtg cgt tgg ccg gga ccc atc ctg gca gtg gcg tgc				1152
Gly Thr Ala Ile Val Arg Trp Pro Gly Pro Ile Leu Ala Val Ala Cys	370	375	380	
gca att gcg gtg gtg ggt ctg ctc gcg ctg ccg gga tac aaa acg agc				1200
Ala Ile Ala Val Val Gly Leu Leu Ala Leu Pro Gly Tyr Lys Thr Ser	385	390	395	400
tac gac got cgc tat tac atg ccc gcc acc gcc ccg gcc aat att ggc				1248
Tyr Asp Ala Arg Tyr Tyr Met Pro Ala Thr Ala Pro Ala Asn Ile Gly				

405	410	415	
tac atg gcc gcg gag cga cat ttt ccc caa gcg cgg ctg aat ccc gaa			1296
Tyr Met Ala Ala Glu Arg His Phe Pro Gln Ala Arg Leu Asn Pro Glu			
420	425	430	
cta ctg atg atc gag acg gat cac gat atg cgc aat ccg gcc gac atg			1344
Leu Leu Met Ile Glu Thr Asp His Asp Met Arg Asn Pro Ala Asp Met			
435	440	445	
ctc atc ttg gat agg atc gcc aag gct gtc ttc cat ctg ccc ggc ata			1392
Leu Ile Leu Asp Arg Ile Ala Lys Ala Val Phe His Leu Pro Gly Ile			
450	455	460	
ggg ctg gtg cag gcc atg acc cgg ccg cta gga acc ccg att gac cac			1440
Gly Leu Val Gln Ala Met Thr Arg Pro Leu Gly Thr Pro Ile Asp His			
465	470	475	480
agc tcg ata ccg ttt cag atc agc atg caa agc gtc ggc cag att cag			1488
Ser Ser Ile Pro Phe Gln Ile Ser Met Gln Ser Val Gly Gln Ile Gln			
485	490	495	
aat ctc aag tat cag agg gac cga gca gcc gac ttg ctg aag cag gcc			1536
Asn Leu Lys Tyr Gln Arg Asp Arg Ala Ala Asp Leu Leu Lys Gln Ala			
500	505	510	
gaa gag ctg ggg aag acg atc gaa atc ttg cag cgc caa tat gcc cta			1584
Glu Glu Leu Gly Lys Thr Ile Glu Ile Leu Gln Arg Gln Tyr Ala Leu			
515	520	525	
cag cag gaa ctc gcg gcc gct act cac gag caa gcc gaa agc ttt cac			1632
Gln Gln Glu Leu Ala Ala Thr His Glu Gln Ala Glu Ser Phe His			
530	535	540	
caa acg atc gcc acg gta aag gaa ctg cga gat agg atc gcc aat ttc			1680
Gln Thr Ile Ala Thr Val Lys Glu Leu Arg Asp Arg Ile Ala Asn Phe			
545	550	555	560
gac gat ttc ttc agg ccg att cgt agt tac ttt tac tgg gaa aag cac			1728
Asp Asp Phe Phe Arg Pro Ile Arg Ser Tyr Phe Tyr Trp Glu Lys His			
565	570	575	
tgc tac gat atc ccg agc tgc tgg gcg ctg			1758
Cys Tyr Asp Ile Pro Ser Cys Trp Ala Leu			
580	585		

<210> 8

<211> 586

<212> PRT

<213> Mycobacterium complex

<220>

<223> mmpL6 truncated protein

<400> 8

Met	Ser	Asn	His	His	Arg	Pro	Arg	Pro	Trp	Leu	Pro	His	Thr	Ile	Arg
1				5					10					15	

Arg	Leu	Ser	Leu	Pro	Ile	Leu	Leu	Phe	Trp	Val	Gly	Val	Ala	Ala	Ile
	20							25					30		

Thr Asn Ala Ala Val Pro Gln Leu Glu Val Val Gly Glu Ala His Asn
 35 40 45
 Val Ala Gln Ser Ser Pro Asp Asp Pro Ser Leu Gln Ala Met Lys Arg
 50 55 60
 Ile Gly Lys Val Phe His Glu Phe Asp Ser Asp Ser Ala Ala Met Ile
 65 70 75 80
 Val Leu Glu Gly Asp Lys Pro Leu Gly Asn Asp Ala His Arg Phe Tyr
 85 90 95
 Asp Thr Leu Leu Arg Asn Leu Ser Asn Asp Thr Lys His Val Glu His
 100 105 110
 Val Gln Asp Phe Trp Gly Asp Pro Leu Thr Ala Ala Gly Ser Gln Ser
 115 120 125
 Thr Asp Gly Lys Ala Ala Tyr Val Gln Val Tyr Leu Ala Gly Asn Gln
 130 135 140
 Gly Glu Ala Leu Ser Ile Glu Ser Val Asp Ala Val Arg Asp Ile Val
 145 150 155 160
 Ala His Thr Pro Pro Pro Ala Gly Val Lys Ala Tyr Val Thr Gly Ala
 165 170 175
 Ala Pro Leu Met Ala Asp Gln Phe Gln Val Gly Ser Lys Gly Thr Ala
 180 185 190
 Lys Val Thr Gly Ile Thr Leu Val Val Ile Ala Val Met Leu Leu Phe
 195 200 205
 Val Tyr Arg Ser Val Val Thr Met Val Leu Val Leu Ile Thr Val Leu
 210 215 220
 Ile Glu Leu Ala Ala Ala Arg Gly Ile Val Ala Phe Leu Gly Asn Ala
 225 230 235 240
 Gly Val Ile Gly Leu Ser Thr Tyr Ser Thr Asn Leu Leu Thr Leu Leu
 245 250 255
 Val Ile Ala Ala Gly Thr Asp Tyr Ala Ile Phe Val Leu Gly Arg Tyr
 260 265 270
 His Glu Ala Arg Tyr Ala Ala Gln Asp Arg Glu Thr Ala Phe Tyr Thr
 275 280 285
 Met Tyr Arg Gly Thr Ala His Val Val Leu Gly Ser Gly Leu Thr Val
 290 295 300
 Ala Gly Ala Val Tyr Cys Leu Ser Phe Thr Arg Leu Pro Tyr Phe Gln
 305 310 315 320
 Ser Leu Gly Ile Pro Ala Ser Ile Gly Val Met Ile Ala Leu Ala Ala
 325 330 335
 Ala Leu Ser Leu Ala Pro Ser Val Leu Ile Leu Gly Ser Arg Phe Gly
 340 345 350

Cys Phe Glu Pro Lys Arg Arg Met Arg Thr Arg Gly Trp Arg Arg Ile
 355 360 365
 Gly Thr Ala Ile Val Arg Trp Pro Gly Pro Ile Leu Ala Val Ala Cys
 370 375 380
 Ala Ile Ala Val Val Gly Leu Leu Ala Leu Pro Gly Tyr Lys Thr Ser
 385 390 395 400
 Tyr Asp Ala Arg Tyr Tyr Met Pro Ala Thr Ala Pro Ala Asn Ile Gly
 405 410 415
 Tyr Met Ala Ala Glu Arg His Phe Pro Gln Ala Arg Leu Asn Pro Glu
 420 425 430
 Leu Leu Met Ile Glu Thr Asp His Asp Met Arg Asn Pro Ala Asp Met
 435 440 445
 Leu Ile Leu Asp Arg Ile Ala Lys Ala Val Phe His Leu Pro Gly Ile
 450 455 460
 Gly Leu Val Gln Ala Met Thr Arg Pro Leu Gly Thr Pro Ile Asp His
 465 470 475 480
 Ser Ser Ile Pro Phe Gln Ile Ser Met Gln Ser Val Gly Gln Ile Gln
 485 490 495
 Asn Leu Lys Tyr Gln Arg Asp Arg Ala Ala Asp Leu Leu Lys Gln Ala
 500 505 510
 Glu Glu Leu Gly Lys Thr Ile Glu Ile Leu Gln Arg Gln Tyr Ala Leu
 515 520 525
 Gln Gln Glu Leu Ala Ala Ala Thr His Glu Gln Ala Glu Ser Phe His
 530 535 540
 Gln Thr Ile Ala Thr Val Lys Glu Leu Arg Asp Arg Ile Ala Asn Phe
 545 550 555 560
 Asp Asp Phe Phe Arg Pro Ile Arg Ser Tyr Phe Tyr Trp Glu Lys His
 565 570 575
 Cys Tyr Asp Ile Pro Ser Cys Trp Ala Leu
 580 585

<210> 9

<211> 447

<212> DNA

<213> Mycobacterium complex

<220>

<221> CDS

<222> (1)..(444)

<220>

<223> mmmpS6 coding sequence and protein

<400> 9

gtg cag ggg att tca gtg act ggc ctg gtc aaa cgc ggc tgg atg gtg 48

```

Val Gln Gly Ile Ser Val Thr Gly Leu Val Lys Arg Gly Trp Met Val
  1              5              10              15

ctg gtt gcc gtg gcg gtg gtg gcg gtc gcg gga ttc agc gtc tat cgg      96
Leu Val Ala Val Ala Val Val Ala Val Ala Gly Phe Ser Val Tyr Arg
              20              25              30

ttg cac ggc atc ttc ggc tcg cac gac acc acc tcg acc gcc ggt ggt      144
Leu His Gly Ile Phe Gly Ser His Asp Thr Thr Ser Thr Ala Gly Gly
              35              40              45

gtc gcg aac gac atc aag ccg ttc aac ccc aaa cag gta acc ctc gag      192
Val Ala Asn Asp Ile Lys Pro Phe Asn Pro Lys Gln Val Thr Leu Glu
              50              55              60

gtc ttt ggc gct ccc gga acc gtg gca acg atc aat tat ctg gac gtg      240
Val Phe Gly Ala Pro Gly Thr Val Ala Thr Ile Asn Tyr Leu Asp Val
              65              70              75              80

gat gcc aca cct cgg caa gtc ctg gac acg acc ctg ccg tgg tca tac      288
Asp Ala Thr Pro Arg Gln Val Leu Asp Thr Thr Leu Pro Trp Ser Tyr
              85              90              95

acg atc acg acg acc ctg ccc gcg gtc ttc gcc aat gtt gtc gcg caa      336
Thr Ile Thr Thr Thr Leu Pro Ala Val Phe Ala Asn Val Val Ala Gln
              100              105              110

ggc gac agc aat tcc atc ggc tgc cgc atc acc gtc aac ggt gta gtc      384
Gly Asp Ser Asn Ser Ile Gly Cys Arg Ile Thr Val Asn Gly Val Val
              115              120              125

aag gac gaa agg atc gtc aac gaa gtg cgc gcc tat acc ttc tgc ctc      432
Lys Asp Glu Arg Ile Val Asn Glu Val Arg Ala Tyr Thr Phe Cys Leu
              130              135              140

gac aag tcc tca tga      447
Asp Lys Ser Ser
145

```

<210> 10

<211> 148

<212> PRT

<213> Mycobacterium complex

<220>

<223> mmpS6 protein

<400> 10

```

Val Gln Gly Ile Ser Val Thr Gly Leu Val Lys Arg Gly Trp Met Val
  1              5              10              15

```

```

Leu Val Ala Val Ala Val Val Ala Val Ala Gly Phe Ser Val Tyr Arg
              20              25              30

```

```

Leu His Gly Ile Phe Gly Ser His Asp Thr Thr Ser Thr Ala Gly Gly
              35              40              45

```

```

Val Ala Asn Asp Ile Lys Pro Phe Asn Pro Lys Gln Val Thr Leu Glu
              50              55              60

```

Val Phe Gly Ala Pro Gly Thr Val Ala Thr Ile Asn Tyr Leu Asp Val
 65 70 75 80

Asp Ala Thr Pro Arg Gln Val Leu Asp Thr Thr Leu Pro Trp Ser Tyr
 85 90 95

Thr Ile Thr Thr Thr Leu Pro Ala Val Phe Ala Asn Val Val Ala Gln
 100 105 110

Gly Asp Ser Asn Ser Ile Gly Cys Arg Ile Thr Val Asn Gly Val Val
 115 120 125

Lys Asp Glu Arg Ile Val Asn Glu Val Arg Ala Tyr Thr Phe Cys Leu
 130 135 140

Asp Lys Ser Ser
 145

<210> 11
 <211> 399
 <212> DNA
 <213> Mycobacterium complex

<220>
 <221> CDS
 <222> (1)..(399)

<220>
 <223> mmpS6 truncated coding sequence and protein

<400> 11
 ctg gtt gcc gtg gcg gtg gtg gcg gtc gcg gga ttc agc gtc tat cgg 48
 Leu Val Ala Val Ala Val Val Ala Val Ala Gly Phe Ser Val Tyr Arg
 1 5 10 15

ttg cac ggc atc ttc ggc tcg cac gac acc acc tcg acc gcc ggt ggt 96
 Leu His Gly Ile Phe Gly Ser His Asp Thr Thr Ser Thr Ala Gly Gly
 20 25 30

gtc gcg aac gac atc aag ccg ttc aac ccc aaa cag gta acc ctc gag 144
 Val Ala Asn Asp Ile Lys Pro Phe Asn Pro Lys Gln Val Thr Leu Glu
 35 40 45

gtc ttt ggc gct ccc gga acc gtg gca acg atc aat tat ctg gac gtg 192
 Val Phe Gly Ala Pro Gly Thr Val Ala Thr Ile Asn Tyr Leu Asp Val
 50 55 60

gat gcc aca cct cgg caa gtc ctg gac acg acc ctg ccg tgg tca tac 240
 Asp Ala Thr Pro Arg Gln Val Leu Asp Thr Thr Leu Pro Trp Ser Tyr
 65 70 75 80

acg atc acg acg acc ctg ccc gcg gtc ttc gcc aat gtt gtc gcg caa 288
 Thr Ile Thr Thr Thr Leu Pro Ala Val Phe Ala Asn Val Val Ala Gln
 85 90 95

ggc gac agc aat tcc atc ggc tgc cgc atc acc gtc aac ggt gta gtc 336
 Gly Asp Ser Asn Ser Ile Gly Cys Arg Ile Thr Val Asn Gly Val Val
 100 105 110

aag gac gaa agg atc gtc aac gaa gtg cgc gcc tat acc ttc tgc ctc 384
 Lys Asp Glu Arg Ile Val Asn Glu Val Arg Ala Tyr Thr Phe Cys Leu
 115 120 125

gac aag tcc tca tga 399
 Asp Lys Ser Ser
 130

<210> 12
 <211> 132
 <212> PRT
 <213> Mycobacterium complex

<220>
 <223> mmpS6 truncated protein

<400> 12
 Leu Val Ala Val Ala Val Val Ala Val Ala Gly Phe Ser Val Tyr Arg
 1 5 10 15

Leu His Gly Ile Phe Gly Ser His Asp Thr Thr Ser Thr Ala Gly Gly
 20 25 30

Val Ala Asn Asp Ile Lys Pro Phe Asn Pro Lys Gln Val Thr Leu Glu
 35 40 45

Val Phe Gly Ala Pro Gly Thr Val Ala Thr Ile Asn Tyr Leu Asp Val
 50 55 60

Asp Ala Thr Pro Arg Gln Val Leu Asp Thr Thr Leu Pro Trp Ser Tyr
 65 70 75 80

Thr Ile Thr Thr Thr Leu Pro Ala Val Phe Ala Asn Val Val Ala Gln
 85 90 95

Gly Asp Ser Asn Ser Ile Gly Cys Arg Ile Thr Val Asn Gly Val Val
 100 105 110

Lys Asp Glu Arg Ile Val Asn Glu Val Arg Ala Tyr Thr Phe Cys Leu
 115 120 125

Asp Lys Ser Ser
 130

<210> 13
 <211> 20
 <212> DNA
 <213> Mycobacterium complex

<400> 13 20
 cgttcaaccc caaacaggta

<210> 14
 <211> 20
 <212> DNA
 <213> Mycobacterium complex

<400> 14
aatcgaactc gtggaacacc 20

<210> 15
<211> 20
<212> DNA
<213> Mycobacterium complex

<400> 15
attcagcgtc tatcggttgc 20

<210> 16
<211> 20
<212> DNA
<213> Mycobacterium complex

<400> 16
agcagctcgg gatatcgtag 20

<210> 17
<211> 20
<212> DNA
<213> Mycobacterium complex

<400> 17
ctacctcatc ttccggtcca 20

<210> 18
<211> 20
<212> DNA
<213> Mycobacterium complex

<400> 18
catagatccc ggacatggtg 20

<210> 19
<211> 2390
<212> DNA
<213> Mycobacterium canettii

<220>
<221> CDS
<222> (517)..(2307)

<400> 19
gatcccgctc cgcgggcgct ggagctggcc gccgggccc cagccgcccc gcgcgaggtc 60
gtgctggcga gcaaagccac catgcgcgcc acagccagcc ccggatcgct ggaccttgag 120
caacacgaac tcgccaaacg cttagaactt gggccgcagg cgaaatcggt ccagtcgccc 180
gagttcgccg ctcgcttggc tgccgctcaa cacaggtagc gcctaccagc ctcgctggtt 240
tccatggcgt gccccagtc gaagctgctg ctgcttgact ccgcgcgctg ggccccgagcg 300
cgcgctgttg tacggcccaa acggcgtgtc ggtgtacagt cgcgcgctcg cggcttcagt 360

BNSDOCID: <WO 03070981A2.1>

gcc cgc gac ggg gtc aaa ggc cgg ctg cag atc gtc tac ggg ctg ctg	1206
Ala Arg Asp Gly Val Lys Gly Arg Leu Gln Ile Val Tyr Gly Leu Leu	
215 220 225 230	
tgc tca ccc aag gga gcg ccg gtg gcc atc gag gtg ttc aag ggc aac	1254
Cys Ser Pro Lys Gly Ala Pro Val Ala Ile Glu Val Phe Lys Gly Asn	
235 240 245	
acc gcc gac ccg aaa act ctg aaa gct caa atc gac aag ctc aaa acc	1302
Thr Ala Asp Pro Lys Thr Leu Lys Ala Gln Ile Asp Lys Leu Lys Thr	
250 255 260	
cgg ttc ggg ttg acc cgc atc gcc ctg gtg ggc gat cgg ggc atg ctc	1350
Arg Phe Gly Leu Thr Arg Ile Ala Leu Val Gly Asp Arg Gly Met Leu	
265 270 275	
act tcc gcg cgc atc cgt gac gag ctg cgt ccg gcg cac ctg gat tgg	1398
Thr Ser Ala Arg Ile Arg Asp Glu Leu Arg Pro Ala His Leu Asp Trp	
280 285 290	
atc agc gcg ctg cgc gcc ccg cag atc aag atc ctg ctc gag gac ggg	1446
Ile Ser Ala Leu Arg Ala Pro Gln Ile Lys Ile Leu Leu Glu Asp Gly	
295 300 305 310	
gcg ctg cag ctg tgc ctg ttc gat gag cag aac ctg ttc gag atc act	1494
Ala Leu Gln Leu Ser Leu Phe Asp Glu Gln Asn Leu Phe Glu Ile Thr	
315 320 325	
cac ccc gac tat ccc ggt gag cgg ctg gtg tgc tgc cac aac ccc gcc	1542
His Pro Asp Tyr Pro Gly Glu Arg Leu Val Cys Cys His Asn Pro Ala	
330 335 340	
ctg gcc gac gag cgc gcc cgc aaa cgc gcc gag ctg ctg gcg gcc acc	1590
Leu Ala Asp Glu Arg Ala Arg Lys Arg Ala Glu Leu Leu Ala Ala Thr	
345 350 355	
gaa aag gag ctg cag gcc atc gcc gaa gcc acc cgc cgc caa cgc cgg	1638
Glu Lys Glu Leu Gln Ala Ile Ala Glu Ala Thr Arg Arg Gln Arg Arg	
360 365 370	
ccg tta cgc ggt aca gac aag atc ggc ctg cgg gtg ggc aag gtg cgc	1686
Pro Leu Arg Gly Thr Asp Lys Ile Gly Leu Arg Val Gly Lys Val Arg	
375 380 385 390	
aac aag ttc aag atg gcc aag cac ttt gac ctg cac atc acc gat gag	1734
Asn Lys Phe Lys Met Ala Lys His Phe Asp Leu His Ile Thr Asp Glu	
395 400 405	
gcc ttc agc ttc acc cgc aac cag aac agt atc gcc gcc gag gcc gcc	1782
Ala Phe Ser Phe Thr Arg Asn Gln Asn Ser Ile Ala Ala Glu Ala Ala	
410 415 420	
ctc gac ggc atc tac gtg cta cgc acc agc ctg ccc gac aac gcc ctg	1830
Leu Asp Gly Ile Tyr Val Leu Arg Thr Ser Leu Pro Asp Asn Ala Leu	
425 430 435	
ggc cgc gac gac gtg gtg ggc cgc tac aaa gac ctc gcc gac gtc gaa	1878
Gly Arg Asp Asp Val Val Gly Arg Tyr Lys Asp Leu Ala Asp Val Glu	
440 445 450	
cgc ttc ttc cgc acc ctc aac agc gaa ctg gac gta cgc ccc atc cgg	1926

Arg Phe Phe Arg Thr Leu Asn Ser Glu Leu Asp Val Arg Pro Ile Arg
 455 460 465 470
 cat cgg ctg gcc gac cgg gtc cgc gcc cac atg ttc ttg cac atg ctc 1974
 His Arg Leu Ala Asp Arg Val Arg Ala His Met Phe Leu His Met Leu
 475 480 485
 tcc tac tac atc agc tgg cac atg aaa caa gcc ctg gcc cca atc ctg 2022
 Ser Tyr Tyr Ile Ser Trp His Met Lys Gln Ala Leu Ala Pro Ile Leu
 490 495 500
 ttc acc gac aac gac aaa ccc gcc gcc gcc gcc aaa cgc gcc gac ccc 2070
 Phe Thr Asp Asn Asp Lys Pro Ala Ala Ala Ala Lys Arg Ala Asp Pro
 505 510 515
 gtc gcg cca gcc caa cgc tcc gac gaa gcg ctg aac aag gca gca cgc 2118
 Val Ala Pro Ala Gln Arg Ser Asp Glu Ala Leu Asn Lys Ala Ala Arg
 520 525 530
 aaa cgc acc gaa gac aac caa ccg gtg cac agc ttc acc agc ctg ctc 2166
 Lys Arg Thr Glu Asp Asn Gln Pro Val His Ser Phe Thr Ser Leu Leu
 535 540 545 550
 acc gac ctg gcc acc atc tgc gcc aac tac atc caa ccc aca gac gac 2214
 Thr Asp Leu Ala Thr Ile Cys Ala Asn Tyr Ile Gln Pro Thr Asp Asp
 555 560 565
 ctg cca gca ttc acc aaa acc acc acc ccc acc ccc aca caa cgg cgc 2262
 Leu Pro Ala Phe Thr Lys Thr Thr Thr Pro Thr Pro Thr Gln Arg Arg
 570 575 580
 gcc ttc gac cta ctg gcc gtt tcc cac cgc cac ggc ctg gcg tag 2307
 Ala Phe Asp Leu Leu Ala Val Ser His Arg His Gly Leu Ala
 585 590 595
 tcagtaccga accacaaatg cccaggtcaa cgacacaaac cgcgccggat caggggggaac 2367
 ttcgggctag cggggcgcgc cgg 2390

<210> 20

<211> 596

<212> PRT

<213> Mycobacterium canettii

<400> 20

Val Ser Ser Ser Asp Asp Ala Ile Ile Ala Leu Thr Ala Cys Tyr Lys
 1 5 10 15

Val Ile Met Tyr Ile Thr Arg Val Pro Asn Arg Gly Ser Pro Pro Ala
 20 25 30

Val Leu Leu Arg Glu Ser Phe Arg Glu Asn Gly Lys Val Lys Thr Arg
 35 40 45

Thr Leu Ala Asn Leu Ser Arg Trp Pro Glu His Lys Leu Asp Arg Leu
 50 55 60

Asp Arg Ala Leu Lys Gly Leu Pro Pro Ala Asp Trp Asp Leu Ala Glu
 65 70 75 80

Ala Phe Asp Ile Thr Arg Ser Leu Pro His Gly His Val Ala Ala Val
 85 90 95
 Ala Gly Thr Ala Glu Lys Leu Gly Ile Pro Glu Leu Ile Asp Pro Thr
 100 105 110
 Pro Ser Arg Arg Arg Asn Leu Val Leu Ala Met Leu Ile Gly Gln Ile
 115 120 125
 Ile Glu Pro Gly Ser Lys Leu Ala Ile Ala Arg Gly Leu Arg Ala Gln
 130 135 140
 Thr Ala Thr Ser Thr Leu Gly Ala Val Leu Gly Val Ser Gly Ala Asp
 145 150 155 160
 Glu Asp Asp Leu Tyr Asp Ala Met Asp Trp Ala Leu Glu Arg Lys Asp
 165 170 175
 Gly Ile Glu Asn Ala Leu Ala Ala Arg His Leu Thr Asn Gly Thr Leu
 180 185 190
 Val Leu Tyr Asp Val Ser Ser Ala Ala Phe Glu Gly His Thr Cys Pro
 195 200 205
 Leu Gly Ala Ile Gly His Ala Arg Asp Gly Val Lys Gly Arg Leu Gln
 210 215 220
 Ile Val Tyr Gly Leu Leu Cys Ser Pro Lys Gly Ala Pro Val Ala Ile
 225 230 235 240
 Glu Val Phe Lys Gly Asn Thr Ala Asp Pro Lys Thr Leu Lys Ala Gln
 245 250 255
 Ile Asp Lys Leu Lys Thr Arg Phe Gly Leu Thr Arg Ile Ala Leu Val
 260 265 270
 Gly Asp Arg Gly Met Leu Thr Ser Ala Arg Ile Arg Asp Glu Leu Arg
 275 280 285
 Pro Ala His Leu Asp Trp Ile Ser Ala Leu Arg Ala Pro Gln Ile Lys
 290 295 300
 Ile Leu Leu Glu Asp Gly Ala Leu Gln Leu Ser Leu Phe Asp Glu Gln
 305 310 315 320
 Asn Leu Phe Glu Ile Thr His Pro Asp Tyr Pro Gly Glu Arg Leu Val
 325 330 335
 Cys Cys His Asn Pro Ala Leu Ala Asp Glu Arg Ala Arg Lys Arg Ala
 340 345 350
 Glu Leu Leu Ala Ala Thr Glu Lys Glu Leu Gln Ala Ile Ala Glu Ala
 355 360 365
 Thr Arg Arg Gln Arg Arg Pro Leu Arg Gly Thr Asp Lys Ile Gly Leu
 370 375 380
 Arg Val Gly Lys Val Arg Asn Lys Phe Lys Met Ala Lys His Phe Asp
 385 390 395 400
 Leu His Ile Thr Asp Glu Ala Phe Ser Phe Thr Arg Asn Gln Asn Ser

405 410 415
 Ile Ala Ala Glu Ala Ala Leu Asp Gly Ile Tyr Val Leu Arg Thr Ser
 420 425 430
 Leu Pro Asp Asn Ala Leu Gly Arg Asp Asp Val Val Gly Arg Tyr Lys
 435 440 445
 Asp Leu Ala Asp Val Glu Arg Phe Phe Arg Thr Leu Asn Ser Glu Leu
 450 455 460
 Asp Val Arg Pro Ile Arg His Arg Leu Ala Asp Arg Val Arg Ala His
 465 470 475 480
 Met Phe Leu His Met Leu Ser Tyr Tyr Ile Ser Trp His Met Lys Gln
 485 490 495
 Ala Leu Ala Pro Ile Leu Phe Thr Asp Asn Asp Lys Pro Ala Ala Ala
 500 505 510
 Ala Lys Arg Ala Asp Pro Val Ala Pro Ala Gln Arg Ser Asp Glu Ala
 515 520 525
 Leu Asn Lys Ala Ala Arg Lys Arg Thr Glu Asp Asn Gln Pro Val His
 530 535 540
 Ser Phe Thr Ser Leu Leu Thr Asp Leu Ala Thr Ile Cys Ala Asn Tyr
 545 550 555 560
 Ile Gln Pro Thr Asp Asp Leu Pro Ala Phe Thr Lys Thr Thr Thr Pro
 565 570 575
 Thr Pro Thr Gln Arg Arg Ala Phe Asp Leu Leu Ala Val Ser His Arg
 580 585 590
 His Gly Leu Ala
 595

<210> 21
 <211> 1191
 <212> DNA
 <213> Mycobacterium tuberculosis

<220>
 <221> CDS
 <222> (1)..(1191)
 <223> Fusion gene between mmpS6 and mmpL6 genes

<220>
 <221> misc_feature
 <222> (1) (1191)
 <223> CDS corresponds to fusion protein of rearranged forms
 of mmpS6 and mmpL6

<400> 1
 gtg cag ggg att tca gtg act ggc ctg gtc aaa cgc ggc tgg atg gtg 48
 Val Gln Gly Ile Ser Val Thr Gly Leu Val Lys Arg Gly Trp Met Val
 1 5 10 15
 aga tcc gtc ttt gac acg atc gac ggt atc gac caa ctc ggc gag cag 96

Arg	Ser	Val	Phe	Asp	Thr	Ile	Asp	Gly	Ile	Asp	Gln	Leu	Gly	Glu	Gln		
		20						25					30				
ctg	gcc	agc	gtg	acc	gta	acc	ttg	gac	aag	ttg	gct	gcg	atc	cag	cct	144	
Leu	Ala	Ser	Val	Thr	Val	Thr	Leu	Asp	Lys	Leu	Ala	Ala	Ile	Gln	Pro		
		35					40				45						
caa	ttg	gtg	gcg	ctg	cta	cca	gac	gag	atc	gcc	agc	cag	cag	atc	aat	192	
Gln	Leu	Val	Ala	Leu	Leu	Pro	Asp	Glu	Ile	Ala	Ser	Gln	Gln	Ile	Asn		
	50					55					60						
cgg	gaa	ctg	gcg	ctg	gct	aac	tac	gcc	acc	atg	tcc	ggg	atc	tat	gcc	240	
Arg	Glu	Leu	Ala	Leu	Ala	Asn	Tyr	Ala	Thr	Met	Ser	Gly	Ile	Tyr	Ala		
	65				70					75					80		
cag	acg	gcg	gcc	ttg	atc	gaa	aac	gct	gcc	gcc	atg	gga	caa	gcc	ttt	288	
Gln	Thr	Ala	Ala	Leu	Ile	Glu	Asn	Ala	Ala	Ala	Met	Gly	Gln	Ala	Phe		
				85				90						95			
gac	gcc	gcc	aag	aac	gac	gac	tcc	ttc	tat	ctg	ccg	ccg	gag	gct	ttt	336	
Asp	Ala	Ala	Lys	Asn	Asp	Asp	Ser	Phe	Tyr	Leu	Pro	Pro	Glu	Ala	Phe		
			100					105					110				
gac	aac	cca	gat	ttc	cag	cgc	ggc	ctg	aaa	ttg	ttc	ctg	tcg	gca	gac	384	
Asp	Asn	Pro	Asp	Phe	Gln	Arg	Gly	Leu	Lys	Leu	Phe	Leu	Ser	Ala	Asp		
		115					120					125					
ggc	aag	gcg	gct	cgg	atg	atc	atc	tcc	cat	gaa	ggc	gat	ccc	gcc	acc	432	
Gly	Lys	Ala	Ala	Arg	Met	Ile	Ile	Ser	His	Glu	Gly	Asp	Pro	Ala	Thr		
	130					135					140						
ccc	gaa	ggc	att	tcg	cat	atc	gac	gcg	atc	aag	cag	gcg	gcc	cac	gag	480	
Pro	Glu	Gly	Ile	Ser	His	Ile	Asp	Ala	Ile	Lys	Gln	Ala	Ala	His	Glu		
	145				150					155					160		
gcc	gtg	aag	ggc	act	ccc	atg	gcg	ggc	gct	ggg	atc	tat	ctg	gcc	ggc	528	
Ala	Val	Lys	Gly	Thr	Pro	Met	Ala	Gly	Ala	Gly	Ile	Tyr	Leu	Ala	Gly		
				165				170					175				
acg	gcc	gcc	acc	ttc	aag	gac	att	caa	gac	ggc	gcc	acc	tac	gac	ctc	576	
Thr	Ala	Ala	Thr	Phe	Lys	Asp	Ile	Gln	Asp	Gly	Ala	Thr	Tyr	Asp	Leu		
			180					185					190				
ctg	atc	gcc	gga	ata	gcc	gcg	ctg	agc	ttg	att	ttg	ctc	atc	atg	atg	624	
Leu	Ile	Ala	Gly	Ile	Ala	Ala	Leu	Ser	Leu	Ile	Leu	Leu	Ile	Met	Met		
		195					200					205					
atc	att	acc	cga	agc	ctg	gtt	gcg	gcg	ctg	gtg	atc	gtg	ggc	acg	gtg	672	
Ile	Ile	Thr	Arg	Ser	Leu	Val	Ala	Ala	Leu	Val	Ile	Val	Gly	Thr	Val		
	210					215					220						
gcg	ctg	tcg	ttg	ggc	gct	tct	ttt	ggc	ctg	tcc	gtg	ctg	gtg	tgg	cag	720	
Ala	Leu	Ser	Leu	Gly	Ala	Ser	Phe	Gly	Leu	Ser	Val	Leu	Val	Trp	Gln		
	225				230				235					240			
cat	ctt	ctc	ggc	atc	cag	ttg	tac	tgg	atc	gtg	ctc	gcg	ctg	gcc	gtc	768	
His	Leu	Leu	Gly	Ile	Gln	Leu	Tyr	Trp	Ile	Val	Leu	Ala	Leu	Ala	Val		
			245					250					255				
atc	ctg	ctc	ctg	gcc	gtg	gga	tcg	gac	tat	aac	ttg	ctg	ctg	att	tcc	816	

```

Ile Leu Leu Leu Ala Val Gly Ser Asp Tyr Asn Leu Leu Leu Ile Ser
      260                      265                      270

cga ttc aag gag gag atc ggt gca ggt ttg aac acc ggc atc atc cgt      864
Arg Phe Lys Glu Glu Ile Gly Ala Gly Leu Asn Thr Gly Ile Ile Arg
      275                      280                      285

gcg atg gcc ggc acc ggc ggg gtg gtg acc gct gcc ggc ctg gtg ttc      912
Ala Met Ala Gly Thr Gly Gly Val Val Thr Ala Ala Gly Leu Val Phe
      290                      295                      300

gcc gcc act atg tct tct ttc gtg ttc agt gat ttg cgg gtc ctc ggt      960
Ala Ala Thr Met Ser Ser Phe Val Phe Ser Asp Leu Arg Val Leu Gly
      305                      310                      315                      320

cag atc ggg acc acc att ggt ctt ggg ctg ctg ttc gac acg ctg gtg      1008
Gln Ile Gly Thr Thr Ile Gly Leu Gly Leu Leu Phe Asp Thr Leu Val
      325                      330                      335

gtg cgc gcg ttc atg acc ccg tcc atc gcg gtg ctg ctc ggg cgc tgg      1056
Val Arg Ala Phe Met Thr Pro Ser Ile Ala Val Leu Leu Gly Arg Trp
      340                      345                      350

ttc tgg tgg ccg caa cga gtg cgc ccg cgc cct gcc agc agg atg ctt      1104
Phe Trp Trp Pro Gln Arg Val Arg Pro Arg Pro Ala Ser Arg Met Leu
      355                      360                      365

cgg ccg tac ggc ccg ccg ccc gtg gtt cgt gaa ttg ctg ctg cgc gag      1152
Arg Pro Tyr Gly Pro Arg Pro Val Val Arg Glu Leu Leu Leu Arg Glu
      370                      375                      380

ggc aac gat gac ccg aga act cag gtg gct acc cac cgt      1191
Gly Asn Asp Asp Pro Arg Thr Gln Val Ala Thr His Arg
      385                      390                      395

```

<210> 22

<211> 397

<212> PRT

<213> Mycobacterium tuberculosis

<220>

<223> Fusion protein of rearranged forms of mmpS6 and mmpL6

<400> 2

```

Val Gln Gly Ile Ser Val Thr Gly Leu Val Lys Arg Gly Trp Met Val
  1                      5                      10                      15

```

```

Arg Ser Val Phe Asp Thr Ile Asp Gly Ile Asp Gln Leu Gly Glu Gln
      20                      25                      30

```

```

Leu Ala Ser Val Thr Val Thr Leu Asp Lys Leu Ala Ala Ile Gln Pro
      35                      40                      45

```

```

Gln Leu Val Ala Leu Leu Pro Asp Glu Ile Ala Ser Gln Gln Ile Asn
      50                      55                      60

```

```

Arg Glu Leu Ala Leu Ala Asn Tyr Ala Thr Met Ser Gly Ile Tyr Ala
      65                      70                      75                      80

```

BNSDOCID: <WO_____03070981A2_1_>

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070981 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
C12R 1/32, C07K 16/12, 14/35, A61K 39/04, G01N
33/569, C12N 5/10, 15/70

Moleculai, re Bacterienne, 25-28, rue du Docteur Roux,
75724 Paris, Cedex 15 (FR).

(21) International Application Number: PCT/IB03/00986

(74) Agent: **MARTIN, Jean-Jacques**; Cabinet Regimbeau, 20,
rue de Chazelles, 75847 Paris, Cedex 17 (FR).

(22) International Filing Date: 25 February 2003 (25.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02290458.5 25 February 2002 (25.02.2002) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **INSTITUT PASTEUR** [FR/FR]; 25-28, rue du Docteur Roux,
F-75015 Paris (FR). **VETERINARY LABORATORIES AGENCY** [GB/GB]; New Ham, Addelstone KT15 3NB,
Surrey (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLE, Stewart**
[GB/FR]; c/o Institut Pasteur- Unite de Genetique Molec-
ulai, re Bacterienne, 25-28 rue du Docteur Roux, 75724
Paris Cedex 15 (FR). **BROSCH, Roland** [AT/FR]; c/o
Institut Pasteur- IP Paris, Unite d' Genetique, Moleculaire
Bacterienne, 25-28 rue du Docteur Roux, 75724 Paris
Cedex 15 (FR). **GORDON, Stephen** [IE/GB]; Glyn
Hewinson, Veterinary Laboratories Agency, Woodham
Lane, New Haw, Addelstone, Surrey KT15 3NB (GB).
EIGLMEIER, Karin [DE/FR]; c/o Institut Pasteur,
Unite de genetique Moleculaire Bacterienne, 25-28, rue du
Docteur Roux, 75724 Paris Cedex 15 (FR). **GARNIER,**
Thierry [FR/FR]; c/o Institut Pasteur- Unite de Genetique

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
4 December 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: SEQUENCES SPECIFICALLY DELETED MYCOBACTERIUM TUBERCULOSIS GENOME AND THEIR USE
IN DIAGNOSTICS AND AS VACCINES

(57) Abstract: The present invention is the identification of a nucleotide sequence which make it possible in particular to distinguish
an infection resulting from the vast majority of *Mycobacterium tuberculosis strains* from an infection resulting from *Mycobacterium*
africanum, *Mycobacterium canetti*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*. The subject of the
present invention is also a method for detecting the sequences in question by the products of expression of these sequences and the
kits for carrying out these methods. Finally, the subject of the present invention is novel vaccines.

WO 03/070981 A3

INTERNATIONAL SEARCH REPORT

Internat application No
PCT/IB 03/00986

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68 C12R1/32 C07K16/12 C07K14/35 A61K39/04
G01N33/569 C12N5/10 C12N15/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, MEDLINE, EMBL, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	COLE S T ET AL: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 393, 11 June 1998 (1998-06-11), pages 537-544, XP002087941 ISSN: 0028-0836 figure 1 table 1	1-5,9, 15-19, 21,29, 30,42, 51-53
X	& DATABASE GENBANK 'Online! NCBI; 7 September 2001 (2001-09-07) COLE S.T. ET AL.: "Mycobacterium tuberculosis H37Rv complete genome." retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. NC_000962 the whole document --- -/-	1-5,9, 15-19, 21,29, 30,42, 51-53

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

10 October 2003

Date of mailing of the international search report

16/10/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ulbrecht, M

INTERNATIONAL SEARCH REPORT

 Internati Application No
 PCT/IB 03/00986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE GENBANK 'Online! NCBI; 3 August 2001 (2001-08-03) COLE S.T. ET AL.: "Mycobacterium tuberculosis H37Rv complete genome; segment 69/162" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. Z74020 XP002206252 the whole document	1-5,9, 15-19, 21,29, 30,42, 51-53
A	WO 00 55362 A (BILLAULT ALAIN ;COLE STEWART (FR); GARNIER THIERRY (FR); GORDON ST) 21 September 2000 (2000-09-21) page 5, line 9 -page 17, line 21 page 22, line 15 -page 32, line 3 figure 1D tables 1-3 claims 3,6,14	46-52, 55,58,59
A	US 6 291 190 B1 (BEHR MARCEL ET AL) 18 September 2001 (2001-09-18) column 11, line 66 -column 18, line 58 table 1	46-52, 55,58,59
A	MAHAIRAS G G ET AL: "MOLECULAR ANALYSIS OF GENETIC DIFFERENCES BETWEEN MYCOBACTERIUM BOVIS BCG AND VIRULENT M. BOVIS" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 178, no. 5, 1 March 1996 (1996-03-01), pages 1274-1282, XP000647583 ISSN: 0021-9193 cited in the application figure 2	46-52, 55,58,59
A	GORDON S V ET AL: "IDENTIFICATION OF VARIABLE REGIONS IN THE GENOMES OF TUBERCLE BACILI USING BACTERIAL ARTIFICIAL CHROMOSOME ARRAYS" MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 32, no. 3, May 1999 (1999-05), pages 643-655, XP000933429 ISSN: 0950-382X cited in the application tables 1-3	46-52, 55,58,59

-/--

INTERNATIONAL SEARCH REPORT

Internal application No
PCT/IB 03/00986

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE TAXONOMY BROWSER 'Online! NCBI; Host: http://www.ncbi.nih.gov, "Mycobacterium tuberculosis complex" XP002206354 Link: http://www.ncbi.nlm.nih.gov/Taxonomy/Browse/r/wwwtax.cgi?id=77643 Retrieved on: 16.07.2001 the whole document</p>	45-47, 51,55
A	<p>SREEVATSAN SRINAND ET AL: "Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 18, 1997, pages 9869-9874, XP002206250 1997 ISSN: 0027-8424 page 9870, left-hand column table 1 figure 1</p>	46-51,55
T	<p>BROSCH R ET AL: "A new evolutionary scenario for the Mycobacterium tuberculosis complex." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 6, 19 March 2002 (2002-03-19), pages 3684-3689, XP002206251 http://www.pnas.org March 19, 2002 ISSN: 0027-8424 the whole document</p>	1-56,58, 59
T	<p>-& DATABASE GENBANK 'Online! NCBI; 16 March 2002 (2002-03-16) BROSCH R ET AL.: "Mycobacterium tuberculosis mmpS6 gene and mmpL6 gene" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV, accession no. AJ426486 XP002251350 the whole document</p>	1-56,58, 59

INTERNATIONAL SEARCH REPORT

Int

International application No.
PCT/IB 03/00986**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 6, 27-29, 51, 52, 58-59 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 6,27-29,51,52,58-59 (partially)

Present claims 6, 27-29, 51, 52, 58 and 59 relate to products defined by reference to a desirable characteristic or property, namely

- a fragment specifically deleted in certain M. tuberculosis strains (claim 6),
- primers defined by reference to claim 25 which relates to a method wherein primers able of amplifying a genomic region harbouring the TbD1 deletion are used (claims 27-29)
- primers specific for various genetic markers (claim 51(b) and claim 52 (b) and (c))
- polynucleotide sequences capable to hybridise with the genetic the RD1, RD4, RD9 and TbD1 genetic markers (claim 58)
- a polypeptide encoded by each of the RD1, RD4, RD9 and TbD1 genetic markers capable to react with an antibody/immune serum raised against the same immunogenic molecules or fragments thereof (claim 59).

The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Art. 6 PCT and is reproducible within the meaning of Art. 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Art. 6 PCT). An attempt is made to define the products by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to

- a nucleic acid as defined by SEQ ID Nos. 4 and 13-16 or their complementary sequences, which nucleic acid is deleted in certain M. tuberculosis strains, but present in other Mycobacteria of the Mycobacterium tuberculosis complex (claim 6)
- the sequences defined in claim 26 (claims 27-29)
- the primer pairs specific for RD4 and RD9 as given by Table 1 (claim 52)
- the oligonucleotide probes/primers specific for RD1, RD4 or RD9 as represented in Table 1, or specific for TbD1 as defined by claim 7 (claim 58)
- the polypeptides as defined by claim 16 (claim 59).

As the polypeptides encoded by RD1, RD4 and RD9 referred to in claim 59 are not defined, they were not searched at all.

Additionally, claim 51 relates to an extremely large number of possible products. In fact, claim 51 contains so many options, variables and possible permutations that a lack of clarity and conciseness within the meaning of Art. 6 PCT arises to such an extent as to render a meaningful search of the claim impossible. Said claim relates to any combination of

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

primers defined in claims 1-14, 17 and 18 with at least one primer pair specific for 24 different genetic markers. Moreover, the primers are defined in terms of the result to be achieved, namely by their specificity for the said 24 different genetic markers (supra) (Art. 6 PCT).

Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely a kit as defined by claim 52, wherein the primer pairs specific for RD4 and RD5 are those given in Table 3.

The nucleic acid referred to in claim 57 is defined by reference to claim 53 which, however, does not relate to any nucleic acids. Claim 57 was thus interpreted as referring to claim 56 (Art. 6 PCT).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Internal application No
PCT/IB 03/00986

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0055362	A	21-09-2000	FR 2791067 A1	22-09-2000
			AU 3298900 A	04-10-2000
			CA 2368088 A1	21-09-2000
			EP 1161562 A1	12-12-2001
			WO 0055362 A1	21-09-2000
US 6291190	B1	18-09-2001	AU 5394699 A	14-03-2000
			EP 1108060 A1	20-06-2001
			WO 0011214 A1	02-03-2000
			US 2002176873 A1	28-11-2002

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 2003/070981 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
C12R 1/32, C07K 16/12, 14/35, A61K 39/04, G01N
33/569, C12N 5/10, 15/70

Moléculaire Bactérienne, 25-28, rue du Docteur Roux,
75724 Paris Cedex 15 (FR).

(21) International Application Number:
PCT/IB2003/000986

(74) Agent: **MARTIN, Jean-Jacques**; Cabinet Regimbeau, 20,
rue de Chazelles, 75847 Paris, Cedex 17 (FR).

(22) International Filing Date: 25 February 2003 (25.02.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02290458.5 25 February 2002 (25.02.2002) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **INSTITUT PASTEUR** [FR/FR]; 25-28, rue du Docteur Roux,
F-75015 Paris (FR). **VETERINARY LABORATORIES AGENCY** [GB/GB]; New Ham, Addelstone KT15 3NB,
Surrey (GB).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLE, Stewart**
[GB/FR]; c/o Institut Pasteur, Unité de Génétique Moléculaire Bactérienne, 25-28 rue du Docteur Roux, F-75724 Paris Cedex 15 (FR). **BROSCH, Roland** [AT/FR]; c/o Institut Pasteur, Unité de Génétique Moléculaire Bactérienne, 25-28 rue du Docteur Roux, F-75724 Paris Cedex 15 (FR). **GORDON, Stephen** [IE/GB]; Glyn Hewinson, Veterinary Laboratories Agency, Woodham Lane, New Haw, Addelstone, Surrey KT15 3NB (GB). **EIGLMEIER, Karin** [DE/FR]; c/o Institut Pasteur, Unité de Génétique Moléculaire Bactérienne, 25-28, rue du Docteur Roux, 75724 Paris Cedex 15 (FR). **GARNIER, Thierry** [FR/FR]; c/o Institut Pasteur, Unité de Génétique

(88) Date of publication of the international search report:
4 December 2003

(48) Date of publication of this corrected version:
7 October 2004

(15) Information about Correction:
see PCT Gazette No. 41/2004 of 7 October 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **SEQUENCES SPECIFICALLY DELETED MYCOBACTERIUM TUBERCULOSIS GENOME AND THEIR USE IN DIAGNOSTICS AND AS VACCINES**

(57) Abstract: The present invention is the identification of a nucleotide sequence which make it possible in particular to distinguish an infection resulting from the vast majority of *Mycobacterium tuberculosis* strains from an infection resulting from *Mycobacterium africanum*, *Mycobacterium canettii*, *Mycobacterium microti*, *Mycobacterium bovis*, *Mycobacterium bovis BCG*. The subject of the present invention is also a method for detecting the sequences in question by the products of expression of these sequences and the kits for carrying out these methods. Finally, the subject of the present invention is novel vaccines.

WO 2003/070981 A3

This Page Blank (uspto)